A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Crohn's Disease
Phase: PHASE2
Conditions: Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis
Sponsor: Bristol-Myers Squibb

 
 
Official Title of Study: 
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of  
BMS-986165 in Subjects with Moderate to Severe Crohn's Disease 
 
Protocol: IM011-023 
 
NCT Number: NCT03599622 
 
Document Date (Date in which document was last revised): 02-Sep-2022 

Page:
1
Protocol Number:
IM011023
Date: 14-Feb-2018
Date:
02-Sep-2022
CLINICAL PROTOCOL IM011023
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 
BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
Protocol Amendment No.: 05
Medical Monitors
Study Director
Medical Monitor-
Americas
Europe and East Asia/Pacific
Bristol-Myers Squibb 
Company
86 Morris Ave.
Summit, NJ 07901 USA
Telephone: 
PRA Health Sciences
4130 ParkLake Ave.; Ste 400
Raleigh, NC 27612 USA
Telephone: 
Fax: 
PRA Health Sciences
EM Building
17 Henrik Ibsen St.
Sofia 1407, Bulgaria
PRA Health Sciences
Otemachi First Square
West Tower 11F
5-1, Otemachi 1-Chome, Chiyoda-ku
Tokyo, 100-0004, Japan
Telephone: 
Fax: 
24-hr Emergency Telephone Number
USA:
International: 
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrenceville, NJ 08648
Avenue de Finlande 4 
B-1420 Braine-l’Alleud, Belgium
1-2-1 Otemachi, Chiyoda-ku
Tokyo, 100-0004, Japan
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
2
REGULATORY AGENCY IDENTIFIER NUMBER(S)
IND Number: 134444
EUDRACT Number: 2017-001976-48
This document is the confidential and proprietary information of Bristol-Myers Squibb Company (BMS) and 
its global affiliates (BMS). By reviewing this document, you agree to keep it confidential and to use and disclose 
it solely for the purpose of assessing whether your organization will participate in and/or the performance of 
the proposed BMS sponsored study. Any permitted disclosures will be made only on a confidential "need to 
know" basis within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly authorized in writing by 
BMS. Any supplemental information (eg, amendments) that may be added to this document is also confidential 
and proprietary to BMS and must be kept in confidence in the same manner as the contents of this document. 
Any person who receives this document without due authorization from BMS is requested to return it to BMS 
or promptly destroy it. All other rights reserved. References to BMS in this protocol may apply to partners to 
which BMS has transferred obligations, eg, a contract research organization.
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
3
DOCUMENT HISTORY
Document
Date of Issue
Summary of Changes
Approvers
Amendment 05
(Global Amendment 
34 v6.0a)
(im011023-
protamend05)
02-Sep-2022
Includes the following modifications:
•
Added diary selection rules for Week 0 
of CDAI/PRO2 calculation
•
Updated efficacy analyses to reflect 
updated planned statistical analyses
•
Clarification of assessments and timing 
for Week 104 visit
•
 
 
 
 
 
 
 
•
Elucidation of treatment failure rules
•
Added 
open-label 
6 mg 
BID 
BMS-986165 arm to the Selection and 
Timing of Dose table
•
Applied minor editorial changes to 
enhance the clarity of the protocol and 
update address information
 
 
Administrative Letter 
07
15-Oct-2021
Corrected numbering in inclusion/exclusion 
criteria.
 
Amendment 01 
Netherlands
Revised Protocol 33a
Netherlands-specific
(im011023-
protamend01-nl)
27-Sep-2021
Netherlands-specific protocol amendment 
incorporating modification to Inclusion 
Criteria 2, Type of Subject and Target 
Disease Characteristics.
 
 
Amendment 05 
China
Revised Protocol 32a
China-specific
(im011023-
protamend05-cn)
27-Sep-2021
China-specific protocol amendment 
incorporating modifications implemented in 
Global Protocol Amendment 04, v5.0, and 
the following additional China-specific 
changes:
 
 
 
•
C. difficile toxin screening procedures 
specific to mainland China sites, as 
previously described in Administrative 
Letter 05 (20-Jan-2021), were added in 
APPENDIX 20
 
 
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
4
Document
Date of Issue
Summary of Changes
Approvers
Amendment 01 
Belgium
Revised Protocol 31a
Belgium-specific
(im011023-
protamend01-be)
08-Sep-2021
Belgium-specific protocol amendment 
clarifying contraceptive requirements for 
male subjects in Belgium.
 
 
Administrative Letter 
06
02-Sep-2021
Clarifies a study endpoint that was 
incorrectly duplicated in both the secondary 
and exploratory endpoint sections.
 
Amendment 05 
Japan
Revised Protocol 30a
Japan-specific
(im011023-
protamend05-jp)
01-Sep-2021
Japan-specific protocol amendment 
incorporating modifications implemented in 
Global Protocol Amendment 04, v5.0.
 
 
Amendment 03 
Portugal
Revised Protocol 29a
Portugal-specific
(im011023-
protamend03-pt)
27-Aug-2021
Portugal-specific protocol amendment 
incorporating modifications implemented in 
Global Protocol Amendment 04, v5.0.
 
 
Amendment 02 
France
Revised Protocol 28a
France-specific
(im011023-
protamend02-fr)
27-Aug-2021
France-specific protocol amendment 
incorporating modifications implemented in 
Global Protocol Amendment 04, v5.0.
 
 
Amendment 03
South Korea and 
Taiwan
Revised Protocol 27a
South Korea and 
Taiwan-specific
(im011023-
protamend03-kr-tw)
27-Aug-2021
South Korea and Taiwan-specific protocol 
amendment incorporating modifications 
implemented in Global Protocol 
Amendment 04, v5.0.
 
 
Amendment 05 Italy
Revised Protocol 26a
Italy-specific
(im011023-
protamend05-it)
27-Aug-2021
Italy-specific protocol amendment 
incorporating modifications implemented in 
Global Protocol Amendment 04, v5.0.
 
 
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
5
Document
Date of Issue
Summary of Changes
Approvers
Amendment 04 
Germany
Revised Protocol 25a
Germany-specific
(im011023-
protamend04-de)
27-Aug-2021
Germany-specific protocol amendment 
incorporating modifications implemented in 
Global Protocol Amendment 04, v5.0.
 
 
Amendment 04
(Global Amendment 
24 v5.0a)
(im011023-
protamend04)
06-Aug-2021
Includes the following modifications:
• Added information, instructions, and 
measures to be taken related to 
SARS-CoV-2 infection.
• Reconfigured secondary and exploratory 
endpoints in response to expert 
consensus on treatment targets in IBD.
•
 
 
• Removed exclusion criterion that 
prohibited the participation of subjects 
who had previously experienced 
inadequate response or loss of response 
to ustekinumab.
• Clarified multiple other inclusion and 
exclusion criteria.
• Updated vendor information
• Added efficacy and safety findings from 
recent BMS-986165 studies
• Removed fasting requirement at 
screening.
• Clarified procedures for C. difficile
testing, endoscopies, unblinding for 
Week 12 analysis, hematocrit analysis, 
potential future analyses, and subjects 
with liver abnormalities and potential 
DILI AEs.
•
 
• Clarified that subjects who need rescue 
treatment must discontinue study 
treatment during the OLE.
• Updated language throughout protocol to 
reflect current BMS procedures, policies, 
and guidelines.
 
 
Revised Protocol 23
IM011023 Revised 
Protocol 01d 
Italy Specifica
08-Jan-2021
This country-specific revised protocol 
applies to all subjects enrolled in Italy.
 
 
 
 
 
 
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
6
Document
Date of Issue
Summary of Changes
Approvers
Revised Protocol 22
IM011023 Revised 
Protocol 03a 
France Specifica
23-Jun-2020
This country-specific revised protocol 
applies to all subjects enrolled in France. It 
encompasses the removal of the first bullet 
point of Inclusion Criterion #2g, which 
allowed patients with only an inadequate 
response, loss of response, or intolerance to 
a standard course of oral aminosalicylates 
for induction therapy for at least 6 weeks to 
be included in the trial.
 
 
Revised Protocol 21
IM011023 Revised 
Protocol 01d 
China Specifica
23-Mar-2020
China-specific including the following 
modifications:
•
Chest imaging for tuberculosis 
screening was amended to allow for 
chest x-ray or computed tomography 
scan
•
A negative result for C. difficile by 
nucleic acid amplification test will only 
be required for rescreening if a 
validated assay is available. If a 
validated nucleic acid amplification test 
is not available, the subject must have 
negative testing for C. difficile toxin 
and C. difficile glutamate 
dehydrogenase in order to be 
rescreened.
•
Optional Therapeutic Drug Monitoring 
to allow washout periods to be waived 
for certain medications was removed.
 
 
Revised Protocol 20
Revised Protocol 01b
Portugal Specifica
12-Mar-2020
Portugal-specific incorporating changes 
from Global Protocol v3.0 (25-Jun-2019) 
and Global Protocol v4.0 (20-Aug-2019). 
 
 
Revised Protocol 19
FINAL APPROVED
(Portugal)
v2.0
19-Nov-2019
 
 
 
 
 
Amendment 18
FINAL APPROVED
(Japan)
v4.0
23-Sep-2019
Japan-specific incorporating Global 
Protocol, v4.0.
 
 
 
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
7
Document
Date of Issue
Summary of Changes
Approvers
Amendment 17
FINAL APPROVED
(China)
v4.0
30-Sep-2019
China specific incorporating Global 
Protocol, v4.0.
 
 
 
Amendment 16
FINAL APPROVED
(Italy)
v4.0
20-Sep-2019
Italy-specific incorporating Global Protocol, 
v4.0.
 
 
 
Amendment 15
FINAL APPROVED
(Germany)
v4.0
27-Aug-2019
Germany-specific incorporating Global 
Protocol, v4.0.
 
 
 
Amendment 14
FINAL APPROVED
(South Korea and 
Taiwan)
v4.0
27-Aug-2019
South Korea and Taiwan-specific 
incorporating Global Protocol, v4.0.
 
 
 
Amendment 13
FINAL APPROVED
(Japan)
v3.0
23-Aug-2019
Japan-specific incorporating Global 
Protocol, v3.0.
 
 
 
Amendment 12b
Global
(Global Revision 03
20-Aug-2019
Includes the following modifications:
•
Clarification of the number of subject 
diary days required to calculate the 
CDAI
 
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
8
Document
Date of Issue
Summary of Changes
Approvers
FINAL APPROVED
v4.0a)
•
Alignment in protocol text and 
Appendix 7 of washout times for 
specific treatments
•
Clarification of rescreening 
requirements for subjects positive for 
C. difficile
 
 
Amendment 11b
FINAL APPROVED
(China)
v3.0 
01-Aug-2019
China-specific Amendment incorporating 
Global Protocol, v3.0. Additional 
modifications include:
 
 
 
 
 
Amendment 10b
FINAL APPROVED
(South 
Korea/Taiwan)
v3.0
26-Jul-2019
South Korea/Taiwan specific incorporating 
Global Protocol Amendment, v3.0. 
 
 
 
 
 
 
 
Amendment 9b
FINAL APPROVED
(Germany)
v3.0
24-Jul-2019
Germany specific incorporating Global 
Protocol Amendment, v3.0.
 
 
 
 
Amendment 8b
FINAL APPROVED
(Italy)
v3.0
24-Jul-2019
Italy specific incorporating Global Protocol 
Amendment, v3.0.
 
 
 
 
Amendment 7b
Global
25-Jun-2019
Includes the following modifications:
•
Change of co-primary endpoint 
(clinical remission) definition
 
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
9
Document
Date of Issue
Summary of Changes
Approvers
(Global Revision 02
FINAL APPROVED
v3.0a)
•
Removal of 12 mg QD treatment arm
•
Addition of 52-week open-label 
extension period
•
Clarification of clinical response, loss 
of response, and treatment failure 
definitions
•
 
•
Revision of the Schedule of Activities 
 to provide 
clarity
•
Update of Multiplicity Adjustment 
Section (10.4.6)
•
Update of wording in various 
appendices to be consistent across 
studies of BMS-986165
•
Minor grammatical and typographic 
corrections
 
 
Amendment 6b
Germany
(Amendment 4
FINAL APPROVED
v2.3a)
04-Dec-2018
Germany specific
 
 
 
 
Amendment 5b
Italy
(Amendment 3
FINAL APPROVED
v2.2a)
29-Oct-2018
Italy specific
 
 
 
 
Amendment 4b
China
(Amendment 2
FINAL APPROVED
v2.1a)
12-Oct-2018
China specific
 
 
 
 
Amendment 3b
27-Aug-2018
Japan specific
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
10
Document
Date of Issue
Summary of Changes
Approvers
Japan specific
(Japan Protocol 
Amendment 2a)
Amendment 2b
Japan specific
(Japan Protocol 
Amendment 1a)
17-Jul-2018
Japan specific
Global Revision 01
FINAL APPROVED 
v2.0
24-May-2018
 
 
 
 
 
 
 
Original protocol 
FINAL APPROVED, 
v1.0
14-Feb-2018
&
27-Mar-2018 
(updated)
Not applicable
 
 
 
 
a Document naming conventions have been updated. Legacy numbering is provided for consistency.
b Protocol Amendment numbering has been updated to reflect total amendment count.
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
OVERALL RATIONALE FOR GLOBAL PROTOCOL AMENDMENT 05
The primary purpose of this protocol amendment is to include the following updates:
•
Added diary selection rules for Week 0 of CDAI/PRO2 calculation
•
 
•
Updated efficacy analyses language to reflect updated planned statistical analyses
The amendment will be implemented after the Investigator receives all appropriate regulatory 
agency and IRB/EC approvals.
Generally, only major additions and deletions are provided in this summary of changes document, 
and all minor grammatical, formatting, rephrasing, stylistic changes, or clarifications, as well as 
organizational changes are not included. All changes applied to the protocol body were applied to 
the protocol synopsis, as necessary; synopsis changes are not included in the summary of key 
changes table. 
The rationale for the change to this amendment is provided in the summary of key changes table, 
as shown below.
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 05
Section Number & Title
Description of Change
Brief Rationale
Title page
Changed the Europe/East 
Asia/Pacific Medical Monitor’s 
address and BMS Japan 
headquarters address
To ensure investigators have 
correct study contact information
2 Schedule of Activities, Table 4
Lengthened visit window of 
Week 104 from ± 3 days to 
± 7 days
To decrease subject burden and 
align with updated endoscopy 
recommendations
2 Schedule of Activities, Table 4
9.2 Laboratory Assessments
9.5.3 Clinical Safety Laboratory 
Assessment
Clarified that a local lab can be 
used to analyze hematocrit at 
Week 104, in addition to Week 2 
through Week 52
To ensure prompt CDAI score 
calculation at Week 104
 
2 Schedule of Activities, Table 4
9.6.1 Sampling Schedule, Table 7
 
 
 
 
 
 
 
 
2 Schedule of Activities, Table 4
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
11
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 05
Section Number & Title
Description of Change
Brief Rationale
3.2.1 Scientific Rationale for Study 
Design
5.1 Overall Design, Figure 1
5.1.3.2 Week 26
7.1 Treatments Administered
Clarified study procedures for 
subjects who do not achieve a 
clinical response by Week 12
To ensure Week 12 nonresponders 
are switched into the open-label 
BMS-986165 treatment group and 
reassessed for clinical response at 
Week 26 (compared to Week 0)
4.3 Exploratory
 
 
 
 
 
 
 
 
 
 
 
5.3 End of Study Definition
 
 
 
 
6.1 Inclusion Criteria
Fixed numbering of Inclusion 
Criterion 2 subcriteria to be 
alphabetical “a” through “g,” in 
place of previous erroneous 
numbering (a, b, c, b, d, e, f)
To incorporate changes from 
Administrative Letter 07 (dated 
15-Oct-2021)
6.5.1 Retesting During the Screening 
Period; Rescreening
Clarified that previously 
randomized subjects are not 
eligible for rescreening, even if 
they did not receive a dose of 
study treatment
To clarify rescreening procedures 
for a subgroup of participants
7.1 Treatments Administered, 
 
 
 
 
9.1 Efficacy Assessments
Added diary selection rules for 
Week 0 of CDAI/PRO2 
calculation
To align with SAP and site training 
materials
10.4 Efficacy Analyses
Updated efficacy analyses
language to reflect updated 
planned statistical analyses
To align with the latest updates to 
the SAP (August 2022 version)
Protocol Amendment No.: 05
Date: 02-Sep-2022
12
2.0
Approved
930173322
2.0
v
Approved
1.0
v

TABLE OF CONTENTS 
 
 
TITLE PAGE ................................................................................................................ 
 
DOCUMENT HISTORY .............................................................................................. 
 
OVERALL RATIONALE FOR GLOBAL PROTOCOL AMENDMENT 05 ............ 
 
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 05 ................ 
 
TABLE OF CONTENTS .............................................................................................. 
 
1 SYNOPSIS ................................................................................................................. 
 
2 SCHEDULE OF ACTIVITIES.................................................................................. 
 
3 INTRODUCTION ..................................................................................................... 
 
3.1 Background ....................................................................................................... 
 
3.1.1 Nonclinical Toxicology ............................................................................ 
 
3.1.2 Early Clinical Experience ........................................................................ 
 
3.2 Study Rationale ................................................................................................. 
 
3.2.1 Scientific Rationale for Study Design ...................................................... 
 
 ......................................................... 
 
3.2.3 Benefit/Risk Assessment ........................................................................... 
 
4 OBJECTIVES AND ENDPOINTS ........................................................................... 
 
4.1 Primary Efficacy ............................................................................................... 
 
4.2 Secondary Efficacy ........................................................................................... 
 
 ....................................................................................................... 
 
4.4 Safety ................................................................................................................ 
 
5 STUDY DESIGN....................................................................................................... 
 
5.1 Overall Design .................................................................................................. 
 
5.1.1 Screening Period ...................................................................................... 
 
5.1.2 Induction Period ...................................................................................... 
 
5.1.3 Maintenance Period ................................................................................. 
 
5.1.3.1 Week 12 (Day 85), End of Induction Period ................................... 
 
5.1.3.2 Week 26 (Day 183).......................................................................... 
 
5.1.3.3 Week 12 Responders: Loss of Response in the Maintenance Period
............................................................................................................... 
 
5.1.3.4 Week 12 Non-responders: Loss of Response after Week 26 in the 
Open-label Arm ..................................................................................... 
 
5.1.3.5 Week 52 (Day 365).......................................................................... 
 
5.1.4 Open-label Extension Period ................................................................... 
 
5.1.4.1 Post-treatment Follow-up ............................................................... 
 
 
 
 
 
5.1.5 Data Monitoring Committee and Other External Committees ................ 
 
 .................................................................................... 
 
5.2 Number of Subjects ........................................................................................... 
 
5.3 End of Study Definition .................................................................................... 
 
6 STUDY POPULATION ............................................................................................ 
 
6.1 Inclusion Criteria .............................................................................................. 
 
6.2 Exclusion Criteria ............................................................................................. 
 
6.3 Randomization Criteria ..................................................................................... 
 










































Clinical Protocol
BMS-986165
IM011023
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
13
2.0
Approved
930173322
2.0
v
Approved
1.0
v

6.4 Lifestyle Restrictions ........................................................................................ 
 
6.5 Screen Failures .................................................................................................. 
 
6.5.1 Retesting During the Screening Period; Rescreening ............................. 
 
7 TREATMENT ........................................................................................................... 
 
7.1 Treatments Administered .................................................................................. 
 
7.2 Method of Treatment Assignment .................................................................... 
 
7.3 Blinding............................................................................................................. 
 
7.3.1 Maintaining the Blind .............................................................................. 
 
7.3.2 Circumstances for Unblinding ................................................................. 
 
7.3.3 Unblinding for Week 12 Analysis ............................................................ 
 
7.4 Dosage Modification and/or Interruption ......................................................... 
 
7.5 Preparation/Handling/Storage/Accountability .................................................. 
 
7.6 Treatment Compliance ...................................................................................... 
 
7.7 Concomitant Therapy........................................................................................ 
 
7.7.1 Prohibited and/or Restricted Treatments................................................. 
 
7.7.2 Existing Therapies for Crohn’s Disease .................................................. 
 
7.8 Treatment After the End of the Study ............................................................... 
 
8 DISCONTINUATION CRITERIA ........................................................................... 
 
8.1 Discontinuation from Study Treatment ............................................................ 
 
8.1.1 Post Study Treatment Study Follow-up.................................................... 
 
8.2 Discontinuation from the Study ........................................................................ 
 
8.2.1 Temporary IP Discontinuation ................................................................ 
 
8.3 Discontinuation of the Study/Study Stopping Rules ........................................ 
 
8.4 Lost to Follow-up .............................................................................................. 
 
8.5 Replacement of Subjects ................................................................................... 
 
9 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 
 
9.1 Efficacy Assessments ........................................................................................ 
 
9.2 Laboratory Assessments ................................................................................... 
 
9.3 Adverse Events ................................................................................................. 
 
9.3.1 Adverse Events of Interest ........................................................................ 
 
9.3.2 Time Period and Frequency for Collecting AE and SAE Information .... 
 
9.3.3 Method of Detecting AEs and SAEs ......................................................... 
 
9.3.4 Follow-up of AEs and SAEs ..................................................................... 
 
9.3.5 Regulatory Reporting Requirements for SAEs ......................................... 
 
9.3.6 Pregnancy ................................................................................................ 
 
9.3.7 Laboratory Test Result Abnormalities ..................................................... 
 
9.3.8 Potential Drug-induced Liver Injury ....................................................... 
 
9.3.9 Other Safety Considerations .................................................................... 
 
9.4 Overdose ........................................................................................................... 
 
9.5 Safety ................................................................................................................ 
 
9.5.1 Physical Examinations ............................................................................. 
 
9.5.2 Tuberculosis Screening and Chest X-ray ................................................. 
 
9.5.3 Clinical Safety Laboratory Assessments .................................................. 
 
9.5.4 Imaging Safety Assessment ...................................................................... 
 
 .............................................................................................. 
 
 ................................................................................... 
 














































Clinical Protocol
BMS-986165
IM011023
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
14
2.0
Approved
930173322
2.0
v
Approved
1.0
v

 ................................................................................... 
 
 ........................................................................................... 
 
 ........................................................................................................ 
 
............................................................... 
 
 ...................................... 
 
9.10 SARS-CoV-2 Testing ..................................................................................... 
 
10 STATISTICAL CONSIDERATIONS .................................................................... 
 
10.1 Sample Size Determination ............................................................................. 
 
10.2 Populations for Analyses ................................................................................ 
 
10.3 Endpoints ........................................................................................................ 
 
10.3.1 Primary Endpoints ................................................................................. 
 
10.3.2 Secondary Endpoints ............................................................................. 
 
 ........................................................................... 
 
10.4 Efficacy Analyses ........................................................................................... 
 
10.4.1 Co-primary Endpoint Analyses .............................................................. 
 
10.4.2 Imputation Methods for Co-primary Endpoints .................................... 
 
10.4.3 Sensitivity Analyses for the Co-primary Endpoints ............................... 
 
10.4.4 Secondary Endpoint Analyses ................................................................ 
 
10.4.5 Imputation Methods for Secondary Endpoints ...................................... 
 
10.4.6 Adjustment for Multiplicity of Co-primary and Secondary Endpoints .. 
 
10.5 Safety Analyses ............................................................................................... 
 
10.6 Other Analyses ................................................................................................ 
 
 ................................................................................... 
 
 ................................................................................ 
 
10.6.3 Week 12 Analysis ................................................................................... 
 
10.6.4 Interim Analysis ..................................................................................... 
 
11 REFERENCES ........................................................................................................ 
 
12 APPENDICES ......................................................................................................... 
 
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ........................................ 
 
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS ................................. 
 
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW-UP AND REPORTING ........................................................................ 
 
 
 
 .......................................................................................... 
 
APPENDIX 5 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ..................................................................... 
 
 ........... 
 
APPENDIX 7 EXAMPLES OF WASHOUT TIMES REQUIRED PRIOR TO 
RANDOMIZATION............................................................................................... 
 
APPENDIX 8 SUBJECT DIARY ................................................................................ 
 
APPENDIX 9 INTERPRETATION OF HBV AND HCV TEST RESULTS ............. 
 
APPENDIX 10 CROHN'S DISEASE ACTIVITY INDEX VARIABLES .................. 
 
 ................................................................................................... 
 







































Clinical Protocol
BMS-986165
IM011023
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
15
2.0
Approved
930173322
2.0
v
Approved
1.0
v

APPENDIX 12 DEFINITIONS OF SIMPLE ENDOSCOPIC SCORE FOR CROHN'S 
DISEASE ................................................................................................................ 
 
 
................................................................................................................................. 
 
 
 ..................................................................... 
 
 
 ................................ 
 
 
 
 ....................................... 
 
 
 
 
................................................................. 
 
APPENDIX 19 COVID-19 VACCINES ...................................................................... 
 
APPENDIX 20 CLOSTRIDIUM DIFFICILE INFECTION SCREENING ................ 
 
APPENDIX 21 PROTOCOL AMENDMENT SUMMARY OF CHANGE HISTORY
................................................................................................................................. 
 
 










Clinical Protocol
BMS-986165
IM011023
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
16
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
1
SYNOPSIS
Protocol Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety 
and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
Study Phase: 2
Background: 
Tyrosine kinase 2 (TYK2) is a protein involved in interleukin (IL)-12, IL-23 and Type I interferon 
(IFN) signaling, and it is required for the activation of downstream signaling pathways. TYK2 is 
a widely expressed, non-receptor tyrosine kinase that catalyzes the phosphorylation of signal 
transducer and activator of transcription (STAT) proteins downstream of the receptors for the p40-
containing cytokines IL-12 and IL-23, as well as the Type I interferon receptor. This results in the 
activation of STAT-dependent transcription and functional responses specific for these cytokines. 
TYK2-dependent cytokines (eg, IL-12, IL-23 and Type I IFNs) are distinct from those dependent 
on closely related Janus kinase (JAK) family members JAK1 and JAK3 (eg, IL-2, IL-6, IL-7, IL-
15) or JAK2 (eg, erythropoietin, thrombopoietin, and granulocyte-monocyte colony-stimulating 
factor). Consequently, a TYK2 inhibitor is expected to have a highly differentiated profile from 
inhibitors of other JAK family kinases. TYK2-dependent pathways and the cytokine networks they 
modulate (eg, IL-23, IL-17, IFNα) have been implicated in the pathophysiology of multiple 
immune-mediated diseases, including Crohn’s disease (CD), ulcerative colitis, psoriasis, psoriatic 
arthritis, systemic lupus erythematosus (SLE) and spondyloarthritides. 
BMS-986165 is an orally administered selective TYK2 inhibitor. A comprehensive in vitro and 
in vivo characterization of BMS-986165 has been established and supports the development of 
this compound in humans. Inhibition of TYK2 is expected to provide therapeutic benefit for 
patients with CD for multiple reasons: 1) IL-12 and IL-23 have been implicated in pathogenesis 
of CD; 2) Biologic agents targeting IL-23p19 and IL-12/23p40 cytokines have been shown to be 
efficacious in CD, and ustekinumab targeting IL-12/23p40 has been approved for the treatment of 
CD; and 3) BMS-986165 has been shown to be efficacious in psoriasis, an IL-23-mediated disease, 
in a recent Phase 2 study.
Overview of Study Design: 
IM011023 is a Phase 2 randomized, double-blind, placebo-controlled clinical study designed to 
assess the safety and efficacy of BMS-986165 compared to placebo in subjects with moderately 
to severely active CD. 
Approximately 240 subjects will be randomized in this study. After a 28-day Screening Period, 
eligible subjects will be randomized in a 3:3:2 ratio to one of three study arms: (i) BMS-986165 
6 mg twice daily (BID) by mouth (PO); n≈90, (ii) BMS-986165 3 mg BID PO; n≈90, or 
(iii) matched placebo; n≈60. 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
17
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
This study has a 12-week double-blind Induction Period, a 40-week double-blind Maintenance 
Period, and a 52-week Open-label Extension (OLE) Period, leading to a total of up to 104 weeks 
of exposure to investigational product (IP). The primary efficacy assessment occurs at Week 12. 
The co-primary endpoints are defined as achieving clinical remission (defined as Crohn’s Disease 
Activity Index [CDAI] of < 150) and achieving endoscopic response (≥50% improvement from 
baseline in the Simple Endoscopic Score for Crohn’s Disease [SES-CD]), on a population basis, 
at Week 12.
This study has a treat-through design in order to explore sustained clinical benefit and safety in the 
Maintenance Period. Subjects who achieve clinical response (a reduction from baseline in the 
CDAI score of ≥100 points or a total CDAI score < 150) at Week 12 (Day 85), are eligible to enter 
the Maintenance Period and to continue on the same double-blind treatment regimen that they 
received in the Induction Period for up to an additional 40 weeks, up to Week 52. Subjects with a 
loss of response (LOR; an increase in the CDAI score of ≥100 points compared to Week 12 and 
a total CDAI score of ≥220 points) at any time from Week 13 through Week 52 are eligible to 
enter an open-label BMS-986165 6 mg BID PO arm through Week 52. 
Subjects who do not achieve clinical response at Week 12 and who have an appropriate safety 
profile are eligible to enter an open-label BMS-986165 6 mg BID PO arm, in which clinical 
response is again assessed at Week 26 (compared to Week 0). Subjects in this open-label study 
arm who achieve clinical response at Week 26 (compared to Week 0) may continue in this arm 
through Week 52. Subjects in this open-label study arm who do not achieve clinical response at 
Week 26 (compared to Week 0) will be considered treatment failures and must permanently 
discontinue IP and enter the Post-treatment Follow-up Period. Throughout the study, subjects who 
permanently discontinue IP prior to Week 52 must enter the Post-treatment Follow-up Period. 
Subjects who continue to derive a clinical benefit from IP at Week 52, as judged by the 
investigator, are eligible to enter the OLE Period. The OLE Period lasts 52 weeks, to Week 104.
Overview of Scientific Rationale:
The scientific rationale for the study is summarized above and further detailed in Section 3 and the 
Investigator Brochure (IB). This Phase 2 randomized, double-blind clinical trial is designed to 
assess the safety and efficacy of BMS-986165 in patients with moderately to severely active CD. 
 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
18
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
 
 
 
 
 
 
The eligibility criteria are designed to ensure that subjects have moderately to severely active CD 
at baseline and to minimize the risk for serious infections that may be associated with immune 
modulating therapies.
Protocol Amendment No.: 05
Date: 02-Sep-2022
19
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
A 
 benefit/risk assessment are provided in 
 Section 3.2.3, 
 
Study Population: 
The study population includes male and female subjects, 18 to 75 years old (inclusive), with a 
documented diagnosis of CD for at least 3 months prior to screening. The diagnosis must be 
confirmed with source document evidence of a colonoscopy with ileal intubation (ileo-
colonoscopy) and histopathology showing features consistent with CD. Subjects with ileal, 
colonic, or ileocolonic disease distribution are eligible to participate in the study. Subjects with 
perianal fistulizing disease are eligible to participate in the study, provided they meet the other 
inclusion/exclusion criteria, eg, subjects with a current abscess or suspected abscess are excluded.
Subjects must have an inadequate response, LOR, or intolerance to a standard treatment course of 
either conventional therapy (eg, 5-ASAs, corticosteroids, immunomodulators) or biologic therapy 
(eg, infliximab, adalimumab, certolizumab pegol, vedolizumab, natalizumab, or ustekinumab) for 
CD.
A subject will be considered enrolled only when the informed consent form (ICF) is signed. 
Subjects must have clinical and endoscopic evidence of moderately to severely active CD, as 
evidenced by the following minimum disease activity criteria, assessed during the Screening 
Period:
Protocol Amendment No.: 05
Date: 02-Sep-2022
20
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
(i) A CDAI score of 220 to 450 (see Section 9.1 and APPENDIX 10)
(ii) An average daily score for AP ≥2 OR average daily number of very soft (loose) or liquid 
(watery) stools (Bristol Stool Scale [BSS] Type 6 or 7 only; 
 ≥4 on the PRO2 
(see Section 9.1 and 
) 
(iii) Evidence of active inflammation in at least 1 of the 5 ileocolonic segments (based on central 
reading) with total SES-CD ≥ 6, or SES-CD ≥ 4 if only isolated ileitis is present on baseline 
endoscopy (other inclusion criteria are listed Section 6.1) 
Subjects will be excluded if they present with severe or fulminant colitis that is likely to require 
surgery or hospitalization; a diagnosis of alternative forms of colitis other than CD; a stoma, gastric 
or ileoanal pouch; a previous proctocolectomy or total colectomy; symptomatic, stenosing disease 
that is likely to confound efficacy assessment (eg, symptomatic CD-related stricture); an abscess 
or suspected abscess; pouchitis; short bowel syndrome; or a history of bowel perforation. In 
addition, subjects with colonic or ileal strictures that are not passable via colonoscope that the 
endoscopist normally uses in clinical practice, or strictures in the ileum or ileocecal valve that are 
fibrotic in nature, will be excluded. Other exclusion criteria are listed in Section 6.2. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
21
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Objectives and Endpoints: 
Key study definitions are provided below.
Clinical remission
CDAI score < 150 
Clinical response
A reduction from baseline in the CDAI score of ≥ 100 points or 
a total CDAI score < 150
Endoscopic response
≥50% improvement from baseline in the SES-CD 
 
 
 
 
 
PRO2 remission
Average daily score for abdominal pain ≤1 and average number 
of very soft (loose) or liquid (watery) stools (BSS Type 6 or 7 
only) ≤3 on the PRO2, and both not worse than baseline. 
 
BSS = Bristol Stool Scale; CD = Crohn’s Disease; CDAI = Crohn’s Disease Activity Index; 
; PRO2 = 
patient (or subject) reported outcome based on the stool frequency and abdominal pain components of the CDAI; 
SES-CD = Simple Endoscopic Score for Crohn’s Disease
Primary Efficacy Objectives and Endpoints:
•
Objective: To assess the effect of BMS-986165 on clinical remission and endoscopic response 
at the end of the Induction Period (Week 12 [Day 85])
•
Co-primary endpoints: 
−
Proportion of subjects achieving clinical remission at Week 12, and
−
Proportion of subjects achieving endoscopic response at Week 12, both at a population 
level.
Protocol Amendment No.: 05
Date: 02-Sep-2022
22
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Secondary Efficacy Objectives and Endpoints:
•
To assess the effect of BMS-986165 on clinical response at the end of the Induction Period
−
Endpoint: Proportion of subjects who achieve a clinical response at Week 12
•
To assess the effect of BMS-986165 on PRO2 remission at the end of the Induction Period
−
Endpoint: Proportion of subjects who achieve PRO2 remission at Week 12
•
To assess the effect of BMS-986165 on gut mucosal disease activity by endoscopy at the end 
of the Induction Period
−
Endpoint: Change from baseline in SES-CD at Week 12
The exploratory objectives and endpoints are summarized in Section 4.3. 
Overall Design:
The IM011023 study is designed as follows:
•
A randomized, double-blind, placebo-controlled, multicenter study 
•
Consists of 5 periods: 
−
Screening Period: up to 4 weeks (28 days)
−
Induction Period: 12 weeks (84 days)
−
Maintenance Period: 40 weeks (280 days)
−
Open-label Extension Period: 52 weeks (364 days)
−
Post-treatment Follow-up Period: 4 weeks (28 days) 
•
On Day 1 of the Induction Period, subjects who have completed screening and met all 
eligibility criteria will be randomized in a 3:3:2 ratio using interactive response technology 
(IRT) to receive oral BMS986165 6 mg BID PO, BMS-986165 3 mg BID PO, or matched 
placebo BID PO, respectively, as described below in Treatments Arms and Durations. 
 
 
 
 
 
•
Endoscopic (ileocolonoscopy) evaluations and collection of ileal and/or colonic tissue biopsies 
will be performed during the Screening Period, at the end of the Induction Period (Week 12), 
 Endoscopy 
should also be performed at Early Termination (ET) visits that occur at least 4 weeks after the
most recent endoscopy. Endoscopy is required at ET visits that occur between Week 4 and 
Week 12. 
 
•
Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), and 
clinical laboratory evaluations will be performed at selected times throughout the study. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
23
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
The study blind will be maintained during the study 
 
 
 
•
Clinical, laboratory, and endoscopic evidence of disease activity will be assessed. Endoscopic 
videos will be scored by blinded, external central readers. 
•
Progression from the Induction Period to the Maintenance Period, and from the Induction to 
or during the Maintenance Period to the Open-label Treatment Arms, and from the 
Maintenance Period to the OLE Period is contingent on an appropriate safety profile in each 
individual subject. 
•
A Data Monitoring Committee (DMC) will assess safety data (Section 5.1.5). 
•
The primary efficacy analysis will be performed after all subjects have completed Week 12 
(Day 85) efficacy assessments (or permanently discontinued study treatment prior to 
Week 12). 
The study design schematic is presented in Figure 1 and Figure 2. 
Figure 1
Study Design Schematic: Induction and Maintenance Periods
BID = twice daily; IP = investigational product; OL = open-label; R = randomization
a Subjects who achieve clinical response at Week 12 can enter the OL “loss of response” arm at any time from 
Week 13 through Week 52. Loss of response is defined as an increase in the CDAI score of ≥ 100 points compared 
to Week 12, and a total CDAI score of ≥ 220.
NOTE: This study has a treat-through design. At Week 12, subjects who achieve clinical response (defined as a 
reduction from baseline in the CDAI score of ≥100 points or a total CDAI score < 150) are eligible to continue to the 
Maintenance Period, where they will continue to receive the double-blind treatment regimen that they received in the 
Induction Period. Subjects who have loss of response in these arms may be eligible to enter the loss of response arm, 
where they will receive open-label BMS-986165 6 mg BID PO through Week 52. Subjects who do not achieve clinical 
response at Week 12 and who have an appropriate safety profile are eligible to enter an open-label treatment arm, in 
which they will receive open-label BMS-986165 6 mg BID PO during the Maintenance Period. Subjects in this arm 
must have clinical response assessed again at Week 26 (compared to Week 0). Subjects in this arm who do not achieve
Protocol Amendment No.: 05
Date: 02-Sep-2022
24
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
clinical response at Week 26 (compared to Week 0) will be considered treatment failures and must permanently 
discontinue IP and enter the Post-treatment Follow-up Period. Subjects in this arm who do achieve clinical response 
at Week 26 may continue IP through Week 52.
Figure 2
Study Design Schematic: OLE
BID = twice daily; OL = open-label; OLE = open-label extension
Subjects who were randomized when earlier versions of the protocol (Protocol v1.0 [27-Mar-2018] 
or Protocol v2.0 [24-May-2018]) were in effect will continue on their currently assigned 
double-blind study treatment. These subjects will complete all study procedures and assessments 
outlined in the current version  of the protocol.
Number of Subjects: 
Approximately 240 subjects will be randomized in a 3:3:2 ratio to receive BMS-986165 6 mg BID, 
BMS-986165 3 mg BID, or placebo BID, resulting in approximately 90 subjects per BMS-986165 
dose arm and 60 subjects in the placebo arm during the Induction Period. 
Treatment Arms and Duration:
The total duration of study participation will be up to approximately 112 weeks (784 days) in 
5 periods including up to a 4-week (28-day) Screening Period, a 12-week (84-day) Induction 
Period, a 40-week (280 day) Maintenance Period, a 52-week (364-day) OLE Period, and a 4-week 
(28-day) Post-treatment Follow-up Period. The total exposure to IP in this study will be up to 
104 weeks.
In all treatment groups, subjects will take their randomly assigned treatment twice daily as oral 
capsules. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
25
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Screening Period (up to 28 days duration):
The purpose of the Screening Period is to determine if a subject meets the enrollment criteria for 
this clinical trial. The suggested order of screening investigations is as follows: 
(i) Screening visit in order to sign the ICF and then obtain a medical history, vital signs and 
physical examination, screening blood tests, chest x-ray, ECG, etc, give the subject the electronic 
study diary and train on the diary, and schedule the screening ileocolonoscopy and Week 0 visit. 
Sites should consider the turnaround time for the centrally read endoscopy result when scheduling 
the ileocolonoscopy and Week 0 visits.
(ii) The subject will then record up to 14 days of daily diary data at home, in order to facilitate 
CDAI and PRO2 calculation. The minimum daily diary requirements for CDAI/PRO2 calculation 
are outlined in Section 9.1. In order to ensure that a subject can be successfully randomized, sites 
should consider periodically confirming that subjects are successfully entering and uploading daily 
diary data. See Section 9.1, APPENDIX 10, and
 for more details.
(iii) Sites should check the results of screening investigations to confirm that a subject remains 
potentially eligible for inclusion before a subject commences bowel preparation for the screening 
ileocolonoscopy.
(iv) The screening ileocolonoscopy will be performed. Subjects should be randomized within 
14 days of the screening ileocolonoscopy.
Induction Period (Weeks 0 through 12): 
During the Induction Period, subjects will take twice daily oral doses of the IP over 12 weeks 
 For each dose level, capsules are taken once in the morning and once in the evening. 
Subjects will be randomized to 1 of the 3 following treatments:
•
BMS986165 6 mg BID 
 
•
BMS986165 3 mg BID 
 
•
Placebo 
Video ileocolonoscopic examination and collection of ileal and/or colonic tissue biopsies should 
be performed within a window of 7 days prior to the Week 12 visit. The CDAI/PRO2 scores for 
determination of clinical response/remission status will be calculated as described in Section 9.1. 
In order to avoid missing data, sites should consider periodically confirming that subjects are 
successfully entering and uploading daily diary data prior to Week 12.
Protocol Amendment No.: 05
Date: 02-Sep-2022
26
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
(i). Subjects Who Demonstrate Clinical Response at Week 12
At Week 12 (Day 85), subjects who achieve a clinical response (as defined above) and who have 
an appropriate safety profile are eligible to continue to receive the same blinded study regimen 
(BMS-986165 6 mg BID or 3 mg BID or placebo BID) during the Maintenance Period. Blinded 
study treatment will continue until these subjects have completed Week 52 (Day 365), or have 
LOR (Section 5.1.3.3), or if they permanently discontinue IP prior to Week 52 for another reason. 
Subjects who achieve a clinical response at Week 12 and subsequently have an LOR during the 
Maintenance Period and who have an appropriate safety profile are eligible to switch to open-label 
treatment with BMS 6 mg BID. Alternatively, they can be permanently discontinued from 
treatment based on subject and/or investigator preference and enter the Post-treatment Follow-up 
Period. 
(ii). Subjects With No Clinical Response at Week 12
Subjects who do not achieve a clinical response at Week 12 and who have an appropriate safety 
profile are eligible to switch to open-label BMS-986165 treatment at the highest dose (6 mg BID), 
regardless of the initial treatment regimen received during the Induction Period.
Subjects who do not achieve protocol-defined clinical response at Week 12 and are switched to 
the open-label BMS-986165 6 mg BID arm, as well as those who are currently receiving 
open-label BMS-986165 12 mg QD prior to implementation of Protocol v3.0, must be assessed 
for clinical response at Week 26. If clinical response at Week 26 (compared to Week 0) is 
achieved, and subjects have an appropriate safety profile, these subjects are eligible to continue on 
the open-label treatment for the remaining duration of the Maintenance Period. Subjects in this 
open-label study arm who do not achieve clinical response at Week 26 (compared to Week 0) will 
be considered treatment failures and must permanently discontinue IP and enter the Post-treatment 
Follow-up Period. Note: These subjects may also be discontinued at any time before Week 26 
based on the clinical judgment of the investigator.
(iii). Subjects Randomized to 12 mg QD Arm in Protocol v1.0 or Protocol v2.0
Subjects who were randomized when Protocol v1.0 (27-Mar-2018) or Protocol v2.0 
(24-May-2018) was in effect will continue on their currently assigned double-blind study 
treatment. Subjects who were randomized to BMS-986165 12 mg QD prior to the current protocol, 
and who have not yet reached Week 12 who then achieve clinical response at Week 12, with an 
appropriate safety profile, are eligible to continue on blinded 12 mg QD study treatment. Subjects 
from this cohort who do not achieve clinical response at Week 12 who have an appropriate safety 
profile are eligible to switch to open-label BMS-986165 6 mg BID for the Maintenance Period, 
and they will be managed as described above.
Protocol Amendment No.: 05
Date: 02-Sep-2022
27
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Open-label Extension Period (Week 52 through Week 104)
Subjects who complete per protocol assessments at Week 52 who have an appropriate safety 
profile and who also continue to derive a clinical benefit from IP at that time in the opinion of the 
investigator, are eligible to enter the OLE Period. The OLE Period lasts 52 weeks, from Week 52 
through Week 104. The final study endoscopy should be performed within a window of 7 days 
prior to the Week 104 visit.
Post-treatment Follow-up Period:
Subjects who permanently discontinue IP prior to Week 52 will enter a 28-day Post-treatment 
Follow-up Period. Subjects will be instructed to report to the investigative site any adverse events 
(AEs) or serious adverse events (SAEs) experienced during this 28-day period. 
 
 
Study Treatment for IM011023
Medication 
Potency 
IP/Non-IP
BMS-986165 
3 mg 
IP
Placebo 
Not applicable
IP
IP = investigational product 
Protocol Amendment No.: 05
Date: 02-Sep-2022
28
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
2
SCHEDULE OF ACTIVITIES
Schedules of procedures are described in Table 1 for the Screening Period, Table 2 for the 
Induction Period, Table 3 for the Maintenance Period, and Table 4 for the OLE Period. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
29
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 1:
Screening Procedural Outline (IM011023)
Procedure
Screening
Visit
Day -28 to -1
Notes
Eligibility and Disease 
Assessments
Informed consent
X
A subject will be considered enrolled only when the ICF is signed.
Enroll subject
X
Obtain number from IRT; contact IRT to screen fail those not eligible.
Inclusion/exclusion criteria 
X
Section 6
Medical history
X
Include any toxicities or allergy related to previous treatments.
Crohn’s disease history
X
Subject input data into the subject 
diary 
X
APPENDIX 8
Endoscopy (ileocolonoscopy)
X
After bowel cleansing, video ileocolonoscopic examination must be performed within Day -28 and Day -1 
of the Screening Period and should be scheduled as close as possible to the Week 0 visit. The Week 0 visit 
should occur within 14 days of the screening endoscopy. Best practice is to complete the other screening 
investigations first and check results to ensure that a subject continues to be potentially eligible for the 
study prior to commencing bowel preparation for the endoscopy. At this examination, endoscopic 
collection of ileal and/or colonic tissue biopsies will be performed.
SES-CD
X
The SES-CD score is centrally read from the screening endoscopy and the central read must be reviewed 
to confirm eligibility prior to randomization. Local reads will not be used for study eligibility. Study sites 
should consider turnaround time for central reads to ensure results are obtained before the Week 0 visit. 
Results from central endoscopy review are final.
Definitions of SES-CD are provided in APPENDIX 12.
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
30
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 1:
Screening Procedural Outline (IM011023)
Procedure
Screening
Visit
Day -28 to -1
Notes
 
 
 
Confirm washout of prohibited 
medication and dose stabilization 
of allowed medication (if 
applicable)
X
Prohibited medications are described in Section 7.7.1. Note: The washout periods for specific 
immunomodulatory and biologic agents required before a subject can be randomized, as shown in
APPENDIX 7, may be longer than the 4-week Screening Period. This needs to be considered at enrollment. 
Prednisone dose stabilization requirements are described in Section 7.7.2.
 
 
Smoking history
X
Record as packs per day multiplied by years of tobacco use (ie, pack-years).
Prior and current concomitant 
medications
X
Section 7.7
Safety Assessments
Physical examination
X
General, head, eyes, ears, nose, throat, neck, cardiovascular, lungs, abdominal, extremities, neurologic, 
skin, musculoskeletal. If the screening physical examination is performed within 7 days prior to dosing on 
Day 1 then a single exam may count as both the screening and predose evaluation.
Physical measurements
X
Height and weight
Vital signs
X
Body temperature, respiratory rate, and seated blood pressure and heart rate; Blood pressure and heart rate 
should be measured after the subject has been resting quietly for at least 5 minutes. 
Electrocardiogram
X
Single 12-lead ECG reading, recorded after the subject has been supine for at least 5 minutes 
Chest x-ray
X
Also acceptable within 6 months of the screening visit with documentation on file
Diagnostic testing for 
SARS-CoV-2
X
To be performed locally, as close as possible to randomization. Diagnostic testing for SARS-CoV-2 
infection refers to a molecular test (eg, PCR) or antigen test. PCR testing is preferred (Section 9.10).
Subjects may receive SARS-CoV-2 testing prior to the screening colonoscopy procedure.a If negative, this 
testing will satisfy the requirement for study eligibility.
Monitor for SAEs and SARS-
CoV-2 related AEs
X
SAEs and all AEs related to SARS-CoV-2 infection should be collected from time of signing of ICF; 
nonserious AEs are collected starting with the first dose. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
31
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 1:
Screening Procedural Outline (IM011023)
Procedure
Screening
Visit
Day -28 to -1
Notes
Breast and cervical cancer
screening
X
Investigators are encouraged to confirm if screening is up to date according to local guidelines (women 
only). Screening for cervical and breast cancer prior to randomization is encouraged as per local guidelines 
due to the small inherent risk of increased malignancy with immunomodulatory agents, but this screening 
is at the investigator’s discretion.
Laboratory Tests
Hematology, chemistry, and 
coagulation 
X
Blood and urine samples; (must be repeated as necessary and verified to ensure that subjects meet study 
inclusion criteria and no exclusion criteria if performed more than 28 days prior to randomization).
Serology
X
Hepatitis B Virus (HBV): HBsAg, HBsAb, anti-HBc (with reflex to HBV DNA if positive). 
Hepatitis C Virus (HCV): Anti-HCV (if positive or indeterminate, HCV RNA testing will be performed 
using a separate blood draw).
Human Immunodeficiency Virus (HIV): HIV-1 and -2 antibody (Section 6.2); HIV-1 and -2 serology may 
be performed centrally, or locally in regions where central laboratory testing for HIV is not available. 
Tuberculosis screening
X
In accordance with standard testing (details are provided in Section 6.2 and Section 9.5.2)
Urine pregnancy test
X
WOCBP only; If the urine pregnancy test is positive, a serum pregnancy test should be done for 
confirmation prior to enrolling the subject. Study treatment should not be administered until the results of 
the confirmatory test are known.
Urinalysis
X
Follicle-stimulating hormone 
X
Postmenopausal women only to confirm status (APPENDIX 5)
Stool culture (performed locally)
X
If subjects are positive for enteric pathogens (not including flora that are considered commensal within a 
study region), they can be rescreened 30 days after completing a full course of standard treatment for 
bacterial enterocolitis and being deemed clinically improved by the investigator. 
Stool C. difficile testing 
(performed centrally) 
X
See APPENDIX 20. If subjects are positive for C. difficile, they can be rescreened as described in 
Section 6.5.1. 
Therapeutic Drug Monitoring 
(TDM)
X
Optional test for subjects who recently received infliximab, adalimumab, certolizumab pegol, 
vedolizumab (> 14 weeks treatment duration), or ustekinumab (> 12 weeks treatment duration) and are 
subject to a washout period for those medications (APPENDIX 7). This washout period will be waived 
Protocol Amendment No.: 05
Date: 02-Sep-2022
32
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 1:
Screening Procedural Outline (IM011023)
Procedure
Screening
Visit
Day -28 to -1
Notes
for subjects who have an undetectable drug level for that specific medication on TDM testing at screening 
or prior to screening.
Diary Training
Subject diary training
X
Along with diary input training, a paper copy of the Bristol Stool Scale (BSS) will be provided to subjects 
to assist with determining daily documentation of the number of very soft (loose) or liquid (watery) stools 
(BSS Type 6 and 7) 
 The subject daily diary information should be 
reviewed during the Screening Period to ensure that subjects are successfully entering and uploading diary 
data. If there are gaps in this process, subjects should be reached during the Screening Period to understand 
the gaps and to offer re-training. 
AE = adverse event; anti-HBc = hepatitis B core antibody; anti-HCV = hepatitis C virus antibody; BSS = Bristol Stool Scale; CDAI = Crohn’s Disease Activity 
Index; C. difficile = Clostridium difficile; 
; 
; ECG = electrocardiogram; HBsAb = hepatitis B surface antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; 
HCV = hepatitis C virus; HIV-1 and -2 = human immunodeficiency virus -1 and -2; ICF = informed consent form; IHC = immunohistochemistry; IRT = interactive 
response technology; 
; PCR = polymerase chain reaction; 
; 
; SAE = 
serious adverse event; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SES-CD = Simple Endoscopic Score for Crohn’s Disease; TDM = 
Therapeutic Drug Monitoring; WOCBP = women of childbearing potential
a Refer to: Sultan S, Siddique SM, Altayar O, et al. AGA Institute rapid review and recommendations on the role of pre-procedure SARS-CoV-2 testing and 
endoscopy. Gastroenterology 2020;159(5):1935-48.e5.
Protocol Amendment No.: 05
Date: 02-Sep-2022
33
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 2:
Induction Period On-Treatment Procedural Outline Up to Week 12 (Day 85) (IM011023)
Procedure/Visit Weeks
(Days)
0 
(1)
2 
(15)
4 
(29)
8 
(57)
12 
(85)
Notes
Visit Window (± n days)
0
3
3
3
3
Study Treatment
Eligibility/randomization criteria
X
Confirm eligibility criteria (Section 6.1 and Section 6.2) and assess randomization 
criteria (Section 6.3). All procedures to be completed before dosing unless otherwise 
specified.
Dispense clinical drug supplies 
(blinded)
X
X
X
X*
Subjects 
are 
to 
receive 
blinded 
IP 
twice 
daily 
PO 
(Section 5.1.2)
*See Section 5.1.3.1 and Section 5.1.3.2 regarding IP based on clinical response at 
Week 12.
Study treatment (blinded)
X-------------------------------------X
Review study drug compliance
X
X
X
X
Safety Assessments
Physical examination
X
X
General, head, eyes, ears, nose, throat, neck, cardiovascular, lungs, abdominal, 
extremities, neurologic, skin, musculoskeletal. 
Vital signs
X
X
X
X
X
See note in the Screening Period procedures (Table 1).
Electrocardiogram
X
ECGs should be recorded after the subject has been supine for at least 5 minutes.
Concomitant medication use
X
X
X
X
X
Monitor AEs
X
X
X
X
X
AEs must be collected from the time of the first dose of the study drug through the 
date of the follow-up or last visit. Monitoring for AEs will occur at every study visit.
Monitor SAEs and SARS-CoV-2 
related AEs
X
X
X
X
X
All SAEs and all AEs related to SARS-CoV-2 infection should be collected from 
the date of subject’s written consent until 30 days after the final dose of the study 
drug or subject’s participation in the study if the last scheduled visit occurs at a later 
time. Monitoring for SAEs will occur at every study visit.
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
34
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 2:
Induction Period On-Treatment Procedural Outline Up to Week 12 (Day 85) (IM011023)
Procedure/Visit Weeks
(Days)
0 
(1)
2 
(15)
4 
(29)
8 
(57)
12 
(85)
Notes
Visit Window (± n days)
0
3
3
3
3
Laboratory Tests
Hematology, chemistry, and 
coagulation
X
X
X
X
X
HBV DNA
X
X
X
To be performed only in subjects with the following HBV serology at screening: 
HBsAg negative, anti-HBc positive, HBV DNA undetectable (APPENDIX 9)
Hematocrit
X*
X
X
X
X
* For CDAI calculation at Week 0, hematocrit obtained during screening will be 
used.
For the purpose of prompt CDAI score calculation at Weeks 2, 4, 8, and 12, the 
hematocrit may be performed by a local laboratory.
Serum Igs
X
X
X
IgM, IgE, IgA, and IgG
TBNK panel
X
X
X
 
Fasting lipid panel
X
X
Subjects are required to fast for ≥ 10 hours prior to the collection of specimens for 
the fasting lipid panel.
Fasting glucose
X
X
Subjects are required to fast for ≥ 10 hours prior to the collection of specimens for 
the fasting glucose evaluation.
Urine pregnancy test
X
X
X
X
X
WOCBP only; If the urine pregnancy test is positive, a serum pregnancy test should 
be done for confirmation prior to discontinuing the subject. Study treatment should 
not be administered until the results of the confirmatory test are known.
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
35
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 2:
Induction Period On-Treatment Procedural Outline Up to Week 12 (Day 85) (IM011023)
Procedure/Visit Weeks
(Days)
0 
(1)
2 
(15)
4 
(29)
8 
(57)
12 
(85)
Notes
Visit Window (± n days)
0
3
3
3
3
 
 
 
 
 
 
 
Efficacy Assessments
Weight
X
X
X
X
X
Required for CDAI assessment
Review subject diary 
X
X
X
X
X
Prior to each scheduled visit at which CDAI/PRO2 is to be calculated, ascertain 
whether an adequate number of days of diary entries have been made. If adequate 
entries have not been made, the site should contact the subject to reschedule the visit 
(or endoscopy, if applicable), and the subject should be counseled about proper 
study procedures. See Section 9.1 and APPENDIX 8. 
CDAI 
Xa
X
X
X
X
a Calculation of CDAI eligibility criterion (220 to 450). Diary data and Hct obtained 
during the Screening Period will be used to calculate the baseline CDAI. 
See Section 9.1 and APPENDIX 10.
PRO2
X
X
X
X
X
See Section 9.1 and
Endoscopy (ileocolonoscopy) 
X*
After bowel cleansing, video ileocolonoscopic examination should be performed 
within a window of 7 days prior to the Week 12 (Day 85) visit.
* Endoscopy is required for ET subjects between Weeks 4 and 12. 
SES-CD
X
Protocol Amendment No.: 05
Date: 02-Sep-2022
36
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 2:
Induction Period On-Treatment Procedural Outline Up to Week 12 (Day 85) (IM011023)
Procedure/Visit Weeks
(Days)
0 
(1)
2 
(15)
4 
(29)
8 
(57)
12 
(85)
Notes
Visit Window (± n days)
0
3
3
3
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AE = adverse event; anti-HBc = hepatitis B core antibody; CDAI = Crohn’s Disease Activity Index; 
 
 DNA = deoxyribonucleic acid; ECG = electrocardiogram; eCRF = electronic case report form; ET = early 
termination; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; Hct = hematocrit;
; IBD = inflammatory 
bowel disease; 
; Ig = immunoglobulin; IgA = immunoglobulin A; IgE = immunoglobulin E; 
IgG = immunoglobulin G; IgM = immunoglobulin M; IHC = immunohistochemistry; IP = investigational product; 
; 
 
; 
; 
; PO = by mouth; PRO2 = patient 
(or subject) reported outcome based on the stool frequency and abdominal pain components of the CDAI; 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
37
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
; 
; SAE = serious adverse event; SARS-CoV-2 = severe acute respiratory 
syndrome coronavirus 2; SES-CD = Simple Endoscopic Score for Crohn’s Disease; 
; TBNK = T cells, B cells, 
and natural killer cells; 
; WOCBP = women of childbearing potential.
Protocol Amendment No.: 05
Date: 02-Sep-2022
38
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 3:
Maintenance Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks
(Days)
16 
(113)
22 
(155)
26
(183)
36 
(253)
44 
(309)
52 
(365)
Notes
Visit window (± n days)
3
3
3
3
3
3
Study Treatment
Dispense clinical drug supplies 
(blinded) 
X
X
X
X
X
Section 5.1.3
Dispense clinical drug supplies 
(open-label) 
X
X
X
X
X
X
Open-label IP will only be dispensed to subjects who have entered an 
open-label treatment arm during the Maintenance Period. Blinded IP 
must be dispensed to all other subjects.
At Week 52, open-label IP will only be dispensed to subjects who 
enter the OLE Period 
Study treatment 
(blinded or open-label)
X--------------------------------------------------X
See notes in previous 2 rows.
Review study treatment 
compliance
X
X
X
X
X
X
Safety Assessments
Physical examination
X
X
X
X
X
X
General, head, eyes, ears, nose, throat, neck, cardiovascular, lungs, 
abdominal, extremities, neurologic, skin, musculoskeletal 
Vital signs
X
X
X
X
X
X
See notes in the Screening Period procedures (Table 1).
Electrocardiograms 
X
ECGs should be recorded after the subject has been supine for at least 
5 minutes.
Concomitant medication use
X
X
X
X
X
X
Monitor for AEs
X
X
X
X
X
X
AE reporting begins at the time of the first dose of blinded study 
treatment.
Monitor for SAEs and SARS-
CoV-2 related AEs
X
X
X
X
X
X
SAEs and all AEs related to SARS-CoV-2 infection should be 
collected from begins at the time of signing of the ICF. 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
39
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 3:
Maintenance Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks
(Days)
16 
(113)
22 
(155)
26
(183)
36 
(253)
44 
(309)
52 
(365)
Notes
Visit window (± n days)
3
3
3
3
3
3
Laboratory Tests
See notes in the Screening Period procedures (Table 1) and 
Section 9.5.3.
Hematology, chemistry, and 
coagulation
X
X
X
X
X
X
HBV DNA 
(Week 12 responder arms)
X
X
X
For subjects with the following HBV serology at screening: HBsAg 
negative, anti-HBc positive, HBV DNA undetectable (APPENDIX 9)
HBV DNA 
(Week 12 responder arms, with 
subsequent LOR and entry to the 
open-label LOR arm)
See note
X
For subjects with HBsAg negative, anti-HBc positive, HBV DNA 
undetectable serology at screening. Subjects who have a clinical 
response at Week 12 and who subsequently have a LOR and enter the 
open-label LOR study arm: Obtain HBV DNA at the following 3 
study visits, and thereafter according to the schedule for the Week 12 
responder arm (above). (APPENDIX 9) 
HBV DNA 
(Week 12 non-responder arm)
X
X
X
X
X
For subjects with the following HBV serology at screening: HBsAg 
negative, anti-HBc positive, HBV DNA undetectable (APPENDIX 9)
Hematocrit
X
X
X
X
X
X
For the purpose of prompt CDAI score calculation at Weeks 16, 22, 
26, 36, 44, and 52, the hematocrit may be performed by a local 
laboratory. If the result cannot be obtained before the end of the visit, 
the subject should return the following day for calculation of the 
CDAI.
Serum Igs 
X
X
X
X
X
IgM, IgE, IgA, and IgG
TBNK panel
X
X
 
 
 
Fasting lipid panel
X
X
X
Subjects are required to fast for at least 10 hours prior to the collection 
of specimens for the fasting lipid panel.
Protocol Amendment No.: 05
Date: 02-Sep-2022
40
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 3:
Maintenance Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks
(Days)
16 
(113)
22 
(155)
26
(183)
36 
(253)
44 
(309)
52 
(365)
Notes
Visit window (± n days)
3
3
3
3
3
3
Fasting glucose
X
X
X
Subjects are required to fast for at least 10 hours prior to the collection 
of specimens for the fasting glucose panel.
Urine pregnancy test
X
X
X
X
X
X
WOCBP only. If the urine pregnancy test is positive, a serum 
pregnancy test should be done for confirmation prior to discontinuing 
the subject. Study treatment should not be administered until the 
results of the confirmatory test are known.
 
 
 
 
 
 
 
 
 
 
Efficacy Assessments
Weight
X
X
X
X
X
X
Required for CDAI assessment
Protocol Amendment No.: 05
Date: 02-Sep-2022
41
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 3:
Maintenance Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks
(Days)
16 
(113)
22 
(155)
26
(183)
36 
(253)
44 
(309)
52 
(365)
Notes
Visit window (± n days)
3
3
3
3
3
3
Review subject diary
X
X
X
X
X
X
Prior to each scheduled visit at which CDAI/PRO2 is to be calculated, 
ascertain whether an adequate number of days of diary entries have 
been made. If adequate entries have not been made, the site should 
contact the subject to reschedule the visit (or endoscopy, if 
applicable), and the subject should be counseled about proper study 
procedures. See Section 9.1 and APPENDIX 8.
CDAI 
X
X
X
X
X
X
See Section 9.1 and APPENDIX 10.
PRO2
X
X
X
X
X
X
See Section 9.1 and
.
Endoscopy (ileocolonoscopy)
X*
After bowel cleansing, video ileocolonoscopic examination should be 
performed within a window of 7 days prior to the Week 52 (Day 365) 
visit.
At this examination endoscopic (ileocolonoscopy) collection of ileal 
and/or colonic tissue biopsies will be performed. 
* Endoscopy is recommended for ET subjects between Weeks 16 
and 52
SES-CD
X
The SES-CD is centrally read from a video of the ileocolonoscopy 
and the result will be provided to sites (APPENDIX 12). 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
42
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 3:
Maintenance Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks
(Days)
16 
(113)
22 
(155)
26
(183)
36 
(253)
44 
(309)
52 
(365)
Notes
Visit window (± n days)
3
3
3
3
3
3
 
 
 
 
 
 
 
 
 
AE = adverse event; anti-HBc = hepatitis B core antibody; CDAI = Crohn’s Disease Activity Index; 
 
 DNA = deoxyribonucleic acid; ECG = electrocardiogram; eCRF = electronic case report form; ET = early 
termination; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus;
 IBD = inflammatory bowel disease; 
; ICF = informed consent form; Ig = immunoglobulin; IgA = immunoglobulin A; IgE = immunoglobulin E; 
IgG = immunoglobulin G; IgM = immunoglobulin M; 
; IP = investigational product; LOR = loss of response; 
 
 OL = open-label; OLE = open-label extension; 
 
 
; PRO2 = patient (or subject) reported outcome based on the stool frequency and abdominal pain components of 
the CDAI; 
; RNA = ribonucleic acid; SAE = serious adverse event; SARS-CoV-2 = 
severe acute respiratory syndrome coronavirus 2; SES-CD = Simple Endoscopic Score for Crohn’s Disease; 
; 
TBNK = T cells, B cells, and natural killer cells; 
; WOCBP = women of childbearing potential
Protocol Amendment No.: 05
Date: 02-Sep-2022
43
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
In the event multiple procedures are required at a single time point, the ECG may be obtained up to 20 minutes earlier, vital signs may 
be obtained up to 20 minutes earlier or later, and clinical laboratory sample may be obtained up to 10 minutes earlier than the nominal 
time point, 
.
Protocol Amendment No.: 05
Date: 02-Sep-2022
44
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 4:
Open-label Extension Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks 
(Days)
56
(393)
60
(421)
64
(449)
78
(547)
90
(631)
104
(729)/
ET
108 (757)
or Post-
treatment
Follow-up
Unscheduled 
Visitb
Notes
Visit Window (± n 
days)
3
3
3
3
3
7
Study Treatment
Dispense clinical drug 
supplies (open-label) 
X
X
X
X
X
Study treatment 
X--------------------------------------------------X
Review study treatment 
compliance
X
X
X
X
X
X
X
Safety Assessments
Physical examination
X
X
X
X
X
X
X
X
General, head, eyes, ears, nose, throat, 
neck, cardiovascular, lungs, abdominal, 
extremities, 
neurologic, 
skin, 
musculoskeletal 
Vital signs
X
X
X
X
X
X
X
X
See notes in the Screening Period 
procedures (Table 1).
Electrocardiograms 
X
X
ECGs should be recorded after the subject 
has been supine for at least 5 minutes.
Concomitant medication 
use
X
X
X
X
X
X
X
X
Monitor for AEs
X
X
X
X
X
X
X
X
Monitor for SAEs and 
SARS-CoV-2 related 
AEs
X
X
X
X
X
X
X
X
SAEs and all AEs related to SARS-CoV-2 
infection should be collected from begins 
at the time of signing of the ICF. 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
45
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 4:
Open-label Extension Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks 
(Days)
56
(393)
60
(421)
64
(449)
78
(547)
90
(631)
104
(729)/
ET
108 (757)
or Post-
treatment
Follow-up
Unscheduled 
Visitb
Notes
Visit Window (± n 
days)
3
3
3
3
3
7
Laboratory Tests
See 
 
 Section 9.5.3.
Hematology, chemistry, 
and coagulation
X
X
X
X
X
X
X
Hematocrit
X
X
X
X
X
X
X
 
 
 
HBV DNA
X
X
X
X
X
X
For subjects with the following HBV 
serology at screening: HBsAg negative, 
anti-HBc 
positive, 
HBV 
DNA 
undetectable (APPENDIX 9)
Serum Igs 
X
X
IgM, IgE, IgA, and IgG
TBNK panel
X
X
 
Fasting lipid panel
X
X
X
Subjects are required to fast for at least 
10 hours prior to the collection of 
specimens for the fasting lipid panel.
Fasting glucose
X
X
X
Subjects are required to fast for at least 10 
hours prior to the collection of specimens 
for the fasting glucose panel.
Urine pregnancy test
X
X
X
X
X
X
X
WOCBP only. If the urine pregnancy test 
is positive, a serum pregnancy test should 
be done for confirmation prior to 
Protocol Amendment No.: 05
Date: 02-Sep-2022
46
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 4:
Open-label Extension Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks 
(Days)
56
(393)
60
(421)
64
(449)
78
(547)
90
(631)
104
(729)/
ET
108 (757)
or Post-
treatment
Follow-up
Unscheduled 
Visitb
Notes
Visit Window (± n 
days)
3
3
3
3
3
7
discontinuing the subject. Study treatment 
should not be administered until the results 
of the confirmatory test are known.
Pharmacokinetic 
 
 
 
 
 
 
 
 
 
 
Efficacy Assessments
Weight
X
X
X
X
X
X
Required for CDAI assessment
Review subject diary
X
X
X
X
X
X
CDAI 
X
X
X
X
X
X
See Section 9.1 and APPENDIX 10.
PRO2
X
X
X
X
X
X
See Section 9.1 and
Protocol Amendment No.: 05
Date: 02-Sep-2022
47
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 4:
Open-label Extension Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks 
(Days)
56
(393)
60
(421)
64
(449)
78
(547)
90
(631)
104
(729)/
ET
108 (757)
or Post-
treatment
Follow-up
Unscheduled 
Visitb
Notes
Visit Window (± n 
days)
3
3
3
3
3
7
Endoscopy 
(ileocolonoscopy)
X*
After bowel cleansing, video ileocolono-
scopic examination should be performed 
within a window of 7 days prior to the 
Week 104 (Day 729) visit.
 
 
 
 
 
 
.
At this examination endoscopic 
(ileocolonoscopy) collection of ileal 
and/or colonic tissue biopsies will be 
performed. 
* Endoscopy is recommended for early 
termination subjects between Weeks 56 
and 104
SES-CD
X
The SES-CD is centrally read.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
48
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 4:
Open-label Extension Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks 
(Days)
56
(393)
60
(421)
64
(449)
78
(547)
90
(631)
104
(729)/
ET
108 (757)
or Post-
treatment
Follow-up
Unscheduled 
Visitb
Notes
Visit Window (± n 
days)
3
3
3
3
3
7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
49
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 4:
Open-label Extension Period On-Treatment Procedural Outline (IM011023)
Procedure/Visit Weeks 
(Days)
56
(393)
60
(421)
64
(449)
78
(547)
90
(631)
104
(729)/
ET
108 (757)
or Post-
treatment
Follow-up
Unscheduled 
Visitb
Notes
Visit Window (± n 
days)
3
3
3
3
3
7
 
AE = adverse event; anti-HBc = hepatitis B core antibody; CDAI = Crohn’s Disease Activity Index; 
 
; DNA = deoxyribonucleic acid; ECG = electrocardiogram; ET = early termination; HBsAg = hepatitis B 
surface antigen; HBV = hepatitis B virus; 
; IBD = inflammatory bowel disease; 
 
; Ig = immunoglobulin; IgA = immunoglobulin A; IgE = immunoglobulin E; IgG = immunoglobulin G; IgM = immunoglobulin M; IHC = 
immunohistochemistry; LTE = long-term extension; 
 
; PRO2 = patient (or subject) 
reported outcome based on the stool frequency and abdominal pain components of the CDAI; 
 
; ; 
SAE = serious adverse eventSARS-CoV-2 = severe acute respiratory syndrome 
coronavirus 2; SES-CD = Simple Endoscopic Score for Crohn’s Disease; 
; TBNK = T cells, B cells, and natural 
killer cells; 
; WOCBP = women of childbearing potential
b Additional procedures/assessments will be done per investigator’s discretion.
In the event multiple procedures are required at a single time point, the ECG may be obtained up to 20 minutes earlier, vital signs may 
be obtained up to 20 minutes earlier or later, and clinical laboratory sample may be obtained up to 10 minutes earlier than the nominal 
time point, 
Protocol Amendment No.: 05
Date: 02-Sep-2022
50
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
3
INTRODUCTION
3.1
Background
Tyrosine kinase 2 (TYK2) is a protein involved in interleukin (IL)-12, IL-23 and Type I interferon 
(IFN) signaling, and it is required for the activation of downstream signaling pathways. TYK2 is 
a widely expressed, non-receptor tyrosine kinase that catalyzes the phosphorylation of signal 
transducer and activator of transcription (STAT) proteins downstream of the receptors for the p40-
containing cytokines IL-12 and IL-23, as well as the Type I IFN receptor. This results in the 
activation of STAT-dependent transcription and functional responses specific for these 
cytokines.1,2,3 TYK2-dependent cytokines (eg, IL-12, IL-23 and Type I IFNs) are distinct from 
those dependent on closely related Janus kinase (JAK) family members JAK1, JAK3 (eg, IL-2, 
IL-15, IL-7, IL-6) or JAK2 (eg, erythropoietin, thrombopoietin, and granulocyte-monocyte 
colony-stimulating factor). Consequently, a TYK2 inhibitor is expected to have a highly 
differentiated profile from inhibitors of other JAK family kinases. TYK2-dependent pathways and 
the cytokine networks they modulate (eg, IL-23, IL-17, IFNα) have been implicated in the 
pathophysiology of multiple immune-mediated diseases, including Crohn’s disease (CD), 
ulcerative colitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE) and 
spondyloarthritides.
BMS-986165 is an orally administered selective TYK2 inhibitor. A comprehensive in vitro and 
in vivo characterization of BMS-986165 has been established and supports the development of 
this compound in humans. Inhibition of TYK2 is expected to provide therapeutic benefit for 
patients with CD for multiple reasons: 1) IL-12 and IL-23 have been implicated in pathogenesis 
of CD;4 2) Biologic agents targeting IL-23p19 and IL-12/23p40 cytokines have been shown to be 
efficacious in CD, and ustekinumab targeting IL-12/23p40 has been approved for the treatment of 
CD; and 3) BMS-986165 has been shown to be efficacious in psoriasis, an IL-23-mediated disease, 
in a recent Phase 2 study.5
IM011023 is a Phase 2 randomized, double-blind placebo-controlled study designed to assess the 
safety and efficacy of BMS-986165 compared to placebo in subjects with moderately to severely 
active CD. Approximately 240 subjects will be randomized in this study. After a 28-day Screening 
Period, eligible subjects will be randomized in a 3:3:2 ratio to one of three study arms: 
(i) BMS-986165 6 mg twice daily (BID) by mouth (PO); n≈90, (ii) BMS-986165 3 mg BID PO; 
n≈90, or (iii) matched placebo; n≈60. 
 
 
 
 
The Induction Period lasts from Week 0 through 
Week 12. The primary outcome for the study will be assessed at Week 12 (Day 85).
The Maintenance Period lasts from Week 12 through Week 52. This study has a treat-through 
study design. Subjects who achieve clinical response at Week 12 (Day 85), with an appropriate 
safety profile, are eligible to continue into the Maintenance Period, during which they will continue 
to receive the same blinded study treatment regimen (BMS-986165 6 mg BID or 3 mg BID or 
Protocol Amendment No.: 05
Date: 02-Sep-2022
51
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
placebo BID) that they received during the Induction Period. Open-label study arms are available 
for subjects who do not achieve a clinical response at Week 12, and for subjects in the treat-through 
study arms who have a loss of response (LOR) to blinded treatment between Week 13 and 
Week 52. The Open-label Extension (OLE) Period lasts from Week 52 through Week 104 and is 
available to subjects who complete per protocol assessments at Week 52 and who continue to 
derive clinical benefit from investigational product (IP) at that time.
 
3.1.1
Nonclinical Toxicology
The projected systemic exposure multiples presented in this section are expressed relative to the 
highest anticipated mean steady-state systemic exposure in human following oral dosing at 
6 mg BID (mean AUC[0-24h] = 857 ng•h/mL) and were calculated as animal sex-combined mean 
AUC ÷ human sex-combined mean AUC at the no-observed-adverse-effect level (NOAEL) or 
level associated with adverse findings in the pivotal toxicology studies.
In single-dose oral toxicity studies, BMS-986165 was well tolerated up to the highest administered 
doses of 75, 100, and 30 mg/kg in rats, dogs, and monkeys, respectively. 
In repeat-dose oral toxicity studies in rats, BMS-986165 was tolerated at all doses (5, 15, or 
75 mg/kg/day for 1 month; 2, 5, or 15 mg/kg/day for 3 months; and 5, 15, or 50 mg/kg/day for 
6 months). All doses were associated with on-target pharmacodynamic (PD) effects. Systemic 
exposures to BMS-986165 increased approximately dose proportionally, with no substantial sex 
differences, accumulation, or loss of exposure in all studies. In the 6-month rat toxicity study with 
2-month postdose recovery period, BMS-986165 was tolerated by rats for 6 months at oral doses 
≤50 mg/kg/day (mean sex-combined AUC[0-24h] ≤117 μg•h/mL; ≤137-fold AUC multiple). 
Consistent with BMS-986165-mediated pharmacologic immunomodulation, the primary findings 
at ≥5 mg/kg/day were decreased peripheral blood lymphocyte counts, lymphoid cellularity in 
lymph nodes and spleen, and/or suppression of T-cell dependent antibody response (TDAR) to 
keyhole limpet hemocyanin (KLH) immunogen. No BMS-986165-related infections were noted. 
Additional BMS-986165-related findings considered adverse at ≥15 mg/kg/day (mean 
sex-combined AUC[0-24h] ≥19.7 μg•h/mL; ≥ 23-fold AUC multiple) included decreased mean 
body weights and body-weight gains, decreased red blood cell (RBC) mass parameters, 
reticulocytes, platelets, and bone marrow cellularity. All BMS-986165-related changes were 
reversible except for the decreased food consumption and body weights, decreased spleen weights, 
and nonadverse increased incidence of macrophage aggregation in the lung. In conclusion, based 
on the absence of adverse findings, the NOAEL was considered to be 5 mg/kg/day (mean 
sex-combined AUC[0-24h] 4.31 μg•h/mL; 5-fold AUC multiple).
In repeat-dose (≤ 3 months) oral toxicity studies in monkeys, BMS-986165 was well tolerated at 
all doses (0.5, 1.5, or 5 mg/kg/day for 1 month; 0.75, 1.5, or 5 mg/kg/day for 3 months). All doses 
were associated with on-target PD effects. Exposures to BMS-986165 increased approximately 
dose proportionally, with no substantial sex differences, loss of exposure or accumulation noted.
There were no BMS-986165-related mortalities at any dose during any monkey toxicity studies. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
52
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
In the 9-month monkey toxicity study (doses of 0, 1, 3, or 10 mg/kg/day; the 10-mg/kg dose was 
changed to 5 mg/kg due to observed toxicity) with 2-month postdose recovery period, the principal 
BMS-986165-related findings at all doses included generally dose-dependent skin changes, which 
were likely infectious in etiology, and secondary to BMS-986165-mediated pharmacologic 
immunomodulation. The various skin changes (swollen, dry, lesion, flaking, papule, red, white, 
scab) were located throughout the body, and could be seen as early as Week 1 in some monkeys. 
The skin changes were noted at necropsy as abrasions, discoloration, foci, nodule, scab, scale, 
and/or thick, and correlated with microscopic findings in the epidermis (hyperkeratosis, erosion, 
and/or crusts) and/or dermis (mixed cell infiltrates and/or subacute inflammation). Although no 
definitive microbial pathogens were confirmed as the causative agents, the skin changes were 
considered likely infectious in etiology, as they improved following antibiotic and antiseptic 
treatments, and were present in the context of BMS-986165-mediated immunomodulation. 
Additional findings at all doses included transient slight to severe liquid feces, which improved 
clinically with veterinary treatments, dose-dependent decreased RBC mass parameters, and 
suppression 
of 
TDAR 
to 
KLH, 
and 
at 
≥3 mg/kg/day 
(mean 
sex-combined 
AUC[0-24h] ≥15.4 μg•h/mL; ≥ 18-fold AUC multiple) decreased activity, hunched posture, pale 
gums, and increased body temperature, with decreased platelets and occult blood in urine at 
10 followed by 5 mg/kg/day (mean sex-combined AUC[0-24h] 30.7 μg•h/mL; 36-fold AUC 
multiple). Following the 2-month recovery period, all BMS-986165-related findings were partially 
or fully reversible. The NOAEL was not identified due to the presence of adverse skin findings at 
doses ≥ 1 mg/kg/day (mean sex-combined AUC[0-24h] ≥3.38 μg•h/mL; ≥ 4-fold AUC multiple). 
Although the NOAEL was not determined in this study, the skin findings did not result in any 
unscheduled euthanasia or preterminal deaths, were clinically monitorable, manageable with 
veterinary treatments, and trended towards reversibility during the 2-month post-dose recovery.
BMS-986165 was not genotoxic or phototoxic. There was no evidence of teratogenicity or effects 
on development up to the highest administered doses of 75 mg/kg/day in the rat (AUC[0-24h] 
126 μg•h/mL; 147-fold AUC multiple) or 10 mg/kg/day in the rabbit (AUC[0-24h] 43.2 μg•h/mL; 
50-fold AUC multiple). BMS-986165 had no effects on male rat reproductive parameters (mating, 
fertility, and sperm morphology), or early embryonic development of the litters sired by treated 
males up to 50 mg/kg/day (AUC[0-24h] 117 μg•h/mL; 137-fold AUC multiple). In a female rat 
fertility study (preliminary results), there were no BMS-986165-related effects on mating and 
fertility parameters up to 50 mg/kg/day, and the maternal and reproductive NOAEL were 
considered to be 50 mg/kg/day (AUC[0-24h] 81.1 μg•h/mL; 95-fold AUC multiple).
In summary, the totality of the toxicity assessments demonstrates that BMS-986165, at doses 
associated with robust PD effects, has a favorable dose-related safety profile in both rodents and 
nonrodents, toxicological findings that are either fully reversible or trending towards recovery, and 
are clinically monitorable and manageable.
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
53
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
54
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
55
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
3.2
Study Rationale
3.2.1
Scientific Rationale for Study Design
IM011023 is a Phase 2 randomized, double-blind, placebo-controlled clinical study designed to 
assess the safety and efficacy of BMS-986165 compared to placebo in subjects with moderately 
to severely active CD. 
Approximately 240 subjects will be randomized in this study. After a 28-day Screening Period, 
eligible subjects will be randomized in a 3:3:2 ratio to one of three study arms: (i) BMS-986165 
6 mg BID by mouth (PO); n≈90, (ii) BMS-986165 3 mg BID PO; n≈90, or (iii) matched placebo; 
n≈60. 
 
 
 
This study has a 12-week Induction Period, a 40-week Maintenance Period, and a 52-week OLE 
Period leading to a total of up to 104 weeks of exposure to IP. The primary efficacy assessment 
occurs at Week 12. The co-primary endpoints are defined as achieving clinical remission (defined 
as Crohn’s Disease Activity Index [CDAI] of < 150) and achieving endoscopic response 
(≥50% improvement from baseline in the Simple Endoscopic Score for Crohn’s Disease 
[SES-CD]), on a population basis, at Week 12. This study is powered for the primary endpoint at 
Week 12.
This study has a treat-through design in order to explore sustained clinical benefit and safety in the 
Maintenance Period. Subjects who achieve clinical response (a reduction from baseline in the 
CDAI score of ≥100 points or a total CDAI score < 150) at Week 12 (Day 85), are eligible to enter 
the Maintenance Period and to continue on the same, double-blind treatment regimen that they 
received in the Induction Period, for up to an additional 40 weeks, up to Week 52. Subjects with 
LOR (an increase in the CDAI score of ≥100 points compared to Week 12, and a total CDAI score 
of ≥220 points, at any time from Week 13 through Week 52) in the Maintenance Period are 
eligible to enter an open-label BMS-986165 6 mg BID PO arm through Week 52.
Subjects who do not achieve clinical response at Week 12 and who have an appropriate safety 
profile are eligible to enter an open-label BMS-986165 6 mg BID PO arm, in which clinical 
response is again assessed at Week 26 (compared to Week 0). This study arm is designed to explore 
the potential benefit of ongoing treatment with BMS-986165 in subjects who do not achieve 
clinical response by that time. This may include subjects who received either BMS-986165 or 
placebo in the Induction Period. Subjects who achieve clinical response at Week 26 (compared to 
Week 0) may continue in this arm through Week 52. Subjects who do not achieve clinical response 
at Week 26 (compared to Week 0) will be considered treatment failures and must permanently 
discontinue IP and enter the Post-treatment Follow-up Period.
Protocol Amendment No.: 05
Date: 02-Sep-2022
56
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Subjects who complete per protocol assessments at Week 52 and who continue to derive clinical 
benefit from IP, in the opinion of the investigator, are eligible to enter the OLE Period, which lasts 
up to Week 104. This period explores safety and efficacy of BMS-986165 beyond Week 52.
Throughout the study, subjects who permanently discontinue IP prior to Week 104 must enter the 
Post-treatment Follow-up Period.
Taken together, these data provide a scientific rationale for studying BMS-986165 in CD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
57
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
 
Clinical disease activity is assessed in this study using the CDAI.10 CDAI is a composite 
instrument that includes patient-reported abdominal pain (AP), stool frequency (SF), general 
well-being, presence of complications of CD, hematocrit, body weight, presence of a CD-related 
abdominal mass, and the use of antidiarrheal medication. CDAI has been widely used in 
registrational clinical trial programs, but does have certain limitations eg, (i) the AP and SF 
components are weighted, (ii) the CDAI incorporates items that are not patient-reported outcomes 
(PROs), (iii) the CDAI does not include an assessment of mucosal inflammation, and (iv) the 
CDAI does not correlate well with endoscopic findings.10,11 In order to address these limitations, 
a PRO2 (patient-reported outcome based on the stool frequency and abdominal pain components 
of the CDAI) instrument that includes unweighted AP and SF will be evaluated during the study,
and mucosal inflammation will also be assessed by endoscopy 
.12 Thus, in addition 
to classical definitions of CDAI response and remission, this study will also examine PRO2-based 
endpoints, endoscopic response and remission, 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
58
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
59
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
3.2.3
Benefit/Risk Assessment
 
 
 
 
 
 
 
These data suggest that subjects with CD are likely to derive clinical benefit 
after treatment with BMS-986165.
As discussed in Section 3.1, and detailed in the Investigator’s Brochure, the safety and tolerability 
of BMS-986165 at multiple doses, including 6 mg BID, have been investigated in normal healthy 
volunteer studies, Phase 2 and Phase 3 clinical studies in psoriasis, and a Phase 2 clinical study in 
psoriatic arthritis. Overall, in the Phase 1 studies, BMS-986165 was generally well tolerated. In 
the Phase 2 study in psoriasis (IM011011), BMS-986165 was generally safe and well tolerated. In 
two Phase 3 clinical studies in psoriasis (IM011046 and IM011047), BMS-986165 6 mg QD PO 
was superior to placebo and apremilast in achieving the coprimary endpoints of PASI 75 and static 
Physician’s Global Assessment (sPGA) 0/1 responses at Week 16. In a recent Phase 2 clinical 
study in psoriatic arthritis (IM011084), BMS-986165 12 mg QD and 6 mg QD demonstrated 
significantly greater American College of Rheumatology 20 (ACR20) responses at Week 16 
compared with placebo. The IL-23/TH17 axis has been implicated as an important immune 
pathway in the pathogenesis of psoriasis, psoriatic arthritis, and CD. Taken together, these data 
indicate an overall favorable benefit-risk assessment for evaluating BMS-986165 as an oral 
treatment for patients with CD. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
60
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
The proposed dosing regimens reflect implementation of appropriate safety margins and are within 
the range of doses tested in the FIH study and within exposure margins based on comparisons of 
systemic exposure and body surface area with toxicology findings.
The effects of TYK2 inhibition by BMS-986165 have been documented in pharmacology studies, 
and the potential for benefit in CD is supported through in vivo studies showing BMS-986165 is 
highly efficacious in murine models for lupus, colitis, and psoriasis. In all models, robust efficacy 
was observed at doses providing continuous coverage of the mouse whole blood IC50 values over 
the dosing interval. 
BMS-986165 was safe when investigated in clinical study IM011002 with healthy subjects at 
single doses up to 40 mg and multiple doses of 24 mg/day (12 mg BID) for 14 days. However, 
BMS-986165 did elicit dose-dependent, mild-to-moderate acne-like skin lesions particularly after 
multiple doses of 24 mg/day (12 mg BID). Importantly, all the skin-related AEs were mild or 
moderate, with no signs or symptoms of circulatory impairment or respiratory distress in these 
subjects; required topical treatment in only a few cases, responded quickly and appropriately when 
treatment was required, and rarely required discontinuation of study drug. Due to these findings, 
the highest proposed dose for the Phase 2 study IM011023 in subjects with CD will be 6 mg BID. 
In case of the occurrence of skin-related events, subjects may receive treatment as per standard 
practice according to investigator’s discretion and followed until resolution. 
 
 
 At the maximum concentrations expected in this study (in portal vein or systemic 
circulation, as appropriate), the potential for DDIs involving CYP450 enzymes and most 
transporters is low. BMS-986165 has low turnover in in vitro metabolism studies, and a number 
of enzymes are involved in the metabolism of the fraction metabolized. Additionally, 
BMS-986165 is not an inhibitor or inducer of CYP450 enzymes at the expected clinical 
concentrations. Therefore, the potential for DDIs resulting from CYP450 inhibition or induction 
is low. BMS-986165 is a breast cancer resistance protein (BCRP) inhibitor with an in vitro 
IC50 = 0.31 μM. However, due to overlapping substrate specificity between BCRP and other 
transporters not affected by BMS-986165 at the expected concentrations, the impact of 
BMS-986165 on the exposures of potential co-medications that are BCRP substrates, such as 
rosuvastatin, was also expected to be low. Based on data from IM011015 DDI study with 
rosuvastatin, co-administration of 12 mg QD BMS-986165 and 10 mg rosuvastatin had no impact 
on the exposure of rosuvastatin. Data from a study evaluating the impact of BMS-986165 in 
women taking oral contraceptives found no impact on exposure of ethinyl estradiol or 
norethindrone. 
The reproductive toxicology studies for BMS-986165 are complete and detailed in the IB. Briefly, 
BMS-986165 is not genotoxic. BMS-986165 was neither teratogenic nor fetotoxic up to the 
highest evaluated dose of 50 mg/kg/day, and there was no evidence of teratogenicity or effects on 
development in reproductive and developmental toxicity studies in rats and/or rabbits. These 
findings support the contraception requirements for this study.
Protocol Amendment No.: 05
Date: 02-Sep-2022
61
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
In addition, a completed thorough QTc study has excluded a clinically meaningful effect on QT 
interval at doses of up to 36 mg (a supratherapeutic dose).
Taken together, these data suggest that BMS-986165 may be beneficial, safe and well tolerated in 
patients with active CD. In addition, there is no evidence for clinically significant DDIs at the 
concentrations expected in this study, or clinically meaningful effects on electrocardiogram (ECG) 
parameters.  The reproductive risk potential has not been comprehensively evaluated in humans.
BMS-986165 is an immunomodulatory IP and a potential immunosuppressant. 
 
 
 
 
 
 
 
 
The global coronavirus disease 2019 (COVID-19) pandemic has been identified as a potential risk 
to clinical study subjects in general, and it may particularly affect individuals with underlying 
chronic diseases. The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection in subjects taking BMS-986165 is unknown. The individual benefit-risk considerations 
regarding COVID-19 infection remains the responsibility of the investigator. In order to reduce
the risk of asymptomatic SARS-CoV-2 at baseline, subjects will be tested for SARS-CoV-2 during 
the screening period, as close as possible prior to randomization (refer to Section 9.10). Testing 
for SARS-CoV-2 to inform decisions on subject care during the study, should follow local standard 
of care and clinical practice. Potential subjects with recent COVID-19 infection will be excluded 
until their symptoms have completely resolved for 30 days prior to receiving first dose of IP. The 
protocol provides guidance to investigators on temporary discontinuation of IP in the case of 
suspected or proven COVID-19 infection. The protocol also provides guidance on restarting IP 
following recovery from a COVID-19 infection, which must be confirmed by a negative diagnostic 
test for SARS-CoV-2 (Section 8.2.1).
Each study visit will include a clinical assessment for signs and/or symptoms of intercurrent 
illness, including COVID-19 and other infections. Subjects will also be encouraged to contact the 
investigator if they develop an intercurrent illness between study visits. The study captures 
treatment-emergent AEs (occurring after randomization). In order to facilitate enhanced reporting 
of SARS-CoV-2–related AEs that occur during the study, these AEs (and serious adverse events 
[SAEs]) must be reported from the time of consent (Section 9.3.2).
 
 Nevertheless, 
BMS-986165 is a potential immunosuppressant, and in line with standard practice for 
immunosuppressant IPs, this study has been designed with eligibility criteria that minimize the 
risk that a subject with malignancy will be enrolled. Subjects with a clinical picture that is 
Protocol Amendment No.: 05
Date: 02-Sep-2022
62
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
suspicious for malignancy are excluded from participation. Subjects are not allowed to enter the 
study with unresected colonic adenomas or unresected colonic dysplasia. Standard-of-care 
screening for colorectal neoplasia and surveillance for dysplasia can be incorporated into the 
baseline endoscopy in this study, and into subsequent annual study endoscopies.
Subjects in IBD clinical studies may experience an increase in disease activity (ie, disease 
exacerbation or a “flare”) during their participation. Investigator recognition of treatment futility 
or a requirement for efficacious treatment outside of the study is important in the management of 
CD patients. Subjects may remain on permitted background standard of care therapy regardless of 
whether they are randomized to one of the active treatment or placebo arms. At the investigator’s 
discretion, rescue therapy can be initiated, or dosing of study medication can be discontinued at 
any time during the study. The protocol provides guidance to investigators on the level of disease 
activity that constitutes a LOR to IP in the maintenance period. The protocol also requires that 
subjects who do not achieve a clinical response at Week 12 and at Week 26 must permanently 
discontinue IP and enter the Post-treatment Follow-up Period. These design elements are intended 
to assist investigators in the recognition and management of treatment failure within the study. 
In addition to a comprehensive monitoring of safety with oversight by the investigators, medical 
monitors from both Bristol-Myers Squibb (BMS) and the partner organization, Pharmaceutical 
Research Associates (PRA), and the BMS Safety Physician, the safety of subjects will also be 
monitored by an independent Data Monitoring Committee (DMC). 
Taken together, the study design, including eligibility criteria, clinical assessments at study visits, 
study investigations such as safety bloods and endoscopies, and guidance for investigators on the 
recognition and/or management of AEs (including potential infections and disease exacerbation) 
mitigate expected risks and facilitate the detection and management of reasonably anticipated AEs 
in this study.
In summary, existing preclinical data and clinical experience in healthy subjects in combination 
with the design and doses selected for the proposed Phase 2 study indicate an overall favorable 
benefit-risk assessment of investigating BMS-986165 as an oral treatment for subjects with CD. 
Additional detailed information on the known and expected benefits and risks and reasonably 
anticipated AEs of BMS-986165 is provided in the IB.
Protocol Amendment No.: 05
Date: 02-Sep-2022
63
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
4
OBJECTIVES AND ENDPOINTS
Key study definitions are provided below.
Clinical remission
CDAI < 150 
Clinical response
A reduction from baseline in the CDAI score of ≥100 points or 
a total CDAI score < 150
Endoscopic response
≥50% improvement from baseline in the SES-CD 
 
 
 
 
 
PRO2 remission
Average daily score for abdominal pain ≤1 and average number 
of very soft (loose) or liquid (watery) stools (BSS Type 6 or 7 
only) ≤3 on the PRO2 and both not worse than baseline
 
 
BSS = Bristol Stool Scale; CD = Crohn’s Disease; CDAI = Crohn’s Disease Activity Index; 
; 
PRO2 = patient (or subject) reported outcome based on the stool frequency and abdominal pain components of the 
CDAI; SES-CD = Simple Endoscopic Score for Crohn’s Disease.
.
Safety endpoints and primary, secondary, and exploratory efficacy endpoints are specified below. 
Additional endpoints may be specified in the statistical analysis plan (SAP).
4.1
Primary Efficacy
•
Objective: To assess the effect of BMS-986165 on clinical remission and endoscopic response 
at the end of the Induction Period (Week 12 [Day 85])
−
Co-primary endpoints: 
♦Proportion of subjects achieving clinical remission at Week 12, and
♦Proportion of subjects achieving endoscopic response at Week 12, both at a population 
level.
Protocol Amendment No.: 05
Date: 02-Sep-2022
64
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
4.2
Secondary Efficacy
•
Objective: To assess the effect of BMS-986165 on clinical response at the end of the Induction 
Period
−
Endpoint: Proportion of subjects who achieve a clinical response at Week 12
•
Objective: To assess the effect of BMS-986165 on PRO2 remission at the end of the Induction 
Period
−
Endpoint: Proportion of subjects who achieve PRO2 remission at Week 12
•
Objective: To assess the effect of BMS-986165 on gut mucosal disease activity by endoscopy 
at the end of the Induction Period
−
Endpoint: Change from baseline in SES-CD at Week 12
Protocol Amendment No.: 05
Date: 02-Sep-2022
65
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
66
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
67
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
68
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
4.4
Safety
•
Objective: To assess the safety and tolerability of BMS-986165
−
Endpoint: Number and proportion of subjects experiencing AEs, SAEs, and abnormalities 
in laboratory testing, physical examination, vital signs, and ECGs
5
STUDY DESIGN
5.1
Overall Design
This is a dose-ranging, randomized, placebo-controlled, double-blind, multicenter clinical trial that 
is designed to evaluate the safety and efficacy of 2 dosing regimens of BMS-986165 in subjects 
with moderately to severely active CD. The primary objective is to assess the effect of 
BMS-986165 on the co-primary endpoints of clinical remission (CDAI < 150) and endoscopic 
response (≥50% improvement from baseline in the SES-CD), on a population basis, at the end of 
the Induction Period (Week 12).
The duration of study participation is approximately 112 weeks (784 days) in 5 periods, as follows:
•
Screening Period: up to 4 weeks (28 days; Section 5.1.1)
•
Induction Period: 12 weeks (84 days; Section 5.1.2) 
•
Maintenance Period: 40 weeks (280 days; Section 5.1.3) 
•
OLE Period: 52 weeks (364 days; Section 5.1.4)
•
Post-treatment Follow-up Period: 4 weeks (28 days; Section 5.1.4.1) 
Protocol Amendment No.: 05
Date: 02-Sep-2022
69
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Subjects should receive and be trained on an electronic patient diary at the screening visit. Subjects 
are expected to complete the electronic diary on a daily basis through the Screening Period, and 
then throughout their ongoing participation in the study.  
Endoscopic (ileocolonoscopy) evaluations and collection of ileal and/or colonic tissue biopsies 
will be performed during the Screening Period, at the end of the Induction Period (Week 12), and 
at the end of the Maintenance Period (Week 52) and OLE Period (Week 104). Ileocolonoscopy 
will also be performed at Early Termination (ET) visits that occur at least 4 weeks after the most 
recent per protocol endoscopy. These are required for ET visits occurring between Week 4 and 
Week 12 (Induction Period), and optional but recommended for ET visits occurring between 
Weeks 16 and Week 52 (Maintenance Period), and Weeks 56 and 104 (OLE Period). Endoscopic 
procedures will be video-recorded and scored for disease activity by a blinded central reader. 
 
 
 
 
 
 
Physical examinations, vital sign measurements, 12-lead ECG, and clinical laboratory evaluations 
will be performed at selected times throughout the dosing interval, as indicated in the Schedule of 
Activities (Section 2). Subjects will be closely monitored for AEs throughout the study. 
 
(Table 2, Table 3, and Table 4). 
A DMC will be instituted to monitor subject safety during the study (Section 5.1.5).
The study design schematic is presented in Figure 1 and Figure 2. 
Subjects who were randomized when Protocol v1.0 (27-Mar-2018) or Protocol v2.0 
(24-May-2018) were in effect will continue on their currently assigned double-blind study 
treatment. These subjects will complete all study procedures and assessments outlined in the 
current version of the protocol.
Protocol Amendment No.: 05
Date: 02-Sep-2022
70
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Figure 1:
Study Design Schematic: Induction and Maintenance Periods
BID = twice daily; IP = investigational product; OL = open-label; R = randomization
a Subjects who achieve clinical response at Week 12 can enter the OL “loss of response” arm at any time from 
Week 13 through Week 52. Loss of response is defined as an increase in the CDAI score of ≥ 100 points compared 
to Week 12, and a total CDAI score of ≥ 220.
NOTE: This study has a treat-through design. At Week 12, subjects who achieve clinical response (defined as a 
reduction from baseline in the CDAI score of ≥100 points or a total CDAI score < 150) are eligible to continue to the 
Maintenance Period, where they will continue to receive the double-blind treatment regimen that they received in the 
Induction Period. Subjects who have loss of response in these arms may be eligible to enter the loss of response arm, 
where they will receive open-label BMS-986165 6 mg BID PO through Week 52. Subjects who do not achieve clinical 
response at Week 12 and who have an appropriate safety profile are eligible to enter an open-label treatment arm, in 
which they will receive open-label BMS-986165 6 mg BID PO during the Maintenance Period. Subjects in this arm 
must have clinical response assessed again at Week 26 (compared to Week 0). Subjects in this arm who do not achieve
clinical response at Week 26 (compared to Week 0) will be considered treatment failures and must permanently 
discontinue IP and enter the Post-treatment Follow-up Period. Subjects in this arm who do achieve clinical response 
at Week 26 may continue IP through Week 52.
Protocol Amendment No.: 05
Date: 02-Sep-2022
71
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Figure 2:
Study Design Schematic: Open-label Extension Period
BID = twice daily; OL = open-label; OLE = open-label extension
5.1.1
Screening Period
Once subjects sign the ICF, they are considered “enrolled” in the study and they enter the 
Screening Period. During the Screening Period, subjects will complete the study procedures 
outlined in the Schedule of Activities to determine if they meet eligibility criteria (Section 6). 
In order to be eligible for the study, a subject must meet minimum disease activity criteria outlined 
in the inclusion criteria (Section 6.1), assessed by CDAI, PRO2, and SES-CD.
Subjects are expected to complete a daily diary throughout the Screening Period. AP and SF data 
recorded in the daily diary contributes to disease activity assessment during screening and 
throughout the study. The minimum daily diary requirements for CDAI/PRO2 calculations are 
outlined in Section 9.1. In order to ensure that a subject can be successfully randomized, sites 
should consider periodically confirming that subjects are successfully entering and uploading daily 
diary data (see Section 9.1, APPENDIX 10, and
.
Screening endoscopy is performed in order to determine if a subject has active intestinal 
inflammation (assessed by centrally read SES-CD), 
 
 For screening and throughout the study, endoscopy should 
ideally be performed on a different day than the office visit, in order to avoid potentially 
confounding effects of bowel preparation, the endoscopy procedure, or sedation on clinical 
assessments, especially patient-reported outcome data.
In order to avoid unnecessary endoscopies, best practice is to complete other screening 
investigations first, and to check the results of those investigations for abnormalities before a 
subject begins bowel preparation for endoscopy. This ensures that a subject continues to be 
Protocol Amendment No.: 05
Date: 02-Sep-2022
72
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
potentially eligible for the study before they commence bowel preparation. Subjects should be 
randomized within 14 calendar days of the endoscopy.
Consequently, when operationalizing the Screening Period, please consider the following:
i.
Study procedures cannot be performed before the subject signs the ICF. Once the ICF is 
signed at the screening visit, sites should consider obtaining a medical history, vital signs 
and physical examination, and other per protocol screening visit investigations such as 
blood tests, ECG, and chest x-ray (if required), giving the subject the electronic study diary 
and training on the diary, and also scheduling the screening ileocolonoscopy and Week 0 
visit. Sites should consider the turnaround time for the centrally read endoscopy result 
when scheduling the ileocolonoscopy and Week 0 visits.
ii.
The study diary requirements for the calculation of CDAI/PRO2 are outlined in 
Section 9.1. In order to ensure that a CDAI score can be determined, sites should consider 
periodically confirming that subjects are successfully entering and uploading daily diary 
data.
iii.
Sites should check the results of screening investigations to confirm that a subject remains 
potentially eligible for inclusion before they commence bowel preparation for the screening 
ileocolonoscopy.
iv.
Once the screening ileocolonoscopy is performed, subjects should be randomized within 
14 days. 
In order to be eligible for randomization, subjects must have had an inadequate response, LOR, or 
intolerance to a standard treatment course of 1 or more of the following medications, as outlined 
in Inclusion Criterion 2)g):
i.
Oral 5-ASAs, oral corticosteroids, intravenous (IV) corticosteroids, or immunomodulators, 
and/or
ii.
Infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or natalizumab.
 
 The prior medication failure or intolerance used to qualify a subject 
for Inclusion Criterion 2)g) must be recorded in source documents. 
The medications outlined in APPENDIX 7 are subject to a washout period prior to the day of 
randomization (Week 0). These medications include immunomodulators (eg, methotrexate 
[MTX], 5-azathioprine [AZA], 6-mercaptopurine [6-MP]) and biologic medications (eg, 
infliximab, adalimumab, certolizumab pegol, vedolizumab, natalizumab, and ustekinumab). In 
order to be eligible for randomization, subjects taking the medications listed in APPENDIX 7  must 
discontinue those medications prior to randomization and comply with washout periods listed in 
APPENDIX 7.
Protocol Amendment No.: 05
Date: 02-Sep-2022
73
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Some subjects will require adequate washout of biologics in order to be eligible for randomization. 
Therapeutic drug monitoring (TDM) assays that test for drug levels of these biologic medications 
are commercially available in routine clinical practice, and also available as an optional test during 
the Screening Period. The washout period for the following biologics can be waived for subjects 
who have an undetectable drug level on a TDM assay, performed either in routine clinical practice 
or during the Screening Period: (i) infliximab, (ii) adalimumab, (iii) certolizumab pegol, (iv) 
vedolizumab (if received > 14 weeks of vedolizumab therapy), or (v) ustekinumab (if received 
> 12 weeks of ustekinumab therapy). If a TDM assay is used to waive the washout period for any 
of the 5 biologics listed above, the result of the TDM assay must be available in source documents, 
and the subject cannot receive another dose of that biologic prior to randomization.
Corticosteroids (prednisone ≤20 mg QD PO or equivalent 
 or ileal-release 
budesonide ≤9 mg QD PO [eg, Entocort® EC]), 5-ASAs, probiotics, and CD-related antibiotics 
are allowed, subject to dose stabilization rules outlined in Section 6.3.
Selected subjects with complicated CD may be eligible to participate in this study. Subjects with 
perianal fistulizing disease are eligible to participate in the study, provided they meet the other 
inclusion/exclusion criteria, eg, perianal abscess should be carefully excluded during the Screening 
Period. In addition, certain subjects with asymptomatic stenosing disease may be eligible to 
participate in this study. However, subjects whose symptoms are primarily attributable to 
CD-related strictures are excluded, as obstructive symptoms or overflow diarrhea caused by a 
CD-related stricture are unlikely to respond to anti-inflammatory treatment and these may 
confound efficacy assessment. Malignancy should be carefully excluded in subjects with 
CD-related colonic strictures. 
5.1.2
Induction Period
On Day 1 of the Induction Period, subjects who have completed the screening procedures and met 
the inclusion/exclusion criteria will be randomized in a 3:3:2 ratio to receive oral BMS-986165 
6 mg BID or 3 mg BID or placebo BID, respectively, 
Video ileocolonoscopic examination and collection of ileal and/or colonic tissue biopsies should 
be performed within a window of 7 days prior to the Week 12 visit. Note: This requirement will 
Protocol Amendment No.: 05
Date: 02-Sep-2022
74
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
also apply to subjects who terminate early and have received study treatment for at least 4 weeks. 
The study diary requirements for the calculation of CDAI/PRO2 are outlined in Section 9.1.
Clinical response will be assessed at Week 12 (Section 5.1.3) to determine whether subjects will 
continue on the initially assigned double-blind dose or be offered the opportunity to switch to 
open-label BMS-986165 6 mg BID for the Maintenance Period. Subjects who were randomized 
prior to the implementation of Protocol v3.0 who have not yet reached Week 12 will likewise be 
offered the opportunity to switch to open-label BMS-986165 6 mg BID for the Maintenance 
Period, if they do not achieve a clinical response at Week 12.
If, in the opinion of the investigator, a subject requires rescue therapy for CD during the Induction 
Period, the subject must permanently discontinue study treatment, complete an ET Visit and enter 
the Post-treatment Follow-up Period. Examples of rescue therapies that are prohibited in this study 
include prednisone > 20 mg QD PO (or equivalent), intramuscular (IM) or IV corticosteroids, and 
biologic therapies that are approved for the treatment of CD in at least 1 country (
and Section 7.7.1). Endoscopy is required at the ET Visit for subjects who permanently discontinue 
study medication between Weeks 4 and 12. Discontinuation criteria are further detailed in 
Section 8.
5.1.3
Maintenance Period
There will be a seamless transition between the Induction Period and Maintenance Period.
The Maintenance Period will last up to 40 weeks (52 weeks total).
Subjects who require prohibited rescue treatment for CD (see 
 Section 7.7.1) 
during the Maintenance Period must permanently discontinue study treatment, complete an 
ET Visit, and enter the Post-treatment Follow-up Period. An exit endoscopy is recommended for 
all subjects who undergo an ET Visit between Weeks 16 and 52. This is not required for ET Visits 
within 4 weeks of the Week 12 endoscopy.
5.1.3.1
Week 12 (Day 85), End of Induction Period 
Subjects who achieve a protocol-defined clinical response at Week 12 are eligible to enter the 
Maintenance Period and continue to receive the same blinded study regimen that they received in 
the Induction Period. Blinded study treatment will continue until the subject completes Week 52, 
experiences LOR (Section 5.1.3.3), and switches to open-label treatment, or discontinues from the 
study. 
At Week 12, subjects who do not achieve a clinical response will be offered the opportunity to 
switch to open-label BMS-986165 treatment at the highest dose (6 mg BID PO), regardless of the 
initial treatment regimen received during the Induction Period. Subjects who were randomized 
prior to the implementation of Protocol v3.0 who have not yet reached Week 12 will likewise be 
offered the opportunity to switch to open-label BMS-986165 6 mg BID for the Maintenance 
Period, if they had not achieved a clinical response at Week 12.
Study treatment may be adjusted by the Sponsor should any emerging safety/tolerability issues be 
identified by the investigators, Sponsor, and/or DMC. Entrance of a subject to the Maintenance 
Protocol Amendment No.: 05
Date: 02-Sep-2022
75
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Period or to an open-label study arm is conditional on an appropriate safety profile. Any safety 
concerns should be discussed with the medical monitor.
5.1.3.2
Week 26 (Day 183) 
Subjects who do not achieve a clinical response at Week 12 and who have an appropriate safety 
profile are eligible to switch to open-label BMS-986165 treatment at the highest dose (6 mg BID), 
regardless of the initial treatment regimen received during the Induction Period.
Subjects who do not achieve protocol-defined clinical response at Week 12 and are switched to 
the open-label BMS-986165 6 mg BID study arm, as well as those who are currently receiving 
open-label BMS-986165 12 mg QD prior to implementation of Protocol v3.0, must be assessed 
for clinical response at Week 26. If clinical response at Week 26 (compared to Week 0) is 
achieved, and subjects have an appropriate safety profile, these subjects are eligible to continue on 
the open-label treatment for the remaining duration of the Maintenance Period.
Subjects in the open-label study arm who do not achieve clinical response at Week 26 (compared 
to Week 0) will be considered treatment failures and must permanently discontinue IP and enter
the Post-treatment Follow-up Period. Note: These subjects may also be discontinued at any time 
before Week 26 based on the clinical judgment of the investigator.
5.1.3.3
Week 12 Responders: Loss of Response in the Maintenance Period
Subjects who achieve clinical response at Week 12 and continue on blinded study treatment will 
be judged to have LOR if they experience a worsening of clinical disease activity between 
Weeks 13 and 52, as defined below:
•
≥ 100 point increase in CDAI score, compared with CDAI score at Week 12, and
•
Total CDAI score ≥220
These subjects are eligible to enter the open-label LOR arm, during which they will receive 
BMS-986165 6 mg BID PO through Week 52.
5.1.3.4
Week 12 Non-responders: Loss of Response after Week 26 in the Open-
label Arm
Subjects who do not achieve clinical response at Week 12 and who have an appropriate safety 
profile are eligible to enter the open-label BMS-986165 6 mg BID PO arm. Subjects in that arm 
who achieve clinical response at Week 26 will be judged to have LOR if they experience a 
worsening of clinical disease activity between Weeks 27 and 52, defined as:
•
≥ 100 point increase in CDAI score compared to Week 26, and
•
Total CDAI score ≥ 220
A subject in this open-label treatment arm with LOR after Week 26 will be considered a treatment 
failure, must permanently discontinue study treatment, and must complete the appropriate per 
protocol procedures.
Protocol Amendment No.: 05
Date: 02-Sep-2022
76
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
5.1.3.5
Week 52 (Day 365)
Video ileocolonoscopic examination and collection of ileal and/or colonic tissue biopsies should 
be performed within a window of 7 days prior to the Week 52 visit. The study diary requirements 
for the calculation of CDAI/PRO2 are outlined in Section 9.1.
5.1.4
Open-label Extension Period
Subjects who continue to derive a clinical benefit from IP at Week 52, as judged by the 
investigator, are eligible to enter the OLE Period. The OLE Period will last 52 weeks, to Week 104. 
Study visits in this period occur every 4 weeks for the first 3 months, then approximately every 
3 months afterwards, to Week 104. The final ileocolonoscopy will occur within a window of 
7 days prior to the Week 104 visit. The study diary requirements for the calculation of CDAI/PRO2 
are outlined in Section 9.1.
Subjects who require prohibited rescue treatment for CD (see 
and Section 7.7.1) 
during the OLE Period must permanently discontinue study treatment, complete an ET Visit, and 
enter the Post-treatment Follow-up Period. An exit endoscopy is recommended for all subjects 
who undergo an ET Visit between Week 56 and Week 104. This is not required for ET Visits 
within 4 weeks of the Week 52 endoscopy.
5.1.4.1
Post-treatment Follow-up
Subjects who complete the Week 104 visit, or who permanently discontinue study drug at any time 
during the study, will enter a 4-week Post-treatment Follow-up Period. Subjects will be encouraged 
to report to the investigative site any SAEs or AEs experienced during the 28-day Follow-up 
Period. 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
77
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
5.1.5
Data Monitoring Committee and Other External Committees
An external DMC will be used in this study to perform safety monitoring by blinded treatment 
group. 
Unblinded data summaries and listings will be provided to the DMC to facilitate their safety 
assessment at the regularly scheduled times and on an ad hoc basis if needed. Further details on 
the frequency, content, and methods of data reports to the DMC will be outlined in the DMC 
charter along with the processes and procedures the committee will follow. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
78
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
5.2
Number of Subjects
Approximately 240 subjects will be randomized in a 3:3:2 ratio to receive BMS-986165 at 
6 mg BID or 3 mg BID or placebo BID, respectively, during the Induction Period. Sample size 
considerations are described in Section 10.1. 
5.3
End of Study Definition
The duration of study participation for individual subjects may be up to approximately 112 weeks 
(784 days). 
The start of the study is defined as the first visit for the first subject screened. The end of the study 
is defined as the last visit or scheduled procedure shown in the Schedule of Activities (Section 2) 
for the last subject. Study completion is defined as the final date on which data were or are expected 
to be collected (Week 108 for collection of potential SAEs). 
 
 
6
STUDY POPULATION
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
subjects and that the results of the study can be valid. It is imperative that subjects fully meet all 
eligibility criteria.
All screening and randomization evaluations must be completed and reviewed to confirm that 
potential subjects meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for screening 
Protocol Amendment No.: 05
Date: 02-Sep-2022
79
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
failure, as applicable. Procedures conducted as part of the subject’s routine clinical management 
(eg, blood count) and obtained before signing of the ICF may be used for pre-screening purposes 
to allow predicting for potential eligibility during the Screening Period.
The duration of the Screening Period is up to 4 weeks. If eligibility parameters cannot be obtained 
within this time period, the Screening Period may be extended by up to 5 days if approved by the 
medical monitor. Rules for retesting and rescreening are provided in Section 6.5.1.
To be eligible for the study, subjects must meet the criteria in Section 6.1 and Section 6.2. To be 
randomized into the study on Day 1, subjects must meet the criteria in Section 6.3.
6.1
Inclusion Criteria
1) Signed Written Informed Consent
a) Willing to participate in the study and sign the ICF.
b) Willing and able to complete all study-specific procedures and visits.
2) Type of Subject and Target Disease Characteristics
a) Not applicable per Global Revised Protocol v3.0
b) Not applicable per Global Revised Protocol v3.0 
c) Not applicable per Global Revised Protocol v3.0 
d) Not applicable per Global Revised Protocol v3.0
e) Documented diagnosis of CD for at least 3 months prior to screening, including ileal, 
colonic, or ileo-colonic disease distribution, confirmed by:
♦Source: Medical records with report of a colonoscopy with ileal intubation 
(ileocolonoscopy), which shows features consistent with CD, as determined by the 
procedure performing physician, AND
♦Source: Medical record documentation of a histopathology report showing features 
consistent with CD, as determined by the local pathologist.
Note: If a histopathology report is not available, histologic samples can be obtained at 
the screening endoscopy and sent to a local laboratory to confirm diagnosis of CD before 
proceeding to randomization. The screening endoscopy must show features consistent 
with CD.
f)
Must have active moderate to severe CD, as defined by:
•
CDAI score of 220 to 450 AND
•
PRO2: Average daily score for abdominal pain ≥ 2 OR average daily number of very 
soft (loose) or liquid (watery) stools (BSS Type 6 or 7 only; 
 ≥4, 
(see Section 9.1), AND
•
Evidence of active inflammation in at least 1 of the 5 ileocolonic segments (based on 
central reading) with total SES-CD ≥ 6 or SES-CD ≥ 4 if only isolated ileitis is present 
on baseline endoscopy
Protocol Amendment No.: 05
Date: 02-Sep-2022
80
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
g) Must have had an inadequate response, LOR, or intolerance to a standard treatment course 
of 1 or more of the following medications as below:
•
Oral 5-ASAs: (eg, mesalamine, sulfasalazine, olsalazine, balsalazine) at or above the 
approved label dose (or per local standard of care) for induction therapy for at least 
6 weeks 
•
Oral corticosteroids: Prednisone ≥ 40 mg/day or equivalent for 2 weeks, or 2 failed 
attempts to taper oral corticosteroids below prednisone or equivalent 10 mg daily, or a 
relapse within 3 months of discontinuing corticosteroids
•
Intravenous (IV) corticosteroids: hydrocortisone ≥ 400 mg/day or equivalent for at least 
1 week 
•
Immunomodulators: 
AZA 
≥ 
1.5 
mg/kg/day, 
6-MP 
≥ 
0.75 
mg/kg/day, 
MTX ≥15 mg/week, or as per Institutional Practice/Country-approved label or 
guideline, for at least 12 weeks. At institutions that utilize thiopurine levels in clinical 
practice: AZA or 6-MP prescribed for at least 12 weeks with at least 1 demonstration 
of therapeutic thiopurine metabolite levels. Note: subjects with defined NUDT15 or 
TPMT mutations who experience intolerance to thiopurines at lower doses than those 
listed above may be eligible for this study. This should be discussed with the medical 
monitor on a case-by-case basis. 
•
Biologics: (eg, infliximab, adalimumab, certolizumab pegol, vedolizumab, 
natalizumab, ustekinumab) 
 Subjects can be included if 
treatment with a biologic was stopped due to primary or secondary nonresponse, or 
were intolerant to treatment, 
.
3) Age and Reproductive Status
a) Men and women aged 18 to 75 years inclusive at the time of screening
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic 
gonadotropin) within 24 hours prior to the start of study treatment.
c) Women must not be breastfeeding
d) Not applicable per Global Revised Protocol v3.0
e) Not applicable per Global Revised Protocol v3.0
f)
Not applicable per Global Revised Protocol v3.0
g) Not applicable per Global Revised Protocol v3.0
h) Azoospermic males are exempt from contraceptive requirements. WOCBP who are 
continuously not heterosexually active are also exempt from contraceptive requirements, 
and still must undergo pregnancy testing as described in this section.
i)
Not applicable per Global Revised Protocol v3.0
j)
Not applicable per Global Revised Protocol v5.0
k) Investigators shall counsel WOCBP and men who are sexually active with WOCBP on the 
importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise on the use of methods of contraception (APPENDIX 5).
l)
Male subjects should maintain their usual practice with regards to contraception (if any). 
However, no specific additional contraceptive measures are required.
Protocol Amendment No.: 05
Date: 02-Sep-2022
81
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
m) WOCBP must agree to at least an acceptable, less than highly effective means of 
contraception (see APPENDIX 5) for the duration of treatment with study treatment(s) 
(BMS-986165 or placebo).
6.2
Exclusion Criteria
1) Target Population
a) Severe or fulminant colitis that is likely to require surgery or hospitalization 
b) Presence of a diagnosis of alternative forms of colitis (infectious, inflammatory including 
ulcerative colitis, malignant, toxic, indeterminate, etc) other than CD
c) Not applicable per Global Revised Protocol v3.0
d) History of intra-abdominal abscess within the last 60 days 
i)
Previous intra-abdominal abscess that has been drained and successfully treated with a 
local standard course of antimicrobial therapy is permitted (the course must be 
completed at least 60 days prior to Day 1)
e) History of diverticulitis within the last 60 days
i)
Previous diverticulitis that has been successfully treated with a local standard course of 
antimicrobial therapy is permitted. (the course must be completed at least 60 days prior 
to Day 1)
f)
Receiving tube feeding, defined formula diets, or total parenteral alimentation
g) Current colonic dysplasia or past colonic dysplasia that has not been definitively treated 
h) History of infectious (bacterial, viral, fungal, parasitic, etc.) colitis within past 30 days; 
must be fully treated to rescreen 
i)
Use of therapeutic enema or suppository, other than required for ileocolonoscopy, within 
7 days prior to screening or during the Screening Period
j)
Not applicable per Global Revised Protocol v3.0
k) Not applicable per Global Revised Protocol v3.0
l)
Previous exposure to BMS-986165 in any study
m) Not applicable per Global Revised Protocol v.5.0 
n) Not applicable per Global Revised Protocol v3.0
o) Not applicable per Global Revised Protocol v.5.0 
p) Prior treatment with specific lymphocyte-depleting agents, such as alemtuzumab and 
rituximab, are prohibited within 12 months prior to the first dose of study treatment during 
the Induction Period.
q) Receipt of either lymphocyte apheresis or selective monocyte, granulocyte apheresis (eg, 
Cellsorba™) is prohibited within 12 months prior to the first dose of study treatment during 
the Induction Period.
r)
Previous treatment with investigational agents within 4 weeks or 5 half-lives (whichever 
is longer) prior to the first dose of study treatment during the Induction Period. Subjects 
treated with investigational agents 4 to 12 weeks prior to the first dose of study treatment 
must be discussed with the medical monitor.
Protocol Amendment No.: 05
Date: 02-Sep-2022
82
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
s) Previous stem cell transplantation, (except local stem cell therapy to treat perianal fistulae 
(eg, Alofisel® [darvadstrocel]). Please discuss on a case by case basis with the medical 
monitor.
t)
Presence of a stoma, gastric or ileoanal pouch, previous proctocolectomy or total 
colectomy, or symptomatic, stenosing disease that is likely to confound efficacy 
assessment (eg, symptomatic CD-related stricture), abscess or suspected abscess, 
pouchitis, short bowel syndrome, or history of bowel perforation. In addition, subjects with 
colonic or ileal strictures that are not passable via colonoscope that the endoscopist 
normally uses in clinical practice, or strictures in the ileum or ileocecal valve that are 
fibrotic in nature, will be excluded.
2) Other Medical Conditions and History
a) Women who are pregnant or breastfeeding
b) Any major illness/condition or evidence of an unstable clinical condition (eg, renal, 
hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, psychiatric, or 
local active infection/infectious illness) that, in the investigator’s judgment, will 
substantially increase the risk to the subject if he or she participates in the study
c) Any major surgery within the last 30 days before the first dose of study treatment, or any 
surgery planned during the course of the study
d) Not applicable per Global Revised Protocol v3.0
e) Female subjects with a breast cancer screen suspicious for malignancy, and in whom the 
possibility of malignancy cannot be reasonably excluded after additional clinical, 
laboratory, or other diagnostic evaluations
f)
Significant blood loss (> 500 mL) or blood transfusion within 4 weeks of study treatment 
administration
g) Inability to tolerate oral medication
h) Inability to undergo venipuncture and/or tolerate venous access
i)
Not applicable per Global Revised Protocol v3.0
j)
Any other sound medical, psychiatric, and/or social reason as determined by the 
investigator
k) Potential subjects with the following characteristics will be excluded from the study:
•
History of any kind of bowel resection within 6 months or any other intra-abdominal 
surgery within 3 months prior to baseline
•
History of any surgical procedure requiring general anesthesia, other than required for 
ileocolonoscopy, within 30 days prior to the first dose of study treatment, or is planning 
to undergo surgery during the study period
•
History of bleeding disorders or recent use of anti-platelet or anti-thrombotic agents 
that in the investigator’s judgment preclude safely performing endoscopic procedures 
and biopsy within the timeframe outlined in the study protocol
•
Currently on any therapy for chronic infection (eg, pneumocystis, cytomegalovirus, 
herpes simplex, herpes zoster, invasive bacterial or fungal infections, or atypical 
mycobacteria)
•
History of congenital or acquired immunodeficiency
Protocol Amendment No.: 05
Date: 02-Sep-2022
83
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
Known serious infection, defined as any infection requiring hospitalization or treatment 
with parenteral (intramuscular [IM] or IV) antimicrobial agents (eg, antibiotics, 
antiviral, antifungal, or antiparasitic agents) within 30 days of the first dose of study 
treatment, or completion of oral antimicrobial agents within 2 weeks of the first dose 
of study treatment. Antibiotics used to cover a procedure such as endoscopy would not 
exclude the subject.
−In the case of prior SARS-CoV-2 infection, symptoms must have completely 
resolved 4 weeks prior to screening and based on investigator assessment in 
consultation with the medical monitor, there are no sequelae that would place the 
subject at a higher risk of receiving BMS-986165. See Section 9.10 for additional
information regarding retesting subjects who have had prior SARS-CoV-2 
infection.
•
Previous history of herpes zoster, herpes simplex, or influenza infection within 
12 weeks 
before 
the 
first 
dose 
of 
study 
treatment 
or 
a 
history 
of 
disseminated/complicated herpes zoster infection (multidermatomal involvement, 
ophthalmic zoster, central nervous system involvement, or post-herpetic neuralgia)
•
Cancer or history of cancer or lymphoproliferative disease within the previous 5 years 
(other than adequately treated cutaneous basal cell or squamous cell carcinoma or 
resected cervix carcinoma in situ with no evidence of recurrence)
•
Class III or IV congestive heart failure, as classified by the New York Heart 
Association (NYHA) Functional Classification or any recent onset of heart failure 
resulting in NYHA Class III/IV symptoms
•
Acute coronary syndrome (eg, myocardial infarction, unstable angina pectoris) and/or 
any history of significant cerebrovascular disease (eg, stroke, cerebral hemorrhage, 
transient ischemic attack) within 24 weeks before screening
•
Administration of a live vaccine within 90 days before the first dose of study treatment 
administration. Heat-killed, or otherwise inactivated, protein or subunit vaccines (eg, 
influenza and pneumococcal vaccines), nucleic acid vaccines that do not encode 
potentially infectious virus, and replication-incompetent recombinant vector vaccines
may be received at any time on study. Furthermore, live vaccines should not be used 
during the study and within the 2 months following last dose, and any other inactivated 
vaccines (eg, tetanus, etc.) should be used according to local guidelines during the 
treatment period.
•
Current or recent (within 3 months before the first dose) gastrointestinal disease, 
including gastrointestinal surgery, that could impact the absorption of study treatment, 
or current or recent (within 6 months before the first dose) gastrointestinal resections
l)
Drug or alcohol abuse, as determined by the investigator, within 6 months prior to Day 1 
(Note: medical marijuana is not allowed)
3) Prior/Concomitant Therapy
a) Inability to comply with restrictions and prohibited treatments, as listed in Section 7.7
b) Not applicable per Global Revised Protocol v3.0
c) Not applicable per Global Revised Protocol v3.0
d) Not applicable per Global Revised Protocol v.5.0
Protocol Amendment No.: 05
Date: 02-Sep-2022
84
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
e) Inadequate response or LOR to medications that target the same pathway as BMS-986165 
such as anti-12/23p40 antibodies (eg, briakinumab) or anti-IL-23p19 antibodies 
(eg, guselkumab, 
risankizumab, 
tildrakizumab, 
brazikumab 
[MEDI2070], 
and 
mirikizumab [LY3074828]). However, subjects who have been exposed to the medications 
listed above but have not had a treatment failure (ie, an inadequate response or LOR) may 
be eligible for inclusion. Similarly, subjects who have experienced intolerance to the 
medications listed above (eg, an infusion reaction) without a treatment failure may be 
eligible for inclusion.
4) Physical and Laboratory Test Findings
a) Evidence of organ dysfunction or any clinically significant deviation from normal in 
physical examinations, vital signs, ECG, chest x-ray, or clinical laboratory determinations 
beyond what is consistent with the target population
b) Not applicable per Global Revised Protocol v3.0
c) Not applicable per Global Revised Protocol v3.0
d) Clinically significant abnormalities on chest x-ray or ECG 
e) Clinically significant abnormalities in laboratory testing including: 
•
Serum alanine aminotransferase (ALT) > 2× upper limit of normal (ULN) 
•
Serum aspartate aminotransferase (AST) > 2× ULN 
•
Serum total bilirubin > 2× ULN (Subjects with total bilirubin > 2× ULN who have a 
confirmed diagnosis of Gilbert’s syndrome are not excluded from this study but must 
be discussed with the BMS medical monitor/designee.)
•
Alkaline phosphatase > 2.5× ULN
•
Serum creatinine > 2× ULN
•
Hemoglobin level < 9 g/dL 
•
Absolute white blood cell count < 3000/mm3
•
Absolute lymphocyte count < 500/mm3
•
Neutrophil count < 1000/mm3
•
Platelet count < 100,000/mm3
f)
Positive stool culture for enteric pathogens (not including flora that are considered 
commensal within a study region) at screening visit; subjects may rescreen 30 days after 
completion of a standard treatment course with antimicrobial agents without recurrence of 
clinical symptoms
g) Not applicable per Global Revised Protocol v3.0
h) Any other significant laboratory abnormalities that, in the opinion of the investigator, might 
place the subject at unacceptable risk for participation in this study
i)
Evidence of active or latent tuberculosis (TB), as follows:
•
History of active TB prior to the screening visit, regardless of completion of adequate 
treatment
•
Has signs or symptoms of active TB as judged by the investigator
Protocol Amendment No.: 05
Date: 02-Sep-2022
85
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
A chest x-ray obtained during the Screening Period or anytime within 6 months before 
screening, with documentation, with evidence of current active or old active pulmonary 
TB 
•
Latent TB infection (LTBI) defined as positive IGRA such as QuantiFERON®-TB 
Gold, QuantiFERON®-TB Gold Plus, or T-Spot® at screening, or other diagnostic test 
in the absence of clinical manifestations
•
Note: such subjects may be eligible if (1) there are no current signs or symptoms of 
active TB and (2) the subject has received adequate documented treatment for LTBI 
within 5 years of screening OR has initiated prophylactic treatment for LTBI per local 
guidelines and is rescreened now after 1 month of treatment. The subject must agree to 
complete a locally recommended course of treatment for LTBI to continue in the study.
•
An indeterminate IGRA result at screening with no signs or symptoms of active TB
•
Note: A subject with an indeterminate IGRA test result must be retested for 
confirmation. If the second result is again indeterminate, the subject will be excluded 
from the study. If the second result is positive, the subject should be treated as having 
LTBI. If the second result is negative, the subject may be eligible provided no other 
exclusion criterion for TB is met.
j)
Evidence of, or positive test for, hepatitis B virus (HBV) at screening as defined per 
APPENDIX 9
k) Evidence of, or positive for, hepatitis C virus (HCV) at screening. A positive test for HCV 
is defined as:
i)
Positive for HCV antibody (anti-HCV) AND
ii) Positive via a confirmatory test for HCV (eg, detectable HCV RNA, HCV polymerase 
chain reaction)
l)
Positive for human immunodeficiency virus (HIV) by antibody testing (HIV-1 and 2 Ab) 
at screening. NOTE: Subjects who are newly found to be HIV-positive should be directed 
to appropriate follow-up
m) Not applicable per Global Revised Protocol v.5.0
n) Stool positive for Clostridium difficile (C. difficile) at screening visit; for full screening 
procedures, refer to APPENDIX 20. Subjects who test positive may be rescreened 30 days 
after completion of an institutional standard of care course of antibiotics and subsequent 
negative testing for C. difficile. For further clarification, contact the medical monitor.
5) Allergies and Adverse Drug Reaction
a) History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
6) Other Exclusion Criteria
a) Prisoners or subjects who are involuntarily incarcerated. If applicable to national or local 
legislation: history of being admitted to an institution under an administrative or court order
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
c) Inability to comply with the study protocol
Protocol Amendment No.: 05
Date: 02-Sep-2022
86
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
subjects and that the results of the study can be used. It is imperative that subjects fully meet all 
eligibility criteria.
6.3
Randomization Criteria
Eligible subjects must meet the following criteria on Day 1 before randomization and the first 
dose: 
1) The subject continues to satisfy all eligibility criteria. 
2) If no previous confirmation of diagnosis is available or if previous diagnosis is not deemed 
conclusive, at time of baseline endoscopy, histology must be performed and read locally to 
confirm diagnosis of CD.
3) Previous therapy must follow the rules outlined below:
a) 5-ASAs must be at stable doses for at least 2 weeks prior to the first dose of study treatment 
on Day 1 of the Induction Period.
b) Probiotics must be at stable doses for at least 2 weeks prior to the first dose of study 
treatment on Day 1 of the Induction Period.
c) CD-related antibiotics (ciprofloxacin, metronidazole, etc.) must be at stable doses for at 
least 2 weeks prior to the first dose of study treatment on Day 1 of the Induction Period.
d) Corticosteroids: 
•
Prednisone ≤ 20 mg QD PO (or equivalent) or ileal-release budesonide ≤ 9 mg QD PO 
(eg, Entocort® EC) must be stable for at least 2 weeks prior to randomization.
•
Use of IV corticosteroid is prohibited within 14 days prior to or during the Screening 
Period.
e) Prior exposure to the immunomodulators 6-MP, AZA, and MTX is permitted, but these 
agents must be discontinued for at least 4 weeks prior to the first dose of study treatment 
on Day 1 of the Induction Period. Treatment with cyclosporine, mycophenolate mofetil, 
leflunomide, tacrolimus, JAK inhibitors, or IFN must be discontinued prior to the first dose 
of study treatment on Day 1 of the Induction Period as described in APPENDIX 7. 
f)
The washout period for biologics is discussed in Section 5.1.1 and APPENDIX 7. The 
washout period for infliximab, adalimumab or certolizumab pegol may be waived for 
subjects with an undetectable drug level on a TDM assay performed in routine clinical 
practice, or in screening. The washout period for subjects who have received vedolizumab 
maintenance therapy for > 14 weeks or ustekinumab therapy for > 12 weeks may similarly 
be waived, if a TDM assay shows undetectable drug levels on a TDM assay.
6.4
Lifestyle Restrictions
No restrictions are required.
Study treatment may be taken without regard to meals. However, subjects are required to fast for 
a minimum of 10 hours before visits on which fasting lipid and fasting glucose samples will be 
drawn (at 2 of these visits [Days 1 and 85], 
Protocol Amendment No.: 05
Date: 02-Sep-2022
87
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
6.5
Screen Failures
Screen failures are defined as subjects who consent to participate in the clinical study but who are 
not subsequently randomized in the study. A minimal set of screen failure information is required 
to ensure transparent reporting of screen failure subjects, to meet the Consolidated Standards of 
Reporting Trials publishing requirements, and to respond to queries from regulatory authorities. 
Minimal information includes date of consent, demography, screen failure details, eligibility 
criteria, and any SAEs.
The study permits the rescreening of a subject who has been deemed as ineligible (screen failure) 
during the Screening Period (ie, the subject has not been randomized/has not been treated). 
Subjects who were screen-failed due to C. difficile infection must be adequately treated and 
subsequently test negative for C. difficile. The subject must be re-consented (ie, re-signing of the 
ICF), and rescreened (if outside the 28-day Screening Period window). Only 1 re-enrollment per 
subject is permissible. 
6.5.1
Retesting During the Screening Period; Rescreening
For laboratory parameters and/or assessments (Table 1) that initially do not meet eligibility 
requirements, a single retest within the 28-day Screening Period is permitted in an effort to find 
all possible well-qualified subjects, unless otherwise noted. Consultation with the medical monitor 
may be needed to identify whether repeat testing of any particular parameter is clinically relevant. 
The study permits the rescreening (after the end of the initial 4-week Screening Period) of a subject 
who discontinues the study as a pretreatment failure (ie, the subject fails screening or 
randomization and has not been treated) or if they have experienced an infection with C. difficile
and were adequately treated, and subsequently test negative for C. difficile (see APPENDIX 20). 
The subject must be re-consented and will be assigned a new identification number, and a full 
screening visit must be performed again. 
A subject can only be rescreened 1 time (ie, if the subject fails 1 rescreening attempt, no additional 
rescreening is allowed). Duration of existing treatments and required discontinuation periods shall 
be considered relative to the given screening visit and/or randomization. 
Subjects who were previously randomized in IM011023 are not eligible for rescreening, even if 
they did not receive a dose of study treatment.
If subjects test positive for C. difficile (see APPENDIX 20), they can be rescreened 30 days after 
completing a full course of standard treatment for C. difficile colitis and subsequently test negative 
for C. difficile. 
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the subject’s most current clinical state. 
7
TREATMENT
Study treatment is defined as any investigational treatment, marketed product, placebo, or medical 
device intended to be administered to a study subject according to the study randomization or 
treatment allocation.
Protocol Amendment No.: 05
Date: 02-Sep-2022
88
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Study treatment includes IP/investigational medicinal product (IMP) and consists of placebo and 
BMS-986165. Information about the pharmacology and previous experience with BMS-986165 is 
provided in Section 3.1.1 and Section 3.1.2. 
An IP, also known as IMP in some regions, is defined as a pharmaceutical form of an active 
substance or placebo being tested or used as a reference in a clinical study, including products
already with a marketing authorization but used or assembled (formulated or packaged) differently 
than the authorized form, or used for an unauthorized indication, or when used to gain further 
information about the authorized form.
Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as non-IPs.
7.1
Treatments Administered
During the Induction Period, subjects will take BMS-986165 6 mg BID or 3 mg BID or 
placebo BID over 12 weeks (Section 5.1.2). For each dose level of BMS-986165 or placebo, 
capsules are taken BID (ie, once in the morning and once in the evening). 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
89
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Study treatment for subjects with no response or who have lost response, and enter into the 
open-label portion of the study will be supplied with the 3 mg hard gelatin capsules. 
 
 
If a subject forgets a dose, but remembers within 4 hours of the expected dose, the dose should be 
taken. If it is past 4 hours, that dose should be missed, and the next expected dose should be taken 
at the usual time. 
Study treatment will be administered in the Maintenance Period, as described in Section 5.1.3 and 
illustrated in Figure 1.
Clinical Responders at Week 12: Subjects who achieve a clinical response (a reduction from 
baseline in the CDAI score of ≥100 points or a total CDAI score < 150) at Week 12 may be 
eligible to enter the double-blind and placebo-controlled Maintenance Period. During the 
Maintenance Period, subjects will take the same blinded study treatment dose level (BMS-986165 
6 mg BID or 3 mg BID or placebo BID) that was assigned during the Induction Period. Subjects 
who were randomized to the BMS-986165 12 mg QD PO study arm when Protocol v1.0 
(27-Mar-2018) or Protocol v2.0 (24-May-2018) were in effect who have not yet reached Week 12 
will continue to receive blinded BMS-986165 12 mg QD for the Maintenance Period if they 
achieve a clinical response at Week 12.
Clinical Non-Responders at Week 12: Subjects who do not achieve a clinical response at Week 12 
and who have an appropriate safety profile are eligible to switch to the BMS-986165 6 mg BID 
PO in the open-label study arm, regardless of the initial treatment regimen received during the 12-
week Induction Period. Subjects who were randomized prior to when Protocol v1.0 (27-Mar-2018) 
or Protocol v2.0 (24-May-2018) were in effect and are currently receiving open-label BMS-
986165 12 mg QD will continue on that dose until discontinuation.
At Week 26 of the Maintenance Period, the investigator will check if these subjects have achieved 
a clinical response (compared to Week 0). Subjects who achieve a clinical response at Week 26 
(compared to Week 0) will continue on open-label treatment at the highest dose level (6 mg BID), 
or continue 12 mg QD if they were already receiving it. Subjects who do not achieve a clinical 
response at Week 26 (compared to Week 0) will be considered treatment failures and must 
permanently discontinue 
Protocol Amendment No.: 05
Date: 02-Sep-2022
90
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
7.2
Method of Treatment Assignment
At the time of the screening visit, immediately after informed consent is obtained and before any 
study-related procedures are performed, the investigative site will access the interactive response 
technology (IRT) for assignment of the subject identification number. This number will be unique 
across all sites. All enrolled subjects, including those not randomized or dosed, will be assigned 
sequential subject numbers. The subject number may not be used for any other subject. If a 
potential subject is rescreened, they will be given a new identification number. 
Eligible subjects will be centrally randomized using IRT to receive oral treatment during the 
Induction Period with BMS-986165 at 6 mg BID or 3 mg BID or placebo BID, according to a 
computer-generated block randomization scheme and in accordance with stratification criteria. 
Randomization numbers will be assigned prior to dosing (Section 5.1).
Before the study is initiated, each user (at investigative sites) will receive log-in information and 
directions on how to access the IRT. Study treatment will be dispensed at study visits as shown in 
Section 2 (Schedule of Activities). 
7.3
Blinding
7.3.1
Maintaining the Blind
Blinded treatment assignments will be managed using IRT. 
All capsules (BMS-986165 3 mg and placebo) have an identical matching placebo capsule in order 
to maintain the blind. 
 Investigative 
site staff, Sponsor and designee personnel, and subjects and their families will remain blinded to 
treatment assignments.
The Sponsor may perform an unblinded interim analysis of study data prior to final data analysis. 
A SAP, which will include a section on interim analysis, will be created to fully detail the activities 
around the interim analysis.
Protocol Amendment No.: 05
Date: 02-Sep-2022
91
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
The DMC may review unblinded data summaries and listings, at their request (see Section 5.1.5). 
DMC processes and procedures will be outlined in the DMC Charter.
Designated staff of Bristol-Myers Squibb Company may be unblinded (obtain the randomization 
codes) prior to database lock to facilitate the bioanalytical analysis of 
 and 
immunogenicity. A bioanalytical scientist in the Bioanalytical Sciences department of 
Bristol-Myers Squibb Research & Development (or a designee in the external central bioanalytical 
laboratory) will be unblinded to (may obtain) the randomized treatment assignments in order to 
minimize bioanalytical analysis of samples.
7.3.2
Circumstances for Unblinding
Blinding of treatment assignment is critical to the integrity of this clinical study. However, in the 
event of a medical emergency or pregnancy in an individual subject in which knowledge of the IP 
is critical to the subject’s management, the blind for that subject may be broken by the investigator. 
The subject’s safety takes priority over any other considerations in determining if a treatment 
assignment should be unblinded.
Before breaking the blind of an individual subject’s treatment, the investigator should determine 
that the unblinded information is necessary (ie, determine if it will alter the subject’s immediate 
management). In many cases, particularly when the emergency is clearly not related to the IP, the 
problem may be properly managed by assuming that the subject is receiving active product. It is 
highly desirable that the decision to unblind treatment assignment be discussed with the medical 
monitor, but the investigator always has ultimate authority for the decision to unblind. The 
principal investigator should only call in for emergency unblinding AFTER the decision to 
discontinue the subject has been made.
In case of an emergency, the investigator has unrestricted access to randomization information via 
IRT and is capable of breaking the blind through the IRT system without prior approval from the 
Sponsor. After the unblinding, the investigator shall notify the medical monitor in order to discuss 
subject safety and whether the subject should remain in the study. The method of unblinding for 
emergency purposes is described in the IRT manual. Subject and unblinded treatment information 
and the reason for the blind being broken, must be recorded on the appropriate study status page 
of the electronic case report form (eCRF). 
In cases of accidental unblinding, contact the medical monitor and ensure every attempt is made 
to preserve the blind. Any request to unblind a subject for nonemergency purposes must be 
discussed with the medical monitor. 
7.3.3
Unblinding for Week 12 Analysis
An unblinded analysis of data through Week 12 will be performed after all subjects complete their 
Week 12 efficacy assessments or have discontinued prior to Week 12. A select group of BMS 
personnel who are not involved in the conduct of the study will review the unblinded results to 
write a clinical study report. Following the Week 12 analysis until the end of the study, the 
investigators, subjects, and clinical study team members who directly cooperate with the site staff 
will continue to remain blinded to the initial treatment assignment. Details of maintaining the blind 
Protocol Amendment No.: 05
Date: 02-Sep-2022
92
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
following the unblinded analysis will be finalized in the SAP prior to the Week 12 database lock. 
A final analysis will be performed after all subjects complete the Week 104 visit or discontinue 
prior to the Week 104 visit, and a clinical study report will be written.
7.4
Dosage Modification and/or Interruption
There is no provision for dose modification of study treatment. 
 
. Modification of other 
background CD therapies or dose regimens is not permitted during study participation. 
 
 
 If a subject’s 
clinical condition worsens (eg, flares) during the Induction Period to the extent that rescue therapy 
is required based on the investigator’s judgment, the subject must discontinue study treatment (IP 
or placebo) for appropriate alternative available treatment. 
If treatment is interrupted for a subject due to an AE, study treatment can be restarted in 
consultation with the medical monitor.
7.5
Preparation/Handling/Storage/Accountability
The IP should be stored in a secure area according to local regulations. It is the responsibility of 
the investigator to ensure that IP is only dispensed to study subjects. The IP must be dispensed 
only from official study sites by authorized personnel according to local regulations.
The product storage manager should ensure that the study treatment is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by BMS. If 
concerns regarding the quality or appearance of the study treatment arise, the study treatment 
should not be dispensed and BMS should be contacted immediately.
Study treatment not supplied by BMS will be stored in accordance with the package insert.
IP documentation (whether supplied by BMS or not) must be maintained that includes all processes 
required to ensure drug is properly stored and administered. This includes documentation of drug 
storage, administration and, as applicable, storage temperatures, reconstitution, and use of required 
processes (eg, required diluents, administration sets).
Guidance and information for the final disposition of unused study treatments are provided in 
APPENDIX 2 and the Study Reference Manual.
7.6
Treatment Compliance
Study treatment compliance will be periodically monitored using standard drug accountability 
procedures (comparing the number of capsules returned to number dispensed, considering the 
expected regimen and any reported missed doses). Drug accountability will be reviewed by the 
investigative site staff at each visit to confirm treatment compliance. Site staff will discuss any 
discrepancies with the subject and remind the subject of the importance of compliance with the 
assigned regimen. A real-time monitoring platform may be used.
Protocol Amendment No.: 05
Date: 02-Sep-2022
93
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
7.7
Concomitant Therapy
All medications taken from within 4 weeks before the first dose of study treatment until 30 days 
after the last dose of IP or last visit (whichever comes later) of study treatment must be recorded 
on the eCRF.
Other than existing treatment for CD (with restrictions as described in the eligibility criteria 
[Section 6]), concomitant medications (prescription, over-the-counter [OTC], or herbal) should be 
administered during the study only if they are prescribed for treatment of specific clinical events. 
7.7.1
Prohibited and/or Restricted Treatments
Restrictions and prohibitions on prior and concomitant medications are as follows:
1) Prior exposure to BMS-986165 is prohibited.
2)
 
 
 
 
 
 
 
 
.
3) Nonsteroidal anti-inflammatory drugs (NSAIDs) may be used on an as-needed basis during 
the study for indications other than CD-related pain (eg, headache), but use is not 
recommended. Assessment of AP is a component of the CDAI and PRO2 instruments, and 
NSAIDs are likely to confound the assessment of efficacy in this study, ie, by improving or 
exacerbating AP related to CD.
4) Prior treatment with specific lymphocyte-depleting agents, such as alemtuzumab, rituximab, 
are prohibited within 12 months prior to the first dose of study treatment during the Induction 
Period.
5) Not applicable per Global Revised Protocol v5.0
6) Receipt of either lymphocyte apheresis or selective monocyte, granulocyte apheresis (eg, 
Cellsorba™) is prohibited. 
7) Required washout periods for individual immunomodulatory and biologic drugs are provided 
in APPENDIX 7.
8) Live vaccines are prohibited 90 days prior to randomization, during the Induction Period or 
Maintenance Period, or within the 2 months after the last dose. Heat-killed, or otherwise 
inactivated, protein or subunit vaccines such as influenza and pneumococcal vaccines, nucleic 
acid vaccines that do not encode potentially infectious virus, and replication-incompetent 
recombinant vector vaccines may be received at any time on study. The effectiveness of 
vaccination in subjects receiving BMS-986165 has not been studied. Similarly, the 
effectiveness of vaccination in subjects who will shortly receive BMS-986165 (eg, subjects in 
the screening period) has not been studied.
9) For COVID-19 vaccine information, refer to APPENDIX 19.
Protocol Amendment No.: 05
Date: 02-Sep-2022
94
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
10) Exposure to any investigational drug within 4 weeks or 5 half-lives (whichever is longer) 
before the first dose of study treatment is prohibited (Exclusion Criterion 1)r); Section 6.2). 
7.7.2
Existing Therapies for Crohn’s Disease 
Use of concomitant 5-ASAs, probiotics, antibiotics to treat luminal CD, and corticosteroids 
(prednisone ≤20 mg/day or equivalent, or ileal-release budesonide ≤ 9 mg/day [eg, Entocort®
EC]) is permitted. All subjects will continue their existing CD treatment(s) during the study as 
follows (if the treatment complies with the eligibility criteria; Section 6), unless dose modification 
or discontinuation is required for subject safety reasons:
•
5-ASAs must be at stable doses for at least 2 weeks prior to the first dose of study treatment 
on Day 1 of the Induction Period and must be maintained at stable doses during the Induction 
Period. 
•
CD-related antibiotics (eg, ciprofloxacin, metronidazole, etc.) must be at stable doses for at 
least 2 weeks prior to the first dose of study treatment on Day 1 of the Induction Period and 
must be maintained at stable doses during the Induction Period. 
If subjects were previously prescribed any of the above medications, they must have been 
discontinued for ≥ 4 weeks prior to the randomization visit.
•
Probiotics must be at stable doses for at least 2 weeks prior to the first dose of study treatment 
on Day 1 of the Induction Period and must be maintained at stable doses during the Induction 
Period. During the Maintenance Period, a dose decrease is permitted if due to probiotics-related 
toxicity.
•
Corticosteroids 
−
Prednisone ≤ 20 mg QD PO (or equivalent) or ileal-release budesonide ≤ 9 mg QD PO (eg, 
Entocort® EC) must be stable for at least 2 weeks prior to randomization, with dose 
stabilization during the Induction Period.
 
 
−
Use of IV corticosteroid is prohibited within 14 days prior to or during the Screening Period 
and throughout the duration of the Induction Period and Maintenance Period. 
Immunomodulators and biologics must be discontinued prior to the first dose of study treatment 
as outlined below and are prohibited during the study:
•
Prior exposure to the immunomodulators 6-MP, AZA, and MTX is permitted, but these agents 
must be discontinued for at least 4 weeks prior to the first dose of study treatment on Day 1 of 
the Induction Period. Treatment with cyclosporine, mycophenolate mofetil, leflunomide, 
tacrolimus, or JAK inhibitors must be discontinued prior to the first dose of study treatment on 
Day 1 of the Induction Period as described in APPENDIX 7.
•
The washout period for biologics is discussed in Section 5.1.1 and APPENDIX 7. The washout 
period for infliximab, adalimumab or certolizumab pegol may be waived for subjects with an 
undetectable drug level on a TDM assay performed in routine clinical practice, or in screening. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
95
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
The washout period for subjects who have received vedolizumab maintenance therapy for > 14 
weeks or ustekinumab therapy for > 12 weeks may similarly be waived, if a TDM assay shows 
undetectable drug levels.
7.8
Treatment After the End of the Study
 
 
 
 
 
BMS reserves the right to terminate access to BMS-supplied study treatment if any of the following 
occur: a) the study is terminated due to safety concerns or other reasons, including but not limited 
to, lack of efficacy and/or failure to meet study objectives; b) development of BMS-986165 for 
the treatment of CD and/or the development of the compound is terminated for other reasons, 
including but not limited to lack of efficacy and/or failure to meet study objectives; c) the subject 
can obtain medication from a government sponsored or private health program. In all cases, BMS 
will follow local regulations. 
8
DISCONTINUATION CRITERIA
8.1
Discontinuation from Study Treatment
Subjects MUST discontinue IP (and non-IP at the discretion of the investigator) for any of the 
following reasons:
•
Subject requests to stop study treatment. Subjects who request to discontinue study treatment 
will remain in the study and must continue to be followed for protocol-specified follow-up 
procedures. The only exception to this is when a subject specifically withdraws consent for 
any further contact with him/her or persons previously authorized by subject to provide this 
information.
•
Subject meets the following criteria for laboratory abnormalities in 2 sequential laboratory 
measurements taken 3 to 5 days apart (2 additional days are permitted to allow for local 
logistics):
−
Absolute neutrophil count < 0.75× 109/L (< 750/mm3)
−
Absolute lymphocyte count < 0.5× 109/L (< 500/mm3)
−
Hemoglobin < 8.0 g/dL or a decrease of > 30% from baseline
−
Platelet count < 75× 109/L (< 75,000/mm3)
−
An increase in serum creatinine > 50% over the average of screening and baseline values 
AND an absolute increase in serum creatinine > 0.5 mg/dL (> 44.2 μmol/L)
−
Creatine kinase (CK) elevations > 10 times the ULN, unless the causality is known not to 
be medically serious (eg, exercise-induced)
Protocol Amendment No.: 05
Date: 02-Sep-2022
96
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
Subjects who develop a significant infection during the study, defined as any infection (viral, 
bacterial, or fungal) requiring parenteral antimicrobial therapy, or meeting the SAE criteria
•
Termination of the study by BMS or a specific dose arm (for subjects receiving that dose) by 
BMS. Subjects enrolled prior to Protocol v3.0 and who may have been randomized to blinded 
BMS-986165 12 mg QD treatment do not need to be discontinued.
•
Loss of ability to freely provide consent through imprisonment or involuntary incarceration for 
treatment of either a psychiatric or physical (eg, infectious disease) illness
•
Unblinding of a subject’s treatment assignment for any reason (emergency or nonemergency)
•
Inability or failure to comply with protocol requirements
•
Pregnancy
•
 
•
Subject meets any of the following criteria for liver-related laboratory abnormalities. If these 
abnormalities are identified, repeat testing should occur within 48 to 72 hours and these results 
should be discussed with the BMS medical monitor/designee. Additional recommendations on 
the recognition and investigation of potential drug-induced liver injury (DILI) are given in 
Section 9.3.8.
−
ALT or AST > 8× ULN on a single occasion
−
ALT or AST > 5× ULN for more than 2 weeks
−
ALT or AST > 3× ULN and total bilirubin > 2× ULN or international normalized ratio 
(INR) > 1.5
•
ALT or AST > 3× ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (> 5%)
•
Any other serious or severe AE or intercurrent illness, that, in the opinion of the investigator 
and after consultation with the medical monitor or designee, indicates that continued 
participation in the study is not in the best interest of the subject. If study treatment is 
discontinued due to an AE, the AE eCRF must be completed to show that the AE caused 
discontinuation
Refer to the Schedule of Activities (Section 2) for data to be collected at the time of treatment 
discontinuation and follow-up and for any further evaluations that can be completed.
In the case of pregnancy, the investigator must immediately notify the BMS medical monitor or 
designee of this event. In the event a female subject becomes pregnant during a clinical trial, the 
study treatment must be discontinued immediately. In most cases, the study treatment will be 
permanently discontinued in an appropriate manner (eg, dose tapering if necessary for subject 
safety). Please call the BMS medical monitor within 24 hours of awareness of the pregnancy. 
All subjects who discontinue BMS-986165 should comply with protocol-specified follow-up 
procedures as outlined in Section 2. The only exception to this requirement is when a subject 
withdraws consent for all study procedures including posttreatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness). Replacement of subjects is not permitted. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
97
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
If study treatment is discontinued prior to the subject’s completion of the study, the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate eCRF page.
8.1.1
Post Study Treatment Study Follow-up
Subjects who discontinue study treatment will continue to be followed for 28 days post last dose 
of study medication. 
8.2
Discontinuation from the Study
Subjects who request to discontinue study treatment (possible circumstances are listed in 
Section 8.1) will remain in the study and must continue to be followed for protocol-specified 
follow-up procedures. The only exception to this is when a subject specifically withdraws consent 
for any further contact with him/her or persons previously authorized by subject to provide this 
information. 
•
Subjects should notify the investigator of the decision to withdraw consent from future follow-
up in writing, whenever possible.
•
The withdrawal of consent should be explained in detail in the medical records by the 
investigator and entered on the appropriate eCRF page.
•
In the event that vital status (whether the subject is alive or dead) is being measured, publicly 
available information should be used to determine vital status only as appropriately directed in 
accordance with local law.
•
If the subject withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.
8.2.1
Temporary IP Discontinuation
The following criteria for temporary interruption of study treatment apply:
•
For those subjects who present with signs and/or symptoms of COVID-19 during the study, 
the study treatment should be temporarily interrupted while the subject undergoes diagnostic 
testing for SARS-CoV-2 (see Section 9.10).
•
Study treatment must be temporarily interrupted for subjects who test positive for 
SARS-CoV-2 until complete recovery (if symptomatic), and a negative molecular test result is 
obtained. Study treatment may be restarted at investigator discretion following consultation 
with the BMS medical monitor/designee provided that the subject meets the criteria outlined 
in Section 9.10.
8.3
Discontinuation of the Study/Study Stopping Rules
There will be a DMC to provide oversight of the safety in this trial as outlined in Section 5.1.5 of 
the protocol. The DMC is responsible for assessing the ongoing acceptability of the benefit/risk 
profile for the study drug in an unblinded manner. Subjects, investigators, site staff, and the 
Sponsor study team all remain blinded to study treatment throughout the conduct of the trial.
Protocol Amendment No.: 05
Date: 02-Sep-2022
98
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
The DMC will review unblinded study treatment information and safety data to adjudicate 
study treatment relatedness and to make a recommendation regarding the appropriateness of 
continuing the study, with or without study modifications, or stopping the study in the event 
that either of the following occur:
•
2 or more subjects experience an SAE of the same preferred term and that is considered related 
to the study treatment by the investigator (for example, not explained by underlying or 
intercurrent medical condition or concomitant medication)
•
2 or more subjects are discontinued due to the same laboratory parameter abnormality as 
defined by the criteria in Section 8.1
8.4
Lost to Follow-up
•
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status. This includes follow-up with persons authorized by the subject.
•
Lost to follow-up is defined by the inability to reach the subject after a minimum of 
3 documented phone calls, faxes, or emails as well as lack of response by subject to 1 registered 
mail letter. All attempts should be documented in the subject’s medical records.
•
If it is determined that the subject has died, the site will use permissible local methods to obtain 
date and cause of death.
•
If investigator’s use of third-party representative to assist in the follow-up portion of the study 
has been included in the subject’s informed consent, then the investigator may use a Sponsor 
retained third-party representative to assist site staff with obtaining subject’s contact 
information or other public vital status data necessary to complete the follow-up portion of the 
study. 
•
The site staff and representative will consult publicly available sources, such as public health 
registries and databases, in order to obtain updated contact information. If after all attempts, 
the subject remains lost to follow-up, then the last known alive date as determined by the 
investigator should be reported and documented in the subject’s medical records.
8.5
Replacement of Subjects
Subject replacement is not permitted.
9
STUDY ASSESSMENTS AND PROCEDURES
Study procedures and timing are summarized in the Schedule of Activities (Section 2). Waivers or 
exemptions from protocol-required evaluations are not allowed.
All immediate safety concerns must be discussed with the medical monitor immediately upon 
occurrence or awareness to determine if the subject should continue or discontinue treatment.
Adherence to the study design requirements, including those specified in the Schedule of Activities 
(Section 2), is essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential subjects meet 
all eligibility criteria before randomization. The investigator will maintain a screening log to record 
Protocol Amendment No.: 05
Date: 02-Sep-2022
99
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
details of all subjects screened and to confirm eligibility or record reasons for screening failure, as 
applicable.
Procedures conducted as part of the subject’s routine clinical management (eg, blood count) and 
obtained before signing of the ICF may be used for screening or baseline purposes provided the 
procedure meets the protocol-defined criteria and has been performed within the time frame 
defined in the Schedule of Activities (Section 2).
The study data includes all the information that is collected as a result of the study, including 
subject demographics, disease characteristics, clinical information, blood tests, 
, 
endoscopic videos, intestinal biopsies obtained during endoscopy, and other tests listed in 
Section 2. Study data collected during this study will be used to help understand how BMS-986165 
works in people with CD and related health conditions. The study data may also be used to help 
understand the biology of CD and related health conditions, study test performance in people with 
CD, and for other relevant health research relating to BMS-986165 or these health conditions.
9.1
Efficacy Assessments
Every effort must be made to ensure that the same evaluator(s) complete the assessment for each 
subject. If the evaluator(s) is unable to complete the evaluation, then a qualified individual with 
overlapping experience may perform the evaluation. Documentation of who performed the 
evaluation is to be recorded in source documents. Assessments are to be performed at 
approximately the same time of day throughout the duration of the study. 
Baseline assessments must be performed per protocol (standard of care assessments may not be 
used for baseline). Procedures not specified in the protocol that are part of standard care may be 
performed if they do not interfere with study procedures; any data arising from such procedures 
are not to be reported in the eCRF. 
The following procedures or tools will be used to assess subjects’ CD activity during the study 
(see schedule in Section 2): 
•
CDAI10,15,16 (APPENDIX 10) and PRO212 (
: The CDAI and PRO2 scores will 
be calculated using 7 days of subject diary entries. CDAI also includes additional components, 
as outlined in APPENDIX 10. The following rules apply to the calculation of CDAI and PRO2 
scores: 
For Week 0, if there are < 14 days between the endoscopy date and the visit date, the bowel 
preparation day will serve as the diary reference point; if there are ≥14 days between the 
endoscopy date and the visit date, the Week 0 visit date will serve as the diary reference point.
−
The collection window for subject diary data used for the calculation of CDAI and PRO2 
scores for a study visit (other than Week 0) should be a maximum of 14 days prior to the 
day of the study visit. For study visits that include endoscopy, the final day of diary 
collection is the day before the subject starts bowel preparation for ileocolonoscopy. 
−
CDAI/PRO2 calculation will be performed using the 7 latest days of diary entry in the 
collection window. These days do not have to be consecutive. At least 4 of those 7 days of 
diary data must be collected in the final 7 days of the collection window. If either of these 
criteria are not met, the CDAI/PRO2 score will be counted as “missing.”
Protocol Amendment No.: 05
Date: 02-Sep-2022
100
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
−
If the requirements outlined above are not met, CDAI/PRO2 cannot be calculated for that 
study visit. If this occurs prior to the Week 0 visit, the subject cannot meet Inclusion 
Criterion 2)f), cannot be randomized, and must be screen-failed. 
−
Prior to each scheduled visit at which CDAI/PRO2 is to be calculated, determine whether 
an adequate number of diary entries have been made. If adequate entries have not been 
made, the site should contact the subject to reschedule the visit (or endoscopy, if 
applicable), and the subject should be counseled about proper study procedures.
•
SES-CD17 (APPENDIX 12): The SES-CD assesses the size of mucosal ulcers, the ulcerated 
surface, the endoscopic extension, and the presence of stenosis. This blinded assessment will 
be carried out by Alimentiv Clinical Trials, and the results will be considered final for this 
study.
•
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
101
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
 
 
 
 
 
 
9.2
Laboratory Assessments
The following laboratory tests will be performed according to the Schedule of Activities in 
Section 2 to gather more information about CD activity: 
 
; stool C. difficile; quantitative immunoglobulins (IgM, IgE, IgA, IgG); T, B, and natural 
killer (TBNK) cells; and hematocrit (ie, for CDAI). For the purpose of prompt CDAI score 
calculation from Week 2 through Week 52 and at Week 104, the hematocrit may be performed by 
a local laboratory.
9.3
Adverse Events
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or the study, or that caused the subject to 
discontinue before completing the study. 
The definitions of an AE or SAE can be found in APPENDIX 3.
 
 
9.3.1
Adverse Events of Interest
AEIs are AEs for a particular product or class of products that a Sponsor may wish to monitor 
carefully. AEIs may be serious or nonserious. Such events may require further investigation to 
better characterize and understand them. In the BMS-986165 clinical development program, 
certain skin-related AEs (eg, acne) and infection AEs have been identified as potential AEIs; 
however, there has been no definitive assessment on the causal relationship between these events 
and treatment with BMS-986165. 
In addition, given that immunomodulation is consistent with the mechanism of action of 
BMS-986165, malignancies are considered to be an important potential risk of therapy with 
BMS-986165 and should be monitored as AEIs. Malignancies were not identified as adverse 
findings in nonclinical studies and no serious adverse reactions of malignancy have been reported 
to date in clinical studies of BMS-986165.
For purposes of reporting these AEIs, specialized eCRF pages will be required to collect additional 
information related to characterization, social/family history, risk factors, signs/symptoms, 
diagnostics, and treatments.
Protocol Amendment No.: 05
Date: 02-Sep-2022
102
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
9.3.2
Time Period and Frequency for Collecting AE and SAE Information
The collection of nonserious AE information should begin at initiation of study treatment until the 
follow-up visit at Week 108 or the last visit, at the time points specified in the Schedule of 
Activities (Section 2). Nonserious AE information should also be collected from the start of the 
treatment period at Day 1.
The Reference Safety Information in Appendix 1 of the IB should be used to determine 
expectedness of SAEs for expedited reporting. 
All SAEs must be collected from the time of signing the consent, including those thought to be 
associated with protocol-specified procedures, and within 30 days of discontinuation of dosing.
All AEs and SAEs related to SARS-CoV-2 infection must be collected from the time of signing 
the consent to the end of the safety follow-up period (30 days after treatment discontinuation) 
 
The investigator must report any SAE that occurs after this time period and that is believed to be 
related to study treatment or protocol-specified procedure.
•
Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the eCRF module.
•
All SAEs will be recorded and reported immediately to Sponsor or designee but no later than 
24 hours after awareness of the event, as indicated in APPENDIX 3. 
•
The investigator will submit any updated SAE data to the Sponsor or designee immediately 
but no later than  24 hours of updated information being available.
Investigators are not obligated to actively seek AEs or SAEs in former study subjects. However, 
if the investigator learns of any SAE, including a death, at any time after a subject has been 
discharged from the study, and he/she considers the event reasonably related to the study treatment 
or study participation, the investigator must promptly notify the Sponsor or designee.
The method of evaluating and assessing causality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in APPENDIX 3.
9.3.3
Method of Detecting AEs and SAEs
AEs can be spontaneously reported or elicited during open-ended questioning, examination, or 
evaluation of a subject. In order to prevent reporting bias, subjects should not be questioned 
regarding the specific occurrence of 1 or more AEs. 
9.3.4
Follow-up of AEs and SAEs
•
AEs should be followed to resolution or stabilization, or until they are reported as SAEs if they 
become serious (APPENDIX 3).
•
Follow-up is also required for AEs that cause interruption or discontinuation of study treatment 
and for those present at the end of study treatment as appropriate. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
103
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
All identified AEs must be recorded and described on the “adverse events” page of the eCRF. 
Completion of supplemental eCRFs may be requested for AEs and/or laboratory abnormalities 
that are reported/identified during the course of the study.
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs, and AEIs (as defined in Section 9.3.1) will be followed until 
resolution, until the condition stabilizes, until the event is otherwise explained, or until the subject 
is lost to follow-up, as defined in Section 8.4.
Further information on follow-up procedures is given in APPENDIX 3.
9.3.5
Regulatory Reporting Requirements for SAEs
•
Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects and the safety of a product 
under clinical investigation are met.
•
An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will file it along with 
the IB and will notify the Institutional Review Board/Independent Ethics Committee, if 
appropriate according to local requirements.
The Sponsor or designee will be reporting AEs to regulatory authorities and ethics committees 
according to local applicable laws including European Directive 2001/20/EC and FDA Code of 
Federal Regulations (CFR) 21, Parts 312 and 320. Suspected, unexpected, serious adverse 
reactions are a subset of SAEs and will be reported to the appropriate regulatory authorities and 
investigators following local and global guidelines and requirements.
9.3.6
Pregnancy
If, following initiation of the study treatment, it is subsequently discovered that a subject is 
pregnant or may have been pregnant at the time of study exposure, including during at least 
5 half-lives after product administration, the investigator must immediately notify the BMS 
medical monitor/designee of this event and complete and forward a Pregnancy Surveillance Form 
to BMS designee within 24 hours of awareness of the event and in accordance with SAE reporting 
procedures described in APPENDIX 3.
Pregnancy occurring in a female subject is a reason for discontinuation of study treatment (see 
Section 8.1). Protocol-required procedures for study discontinuation (except endoscopy) and 
follow-up should be performed on the subject.
Any pregnancy that occurs in a female partner of a male study subject should be reported to PRA 
Drug Safety. In order for Sponsor or designee to collect any pregnancy surveillance information 
from the female partner, the female partner must sign an ICF for disclosure of this information. 
Information on this pregnancy will be collected on the Pregnancy Surveillance Form.
Protocol Amendment No.: 05
Date: 02-Sep-2022
104
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
9.3.7
Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the AE eCRF page or 
SAE Report Form electronic, as appropriate. 
•
Any laboratory test result that is clinically significant or meets the definition of an SAE 
•
Any laboratory test result abnormality that required the subject to have study treatment 
discontinued or interrupted
•
Any laboratory test result abnormality that required the subject to receive specific corrective 
therapy
If a laboratory test result meets the definition of an AE or SAE, the laboratory test result should be 
reported as an AE or SAE and submitted to PRA Drug Safety, as specified in APPENDIX 3.
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, “anemia” is preferable to “low hemoglobin value”). 
9.3.8
Potential Drug-induced Liver Injury 
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (APPENDIX 3). The Sponsor will require follow-up 
testing when DILI is suspected (eg, HBV DNA, IgM anti-HEV, HEV RNA, IgM & IgG anti-HSV, 
etc).
Potential DILI is defined by presence of all of the following characteristics: 
•
Transaminase (ALT or AST) elevation > 3× ULN
•
Total bilirubin > 2× ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase)
•
No other immediately apparent possible causes of transaminase elevation and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, preexisting chronic or acute 
liver disease, or the administration of other drug(s) known to be hepatotoxic 
Identification of a clinically significant elevation(s) in liver-related chemistry or coagulation tests 
(including those defined in Section 8.1, or meeting the definition for potential DILI) should be 
followed by repeat testing of ALT, AST, total bilirubin, ALP, and INR within 48 to 72 hours to: 
(1) confirm the abnormalities, and (2) determine if they are increasing or decreasing.
Investigators should consult with the BMS medical monitor/designee immediately if a subject 
meets the laboratory criteria for potential DILI.
Protocol Amendment No.: 05
Date: 02-Sep-2022
105
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Investigators should consider gathering additional clinical information and laboratory and imaging 
tests to seek other possible causes of the observed liver blood test abnormalities, including (but 
not limited to) acute viral hepatitis, alcoholic and autoimmune hepatitis, biliary obstruction (small 
and large duct), cardiovascular causes (eg, ischemic hepatitis), nonalcoholic steatohepatitis, and 
the effect of concomitant treatments.
A review of all concomitant medications should include herbal medicines, dietary supplements, 
nonprescription OTC medications, including acetaminophen/paracetamol, and occupational 
exposure to chemical agents.
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 9.3 and APPENDIX 3 for reporting 
details). All subjects with clinically significant abnormalities in liver-related blood tests, or 
potential DILI, must be followed until all abnormalities return to normal or to the baseline state.
9.3.9
Other Safety Considerations
Any significant worsening noted during interim or final physical examinations, ECG, or any other 
potential safety assessment required or not required by protocol should also be recorded as a 
nonserious or serious AE, as appropriate, and reported accordingly.
9.4
Overdose
For this study, any dose of BMS-986165 that is more than 2-days’ worth of study treatment within 
a 24-hour time period will be considered an overdose.
In the event of an overdose, the investigator should do the following:
1) Contact the medical monitor immediately.
2) Closely monitor the subject for AEs/SAEs and laboratory abnormalities until BMS-986165 
can no longer be detected systemically (at least 3 days).
3) Document the quantity of the excess dose as well as the duration of the overdosing in the eCRF.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the medical monitor based on the clinical evaluation of the subject. 
9.5
Safety
Planned time points for all safety assessments are listed in the Schedule of Activities (Section 2). 
All urgent safety concerns must be discussed with the Sponsor immediately upon occurrence or 
awareness to determine if the subject should continue or discontinue treatment.
Safety evaluations that will be performed in addition to AE monitoring are physical examination 
(Section 9.5.1), TB screening (Section 9.5.2), vital signs, ECGs, concomitant medication use, 
laboratory tests (Section 9.5.3).
Planned time points for all safety assessments are listed in the Schedule of Activities.
Protocol Amendment No.: 05
Date: 02-Sep-2022
106
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
9.5.1
Physical Examinations
Schedules for physical examinations are provided in Section 2. Complete physical examinations 
may be performed by a Doctor of Medicine (MD), or someone who is authorized to perform the 
examinations by training and has been delegated this task by the Principal investigator. Key aspects 
of the examination should evaluate important body systems as clinically indicated. These body 
systems can include lymph nodes, liver, spleen, and breast at the discretion of the examiner. Every 
effort should be made to ensure the same evaluator will complete the examination for each subject 
at all visits throughout the study. Documentation of who performed the examination is to be 
recorded in source notes. 
9.5.2
Tuberculosis Screening and Chest X-ray
A chest x-ray and physical examination are part of the process to assess a subject’s eligibility, as 
outlined in Section 2, and as defined in Exclusion Criterion 4)i) (Section 6.2). A chest x-ray at the 
screening visit is required if not already performed and documented within 6 months of obtaining 
written informed consent. A subject must not have active signs or symptoms of TB, as judged by 
the investigator, to be eligible for the study.
In addition to a complete physical examination and medical history to evaluate exposure to TB, all 
subjects will have a screening test, an IGRA (eg, T-spot® or QuantiFERON®-TB Gold, or
QuantiFERON®-TB Gold Plus) performed centrally. If unable to obtain central laboratory results, 
an IGRA test could be obtained locally, after consultation with the PRA medical monitor. A 
negative IGRA performed within 6 months of the screening visit may be acceptable, provided a 
copy of the report is in the subject's source documentation, and the subject has no new risks for 
LTBI in the interim. A subject with an indeterminate IGRA test result must be retested for 
confirmation. If the second result is again indeterminate, the subject will be excluded from the 
study. If the second result is positive, the subject should be treated as having LTBI provided there 
are no signs or symptoms of active TB. If the second result is negative, the subject may be eligible
provided no other exclusion criterion for TB is met.
9.5.3
Clinical Safety Laboratory Assessments
A central laboratory will perform assessments of safety laboratory assessments (except pregnancy 
tests) and provide reference ranges and laboratory reports. For the purpose of prompt CDAI score 
calculation from Week 2 through Week 52 and at Week 104, the hematocrit may be performed by 
a local laboratory. If the result cannot be obtained before the end of the visit, the subject should 
return the following day for calculation of the CDAI. Investigators must document their review of 
each laboratory safety report. Any laboratory test result that the investigator considers clinically 
relevant for safety is to be recorded on the appropriate AE page of the eCRF (Section 9.3.7). 
Results of clinical laboratory tests performed during the Screening Period must be available prior 
to randomization. The laboratory parameters to be assessed are as follows: 
•
Hematology: hemoglobin, hematocrit, total leukocyte count (including absolute neutrophil 
count and absolute lymphocyte count), platelet count, RBC count, and manual differential 
(separate smear) 
Protocol Amendment No.: 05
Date: 02-Sep-2022
107
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
Chemistry: AST, ALT, gamma glutamyltransferase, total bilirubin, direct bilirubin, alkaline 
phosphatase, lactate dehydrogenase, creatinine, blood urea nitrogen, uric acid, fasting glucose, 
fasting lipids, total protein, albumin, sodium, potassium, chloride, calcium, phosphorus, 
magnesium, CK, creatinine clearance (screening only), and thyroid-stimulating hormone blood 
test (with reflex T3 and T4 testing)
•
Coagulation: prothrombin time, INR, and either partial thromboplastin time or activated partial 
thromboplastin time
•
Tests performed after a ≥10-hour fast: lipid panel (total cholesterol, high-density lipoprotein 
cholesterol, low-density lipoprotein cholesterol, and triglycerides) and glucose 
•
Urinalysis: protein, glucose, blood, leukocyte esterase, specific gravity, pH; microscopic 
examination of the sediment if blood, protein, or leukocyte esterase are positive on dipstick; 
spot urine will be assessed for urine protein and urine creatinine
•
Serology to be performed at screening: anti-HCV, HCV RNA if anti-HCV is positive or 
indeterminate, HBsAb, HBsAg, anti-HBc, reflex to HBV DNA, HIV-1 and -2 antibody, and 
TB testing 
•
Quantitative serum immunoglobulins: IgG, IgE, IgA, and IgM
•
TBNK
•
In addition, urine pregnancy testing will be performed for WOCBP, and follicle-stimulating 
hormone (FSH) will be measured to confirm postmenopausal status (as applicable; at screening 
only). 
9.5.4
Imaging Safety Assessment
Not applicable. 
 
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
108
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
109
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
 
 
 
 
 
 
 
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
110
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
111
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
112
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
113
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
114
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Sample Collection and Storage
All requests for access to samples or data for additional research will be vetted through a diverse 
committee of the study Sponsor’s senior leaders in Research and Development (or designee) to 
ensure the research supports appropriate and well-defined scientific research activities. 
•
 
 
Samples kept for future research will be stored at the BMS Biorepository in 
 or 
an independent, BMS-approved storage vendor.
The manager of these samples will ensure they are properly used throughout their usable life and 
will destroy the samples at the end of the scheduled storage period, no longer than 15 years after 
the end of the study or the maximum allowed by applicable law.
Transfers of samples by research Sponsor to third parties will be subject to the recipient’s 
agreement to establish similar storage procedures.
Samples will be stored in a coded fashion, and no researcher will have access to the key. The key 
is securely held by the investigator at the clinical site, so there is no direct ability for a researcher 
to connect a sample to a specific individual.
Protocol Amendment No.: 05
Date: 02-Sep-2022
115
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Further details of sample collection and processing will be provided to the site in the procedure 
manual.
 
 
 
9.10
SARS-CoV-2 Testing
Diagnostic testing for SARS-CoV-2 infection refers to a molecular test (PCR) or antigen test for 
SARS-CoV-2 infection, performed according to local standard of care. PCR testing is preferred. 
Antibody testing is not acceptable as a diagnostic test for SARS-CoV-2 infection.
Diagnostic testing for SARS-CoV-2 infection should be performed as close as possible to 
randomization and must be confirmed as “negative” prior to randomization.
Subjects will be screened for AEs (including signs and symptoms of COVID-19) at each study 
visit. Subjects will be instructed to contact the investigator at any time if they develop an 
intercurrent illness, including a diagnosis, or signs and symptoms of COVID-19, which will enable 
close monitoring and additional screening for the infection between study visits. 
The investigator should obtain a diagnostic test for SARS-CoV-2 infection if COVID-19 is 
clinically suspected. If a subject report having recent direct contact with someone known to have 
COVID-19, the subject should undergo diagnostic testing for SARS-CoV-2. 
IP should be temporarily interrupted in subjects who present with signs and/or symptoms 
suggestive of COVID-19 while the subject undergoes diagnostic testing for SARS-CoV-2 
infection. This testing should be performed as soon as feasible.
Protocol Amendment No.: 05
Date: 02-Sep-2022
116
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
IP must be temporarily interrupted in subjects who test positive for SARS-CoV-2 infection. Such 
subjects should continue to be followed by the investigator. Such subjects must meet all the criteria 
outlined below prior to restarting IP. The final decision to restart IP must be made in consultation 
with the BMS medical monitor/designee.
Subjects with a positive diagnostic test for SARS-CoV-2 infection during the screening period 
may be considered eligible for the study once they meet all eligibility criteria related to active 
infection, and after meeting the criteria outlined below.
Criteria to rescreen or recommence IP after a positive SARS-CoV-2 test:
•
Negative follow-up molecular test for COVID-19 based on institutional, local, or regional 
guidelines, and
•
At least 10 days (20 days for severe/critical illness) have passed since symptoms first appeared 
or positive test result, and
•
At least 24 hours have passed since last fever without the use of fever-reducing medications, 
and
•
Symptoms (eg, cough, shortness of breath) have resolved, and
•
In the opinion of the investigator, there are no COVID-19 sequelae that may confound the 
assessment of safety or efficacy within the study and place the subject at a higher risk from 
receiving investigational treatment, and
•
The above must be discussed with the BMS medical monitor prior to rescreening or 
recommencing IP (as applicable).
10
STATISTICAL CONSIDERATIONS
10.1
Sample Size Determination 
Approximately 240 subjects will be randomized into 1 of 3 treatment arms on Day 1 in a 3:3:2 
ratio, resulting in approximately 90 subjects in each BMS-986165 dose arm and 60 subjects in the 
placebo arm. Sample size is based on the power to compare the response rates of the BMS-986165 
3 mg BID treatment arm with placebo, or the BMS-986165 6 mg BID treatment arm with placebo 
for each of the co-primary endpoints at Week 12 (Day 85). A Bonferroni adjustment will be used 
to compare the BMS-986165 3 mg BID and BMS-986165 6 mg BID active treatment groups to 
placebo. Response rates for clinical remission and endoscopic response are based on published 
response rates using similar endpoints.27
 
 
. With a 2-sided chi-square test at a significance level 0.025 and a sample 
size of 90 subjects for each BMS-986165 treatment arm and 60 subjects in the placebo arm, 
 
 
 Additionally, with a 
2-sided chi-square test at a significance level of 0.025 and a sample size of 90 subjects for each 
BMS-986165 treatment arm, and 60 in the placebo arm, 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
117
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
10.2
Populations for Analyses
Population
Description
Enrolled 
All subjects who sign the ICF 
Full Analysis Set (FAS)
All subjects who are randomized to study treatment; subjects will be 
grouped according to the treatment to which they are randomized within the 
IRT. The FAS population is the primary efficacy analysis population
 
 
As-treated
All subjects who receive at least 1 dose of double-blind study treatment, 
analyzed according to the treatment actually received, regardless of 
assigned treatment
FAS = Full Analysis Set; IRT = interactive response technology; 
 
10.3
Endpoints
10.3.1
Primary Endpoints
The co-primary efficacy endpoints for BMS-986165 3 mg BID compared to placebo and 
BMS-986165 6 mg BID compared to placebo are: 
•
Clinical remission at Week 12 assessed as the proportion of subjects achieving clinical 
remission at Week 12 
•
Endoscopic Response at Week 12 assessed as the proportion of subjects achieving an 
endoscopic response at Week 12
10.3.2
Secondary Endpoints
Secondary efficacy endpoints for BMS-986165 doses compared to placebo are defined below: 
•
Clinical response at Week 12 assessed as the proportion of subjects achieving clinical response 
at Week 12
•
PRO2 remission at Week 12 assessed as the proportion of subjects achieving PRO2 remission 
at Week 12
•
Change from baseline in SES-CD at Week 12
Protocol Amendment No.: 05
Date: 02-Sep-2022
118
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
10.4
Efficacy Analyses
The SAP will be developed and finalized before database lock for the interim analysis, if any, (see 
Section 10.6.3), and will provide detailed specifications of the analysis of all efficacy endpoints 
and safety and will also describe the selection of subjects to be included in the analyses and 
procedures for accounting for missing data. This section provides a summary of planned statistical 
analyses of the efficacy endpoints.
Categorical data will be summarized as frequency counts and percentages. Continuous data will 
be summarized using n, mean, standard deviation, median, minimum, and maximum unless 
otherwise specified. Subjects who continue the randomized double-blind treatment group will be 
summarized according to their original treatment assignment during the Maintenance Period. 
Subjects who switch to open-label treatment of the 6 mg BID dose at Week 12 or Week 26 will be 
summarized separately.
Subjects who were enrolled prior to Protocol v3.0 and were assigned to BMS-986165 12 mg QD 
will not be included in the primary efficacy analysis. Further details of summarizing data for these 
subjects will be included in the SAP.
10.4.1
Co-primary Endpoint Analyses
The co-primary endpoints, the proportion of subjects achieving clinical remission at Week 12 and 
the proportion of subjects achieving endoscopic response at Week 12, will be analyzed separately 
using stratified Cochran-Mantel-Haenszel (CMH) tests stratified by geographic region (US, Japan, 
 
 
 Differences in response rates and corresponding 2-sided 95% and 97.5% 
confidence intervals (CIs) will be provided along with the point estimates and corresponding 
95% and 97.5% CIs for each treatment group using a binomial model. The odds ratio (odds in an 
active treatment group/odds in placebo), and the corresponding 2-sided 95% and 97.5% CIs will 
be provided as well.
10.4.2
Imputation Methods for Co-primary Endpoints
Non-responder imputation (NRI) will be used for co-primary efficacy endpoints for subjects who 
discontinue treatment prior to Week 12 and have no Week 12 assessments after treatment 
discontinuation, 
 initiate use or 
continue to use prohibited medications in the Induction Period, require surgical procedure(s) for 
treatment of CD or related complications in the Induction Period, or have otherwise missing 
endpoint data at the Week 12 (Day 85) timepoint, ie, the NRI will be the primary method of 
imputation for the co-primary efficacy endpoints.
10.4.3
Sensitivity Analyses for the Co-primary Endpoints
The following sensitivity analysis will be performed on the co-primary efficacy endpoints:
Protocol Amendment No.: 05
Date: 02-Sep-2022
119
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
Additional sensitivity analyses of the co-primary endpoints may be defined in the SAP.
10.4.4
Secondary Endpoint Analyses
The analysis model for the binary secondary endpoints will use CMH tests 
 
 
 
 Differences in response rates and corresponding 2-sided 
95% and 97.5% CIs will be provided along with the point estimates and corresponding 95% and 
97.5% CIs for each treatment group using a binomial model. The odds ratio (odds in an active 
treatment group/odds in placebo), and the corresponding 2-sided 95% and 97.5% CIs will be 
provided as well.
The analysis model for continuous secondary endpoints will use analysis of covariance 
(ANCOVA) 
 
 
 baseline value will be added into the model as a covariate. Treatment differences 
based on least squares means and the corresponding 2-sided 95% and 97.5% CIs will be provided 
for the difference between each active treatment and placebo.
10.4.5
Imputation Methods for Secondary Endpoints
NRI will be used for subjects who discontinue treatment prior to Week 12 and have no Week 12 
assessments after treatment discontinuation,
 
 initiate use or continue to use prohibited medications in the Induction Period, 
require surgical procedure(s) for treatment of CD of related complications in the Induction Period, 
or have otherwise missing endpoint data at the specified timepoint for binary endpoints.
For continuous secondary efficacy endpoints, a multiple imputation (MI) analysis will be used for 
subjects who discontinue study treatment prior to Week 12 and have no Week 12 assessments after 
treatment 
discontinuation, 
and 
for 
subjects 
who 
require 
a 
protocol-prohibited 
medication/therapy/surgical procedure that could improve the disease prior to the Week 12 
endpoint, or who have otherwise missing endpoint data at the specified time point for continuous 
endpoints.
10.4.6
Adjustment for Multiplicity of Co-primary and Secondary Endpoints
Alpha will be split in 2 separate testing branches at a 2-sided alpha=0.025 for BMS-986165 3 mg 
BID compared to placebo and BMS-986165 6 mg BID compared to placebo. The testing order of 
co-primary and secondary endpoints will be tested in the sequence shown in Table 18.
Protocol Amendment No.: 05
Date: 02-Sep-2022
120
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Table 18:
Testing Order of Co-primary and Secondary Endpoints
BMS-986165 3 mg BID 
Comparisons to Placebo (alpha=0.025)
BMS-986165 6 mg BID 
Comparisons to Placebo (alpha=0.025)
Co-primary Endpoints
Clinical remission at Week 12
Endoscopic response at Week 12
Clinical remission at Week 12
Endoscopic response at Week 12
Secondary Endpoints
1.
Clinical response at Week 12
1.
Clinical response at Week 12
2.
PRO2 remission at Week 12
2.
PRO2 remission at Week 12
3.
Change from baseline in SES-CD at Week 12
3.
Change from baseline in SES-CD at Week 12
There will be no multiplicity adjustment for any other endpoints including exploratory efficacy 
endpoints; however, nominal p-values will be provided as descriptive statistics.
10.5
Safety Analyses
Safety analyses will be performed using the as-treated population. Subjects will be summarized 
according to the treatment they are taking at the start of the AE for those subjects who switch to 
active treatment or a different active dose level during the Maintenance Period. For analysis, all 
recorded AEs will be listed and tabulated by system organ class, preferred term, and treatment. 
Vital signs and clinical laboratory test results will be listed and summarized by treatment. ECG 
readings will be evaluated by the investigator and abnormalities, if present, will be summarized 
and listed.
10.6
Other Analyses 
 
 
 
 
 
 
 
10.6.3
Week 12 Analysis 
When all randomized subjects have completed the Week 12 efficacy assessments or have 
discontinued prior to Week 12, the database will be locked and the primary analysis will be 
conducted. Details of this analysis will be described in the SAP. An unblinded BMS team that is 
independent from the blinded study team will review the results of this primary analysis. The study 
team members, including the medical monitors and other study personnel, will remain blinded and 
Protocol Amendment No.: 05
Date: 02-Sep-2022
121
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
will not have access to any unblinded interim analysis results or data until the final database lock 
for the Week 52 data has occurred.
10.6.4
Interim Analysis
In addition to the primary efficacy analysis conducted when 12-week data are available for all 
randomized subjects, interim analyses may be performed. The purpose of interim analyses will be 
to help in early planning for further clinical development of the compound.
To maintain the overall probability of Type I error at the specified 0.05 level, a modified 
Haybittle-Peto method28 will be used as the alpha-spending function, which assigns alpha=0.001 
to each interim analysis, and the remaining alpha to the final (Week 12) analysis of the primary 
efficacy endpoints.
The SAP for the study will be finalized prior to any interim analysis. The details (including the 
timing) of the interim analyses will be provided in an Interim Analysis Plan prior to the database 
lock for any interim analysis. The results of the interim analyses will be reviewed by an unblinded 
internal BMS team that is independent of the study team responsible for the conduct of the study. 
The study team members, including the medical monitors and other study personnel, will remain 
blinded and will not have access to any unblinded interim analysis results or data until the final 
database lock for the Week 52 data has occurred.
Protocol Amendment No.: 05
Date: 02-Sep-2022
122
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
11
REFERENCES
1
Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the 
immunoregulatory roles of STAT4. Immunol Rev 2004;202:139-56.
2
Tokarski JS, Zupa-Fernandez A, Tredup JA, et al. Tyrosine kinase 2-mediated signal 
transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase 
domain. J Biol Chem 2015;290(17):11061-74.
3
Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain 
underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad 
Sci U S A 2003;100(20):11594-9.
4
Bruce ES. Inhibition of Interleukin-12 and/or -23 for the Treatment of Inflammatory Bowel 
Disease. 
Presented 
at 
Millennium 
Medical 
Publishing. 
Gastroenterol 
Hepatol 
2016;12(12):784-6.
 
 
 
 
 
 
10 Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. 
National Cooperative Crohn's Disease Study. Gastroenterology 1976;70(3):439-44.
11 Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks 
of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections 
Inflammatoires Digestives. Gastroenterology 1990;98(4):811-8.
12 Khanna R, Zou G, D'Haens G, et al. A retrospective analysis: the development of patient 
reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol 
Ther 2015;41(1):77-86.
13 Kim J, Krueger JG. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 
T Cell Autoimmune Axis. Annu Rev Med 2017;68(1):255-69.
Protocol Amendment No.: 05
Date: 02-Sep-2022
123
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
14 BMS-986165 Investigator's Brochure, Version 04. Bristol-Myers Squibb Company, 2018. 
Document Control No. 930090873.
15 Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's 
Disease Activity Index (CDAI). Gastroenterology 1979;77(4 Pt 2):843-6.
16 Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy 
endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 
2002;122(2):512-30.
17 Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified 
endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 
2004;60(4):505-12.
18 D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by 
infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114(2):262-7.
19 Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for 
UC. Gut 2017;66(1):50-8.
20 Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of 
the Nancy histological index for UC. Gut 2017;66(1):43-9.
 
 
 
24 Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in 
inflammatory bowel disease. Gastroenterology 1989;96(3):804-10.
25 Bodger K, Ormerod C, Shackcloth D, et al. Development and validation of a rapid, generic 
measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut 
2014;63(7):1092-102.
26 Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease 
activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995;20(1):27-32.
27 Sandborn WJ, Feagan BG, Panes J, et al. Safety and Efficacy of ABT-494 (Upadacitinib), an 
Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from 
Celest. Presented at Elsevier. Gastroenterology 2017;152(5):S1308-S9.
28 Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. 
Lancet 2005;365(9471):1657-61.
Protocol Amendment No.: 05
Date: 02-Sep-2022
124
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
12
APPENDICES 
Protocol Amendment No.: 05
Date: 02-Sep-2022
125
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 1
ABBREVIATIONS AND TRADEMARKS
Term
Definition
5-ASA
5-aminosalicylate
6-MP
6-mercaptopurine
ACR20
American College of Rheumatology 20
ADME
absorption, distribution, metabolism, and excretion
AE
adverse event
AEI
adverse event of interest
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
Anti-HBc
hepatitis B core antibody
Anti-HCV
hepatitis C virus antibody
AP
abdominal pain
AST
aspartate aminotransferase
AUC
area under the concentration-time curve
AUC(0-24h)
area under the concentration-time curve from 0 to 24 hours
AUC(0-INF)
area under the concentration-time curve extrapolated to infinity
AZA
azathioprine
BCRP
breast cancer resistance protein
BID
twice daily
BMS
Bristol-Myers Squibb
BSS
Bristol Stool Scale
Cavg
average concentration
CD
Crohn’s disease
CDAI
Crohn’s Disease Activity Index
C. difficile
Clostridium difficile
CFR
Code of Federal Regulations
CI
confidence interval
CK
creatine kinase
Cmax
maximum plasma concentration
Protocol Amendment No.: 05
Date: 02-Sep-2022
126
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Term
Definition
CMH
Cochran-Mantel-Haenszel 
COVID-19
coronavirus disease 2019
Ctrough
trough observed plasma concentration 
CYP450
cytochrome P450
DDI
drug-drug interaction
DILI
drug-induced liver injury
DMC
Data Monitoring Committee
DNA
deoxyribonucleic acid
ECG
electrocardiogram
eCRF
electronic case report form
Emax
direct effect
ET
Early Termination
FAS
Full Analysis Set
FDA
Food and Drug Administration
FIH
first-in-human
FSH
follicle-stimulating hormone
GDH
glutamate dehydrogenase
HBsAb
hepatitis B surface antibody
HBsAg
hepatitis B surface antigen
HBV
hepatitis B virus 
Hct
hematocrit
HCV
hepatitis C virus
HCV RNA
hepatitis C virus ribonucleic acid
HIV
human immunodeficiency virus
IB
Investigator Brochure
IBD
inflammatory bowel disease
IC50
half-maximal inhibitory concentration
ICF
informed consent form
Protocol Amendment No.: 05
Date: 02-Sep-2022
127
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Term
Definition
ICH
International Council for Harmonisation
IEC
Independent Ethics Committee
IFN
interferon
IFNα
interferon alpha
IFN-γ 
interferon gamma
Ig
immunoglobulin
IgA
immunoglobulin A
IgE
immunoglobulin E
IgG
immunoglobulin G
IgM
immunoglobulin M
IGRA
interferon gamma release assay
IHC
immunohistochemistry
IL
interleukin
IM
intramuscular
IMP
investigational medicinal product
IP
investigational product 
IRB
Institutional Review Board
IRT
interactive response technology
IV
intravenous
JAK
Janus kinase
KLH
keyhole limpet hemocyanin
LOCF
last observation carried forward
LOR
loss of response
LTBI
latent tuberculosis infection
LTE
long-term extension
MTX
methotrexate
NOAEL
no-observed-adverse-effect-level
NRI
non-responder imputation
Protocol Amendment No.: 05
Date: 02-Sep-2022
128
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Term
Definition
NSAID
nonsteroidal anti-inflammatory drug
NYHA
New York Heart Association
OL
open-label
OLE
Open-Label Extension
OTC
over-the-counter
PASI
Psoriasis Area and Severity Index
PASI 75
≥ 75% reduction in the Psoriasis Area and Severity Index
PASI 90
≥ 90% reduction in the Psoriasis Area and Severity Index
PCR
polymerase chain reaction
PD
pharmacodynamic
PK
pharmacokinetics
PO
by mouth
PRA
Pharmaceutical Research Associates
PRO
patient (or subject) reported outcome
PRO2 or 
CDAI/PRO2
patient (or subject) reported outcome based on the stool frequency and 
abdominal pain components of the CDAI 
QD 
once daily
RBC
red blood cell
RNA
ribonucleic acid 
SAE
serious adverse event
SAP
statistical analysis plan
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
SES-CD
Simple Endoscopic Score for Crohn’s Disease
SF
stool frequency
Protocol Amendment No.: 05
Date: 02-Sep-2022
129
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Term
Definition
SLE
systemic lupus erythematosus
sPGA
static Physician’s Global Assessment
STAT
signal transducer and activator of transcription
TB
tuberculosis
TBNK
T cells, B cells, and natural killer cells 
TDAR 
T-cell-dependent antibody response 
TDM
therapeutic drug monitoring
Tmax
time of maximum concentration
TNF
tumor necrosis factor 
TNFi
tumor necrosis factor inhibitor 
TYK2
tyrosine kinase 2
ULN
upper limit of normal
WOCBP
women of childbearing potential
Protocol Amendment No.: 05
Date: 02-Sep-2022
130
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 2
STUDY GOVERNANCE CONSIDERATIONS
REGULATORY AND ETHICAL CONSIDERATIONS
This study will be conducted in accordance with:
•
Consensus ethical principles derived from international guidelines, including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines
•
Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP)
Guidelines
•
Applicable laws, regulations, and requirements
The study will be conducted in compliance with the protocol. The protocol, any 
revisions/amendments, and the subject informed consent form (ICF) will receive 
approval/favorable opinion by Institutional Review Board/Independent Ethics Committee 
(IRB/IEC), and regulatory authorities according to applicable local regulations prior to initiation 
of the study.
All potential serious breaches must be reported to Sponsor or designee immediately. A potential 
serious breach is defined as a Quality Issue (eg, protocol deviation) that is likely to affect, to a 
significant degree, one or more of the following: (1) the rights, physical safety, or mental integrity 
of one or more subjects; (2) the scientific value of the clinical trial (eg, reliability and robustness 
of generated data). Items (1) or (2) can be associated with either GCP regulation(s) or trial 
protocol(s).
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, Investigator’s Brochure, product labeling information, ICF, 
subject recruitment materials (eg, advertisements), and any other written information to be 
provided to subjects. 
The investigator, Sponsor, or designee should also provide the IRB/IEC with reports, updates, and 
other information (eg, expedited safety reports, amendments, administrative letters) annually, or 
more frequently, in accordance with regulatory requirements or institution procedures.
The investigator is responsible for providing oversight of the conduct of the study at the site and 
adherence to requirements of the following where applicable:
•
ICH guidelines, 
•
United States Code of Federal Regulations, Title 21, Part 50 (21CFR50)
Protocol Amendment No.: 05
Date: 02-Sep-2022
131
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
European Union Directive 2001/20/EC; or
•
European Regulation 536/2014 for clinical studies (if applicable), 
•
European Medical Device Regulation 2017/745 for clinical device research (if applicable),
•
the IRB/IEC
•
and all other applicable local regulations.
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any deviation or change to the protocol without prior 
review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if 
applicable, also by local health authority) except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opinion(s) the deviation or change will be submitted, as soon 
as possible to:
•
IRB/IEC
•
Regulatory Authority(ies), if applicable by local regulations (per national requirements)
Documentation of approval/favorable opinion signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority must be sent to Bristol-Myers 
Squibb (BMS).
If an amendment substantially alters the study design or increases the potential risk to the subject: 
(1) the ICF must be revised and submitted to the IRB(s)/IEC(s) for review and approval/favorable 
opinion; (2) the revised form must be used to obtain consent from subjects currently enrolled in 
the study if they are affected by the amendment; and (3) the new form must be used to obtain 
consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and subinvestigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate health authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
132
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
The sponsor or designee will provide the investigator with an appropriate sample ICF, which will 
include all elements required by ICH GCP and applicable regulatory requirements. The sample 
ICF will adhere to the ethical principles that have their origin in the Declaration of Helsinki.
The investigator or his/her representative must:
•
Obtain IRB/IEC written approval/favorable opinion of the written ICF and any other 
information to be provided to the subject prior to the beginning of the study and after any 
revisions are completed for new information.
•
Provide a copy of the ICF and written information about the study in the language in which 
the subject is proficient prior to clinical study participation. The language must be nontechnical 
and easily understood. 
•
Explain the nature of the study to the subject and answer all questions regarding the study.
•
Inform subject that his/her participation is voluntary. Subject will be required to sign a 
statement of informed consent that meets the requirements of 21CFR50, local regulations, ICH 
guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where 
applicable, and the IRB/IEC or study center.
•
Allow time necessary for subject to inquire about the details of the study.
•
Obtain an ICF signed and personally dated by subject and by the person who conducted the 
informed consent discussion. 
•
Include a statement in subject’s medical record that written informed consent was obtained 
before subject was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.
•
Re-consent subject to the most current version of the ICF(s) during his/her participation in the 
study, as applicable.
Revise the ICF whenever important new information becomes available that is relevant to the 
subject’s consent. The investigator, or a person designated by the investigator, should fully inform 
the subject, of all pertinent aspects of the study and of any new information relevant to the subject’s 
willingness to continue participation in the study. This communication should be documented. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements, the subjects’ signed ICF and, in 
the US, the subjects’ signed HIPAA Authorization.
The ICF must also include a statement that BMS and local and foreign regulatory authorities have 
direct access to subject records. 
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
SOURCE DOCUMENTS
Source documents provide evidence for the existence of the subject and substantiate the integrity 
of the data collected. Source documents are filed at the investigator’s site.
Protocol Amendment No.: 05
Date: 02-Sep-2022
133
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Data reported on the case report form (CRF) or entered in the electronic CRF (eCRF) that are 
transcribed from source documents must be consistent with the source documents or the 
discrepancies must be explained. 
•
The investigator may need to request previous medical records or transfer records, depending 
on the study. Also, current medical records must be available.
The investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event (AE) tracking/reporting, protocol-required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for review at the request of BMS/designee 
or a health authority.
Protocol Amendment No.: 05
Date: 02-Sep-2022
134
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
If
Then
Supplied by BMS (or its vendors):
Records or logs must comply with applicable 
regulations and guidelines and should include:
•
amount received and placed in storage 
area
•
amount currently in storage area
•
label identification number or batch 
number
•
amount dispensed to and returned by each 
subject, including unique subject 
identifiers
•
amount transferred to another area/site for 
dispensing or storage
•
nonstudy disposition (eg, lost, wasted) 
•
amount destroyed at study site, if 
applicable
•
amount returned to BMS
•
retain samples for bioavailability/ 
bioequivalence, if applicable 
•
dates and initials of person responsible for 
Investigational Product (IP) dispensing/ 
accountability, as per the Delegation of 
Authority Form.
Sourced by site, and not supplied by BMS or 
its vendors (examples include IP sourced 
from the sites stock or commercial supply, or 
a specialty pharmacy)
The 
investigator 
or 
designee 
accepts 
responsibility for documenting traceability and 
study treatment integrity in accordance with 
requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.
BMS or designee will provide forms to facilitate inventory control if the investigational site does 
not have an established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
Protocol Amendment No.: 05
Date: 02-Sep-2022
135
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs will be 
prepared for all data collection fields except for fields specific to serious AEs (SAEs) and 
pregnancy, which will be reported on the electronic SAE form and paper Pregnancy Surveillance 
Form, respectively. If an electronic SAE form is not available, a paper SAE form can be used. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF and SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by 
the investigator or qualified physician who is a subinvestigator and who is delegated this task on 
the Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF 
approval task. For electronic CRFs, review and approval/signature is completed electronically 
through the electronic data capture tool. The investigator must retain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically signing electronic CRFs must meet Sponsor or designee training 
requirements and must only access the electronic data capture tool using the unique user account 
provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals.
MONITORING
Monitoring details describing strategy, including definition of study critical data items and 
processes (eg, risk-based initiatives in operations and quality such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques (central, 
remote, or on-site monitoring) are provided in the monitoring plan.
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site, they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable.
Certain CRF pages and/or electronic files may serve as the source documents. 
In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to Sponsor or designee. 
RECORDS RETENTION
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by applicable regulations and guidelines, or 
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
Protocol Amendment No.: 05
Date: 02-Sep-2022
136
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vendor, or sourced by the investigator)
such as partially used study treatment containers, vials, and syringes may be destroyed on site. 
If …
Then
Study treatments supplied by BMS (including 
its vendors)
Any unused study treatments supplied by 
BMS can only be destroyed after being 
inspected and reconciled by the responsible 
Study Monitor unless study treatments 
containers must be immediately destroyed as 
required for safety, or to meet local 
regulations (eg, cytotoxics or biologics).
If study treatments will be returned, the return 
will be arranged by the responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study treatments sourced from the site’s stock 
or commercial supply, or a specialty 
pharmacy)
It is the investigator’s or designee’s 
responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:
•
On-site disposal practices must not expose humans to risks from the drug.
•
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
•
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.
•
Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
Protocol Amendment No.: 05
Date: 02-Sep-2022
137
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
method of disposal (eg, incinerator, licensed sanitary landfill, or licensed waste disposal 
vendor) must be documented.
•
Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period.
It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met, the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of non-study 
treatments sourced by the site, not supplied by BMS, is solely the responsibility of the investigator 
or designee.
STUDY AND SITE START AND CLOSURE
The Sponsor/designee reserves the right to close the study site or to terminate the study at any time 
for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies have 
been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the Sponsor or investigator may include, but are 
not limited to:
•
Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local regulatory authorities, the Sponsor’s procedures, or GCP guidelines
•
Inadequate recruitment of subjects by the investigator
•
Discontinuation of further study intervention development
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by the applicable 
regulatory requirements. The investigator shall promptly inform the subject and should assure 
appropriate subject therapy and/or follow-up.
DISSEMINATION OF CLINICAL STUDY DATA
In order to benefit potential study subjects, patients, healthcare providers and researchers, and to 
help BMS honor its commitments to study subjects, BMS will make information about clinical 
research studies and a summary of their results available to the public as per regulatory and BMS 
requirements. BMS will post study information on local, national or regional databases in 
compliance with national and international standards for disclosure. BMS may also voluntarily 
disclose information to applicable databases.
Protocol Amendment No.: 05
Date: 02-Sep-2022
138
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
In the European Union (EU), the summary of results and summary for laypersons will be submitted 
within 1 year of the end of trial in EU/European Economic Area and third countries.
CLINICAL STUDY REPORT 
A Signatory Investigator must be selected to sign the clinical study report (CSR). 
For each CSR related to this protocol, the following criteria will be used to select the Signatory 
Investigator:
•
External Principal investigator designated at protocol development
•
National Coordinating investigator 
•
Study Steering Committee chair or their designee
•
Subject recruitment (eg, among the top quartile of enrollers)
•
Involvement in trial design
•
Regional representation (eg, among top quartile of enrollers from a specified region or country)
•
Other criteria (as determined by the study team)
The data collected during this study are confidential and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTA) governing study site or investigator participation in the 
study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTA.
SCIENTIFIC PUBLICATIONS
The data collected during this study are confidential and proprietary to the Sponsor or designee. 
Any publications or abstracts arising from this study must adhere to the publication requirements 
set forth in the Clinical Trial Agreement (CTAg) governing [study site or investigator] 
participation in the study. These requirements include, but are not limited to, submitting proposed 
publications to the Sponsor or designee at the earliest practicable time prior to submission or 
presentation and otherwise within the time period set forth in the CTAg.
Scientific publications (such as abstracts, congress podium presentations and posters, and 
manuscripts) of the study results will be a collaborative effort between the study Sponsor and the 
external authors. No public presentation or publication of any interim results may be made by any 
Principal Investigator, subinvestigator, or any other member of the study staff without the prior 
written consent of the Sponsor.
Authorship of publications at BMS is aligned with the criteria of the International Committee of 
Medical Journal Editors (ICMJE, www.icmje.org). Authorship selection is based upon significant 
Protocol Amendment No.: 05
Date: 02-Sep-2022
139
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
contributions to the study (ie, ICMJE criterion #1). Authors must meet all 4 ICMJE criteria for 
authorship:
1) Substantial intellectual contribution to the conception or design of the work; or the acquisition 
of data (ie, evaluable subjects with quality data), analysis, or interpretation of data for the 
work (eg, problem solving, advice, evaluation, insights and conclusion); AND
2) Drafting the work or revising it critically for important intellectual content; AND
3) Final approval of the version to be published; AND
4) Agreement to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Those who make the most significant contributions, as defined above, will be considered by BMS 
for authorship of the primary publication. Sub-investigators will generally not be considered for 
authorship in the primary publication. Geographic representation will also be considered.
Authors will be listed by order of significant contributions (highest to lowest), with the exception 
of the last author. Authors in first and last position have provided the most significant contributions 
to the work. 
For secondary analyses and related publications, author list and author order may vary from 
primary to reflect additional contributions.
Protocol Amendment No.: 05
Date: 02-Sep-2022
140
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 3
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation subject administered study treatment 
and that does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
•
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
results from other safety assessments (eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically significant 
in the medical and scientific judgment of the investigator. Note that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not 
available. Once the final diagnosis is known, the reported term should be updated to be the 
diagnosis. 
•
Exacerbation of a chronic or intermittent preexisting condition including either an increase 
in frequency and/or intensity of the condition.
•
New conditions detected or diagnosed after study intervention administration even though 
it may have been present before the start of the study.
•
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
•
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose, as a verbatim term (as reported by the 
investigator), should not be reported as an AE/SAE unless it is an intentional overdose taken 
with possible suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae and should specify ”intentional overdose” as the verbatim term.
Events NOT Meeting the AE Definition
•
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
DEFINITION OF SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met.
Protocol Amendment No.: 05
Date: 02-Sep-2022
141
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
SERIOUS ADVERSE EVENTS
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE 
below)
NOTE: 
The following hospitalizations are not considered SAEs in BMS clinical studies: 
•
A visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-threatening event)
•
Elective surgery, planned prior to signing consent
•
Admissions as per protocol for a planned medical/surgical procedure
•
Routine health assessment requiring admission for baseline/trending of health status (eg, 
routine colonoscopy)
•
Medical/surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
•
Admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)
•
Admission for administration of anticancer therapy in the absence of any other SAEs 
(applies to oncology protocols)
Results in persistent or significant disability or permanent damage
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above); examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization. A potential drug-induced liver injury (DILI) is also considered an important 
medical event. (See Section 9.3.8 for the definition of potential DILI.)
Pregnancy and potential DILI must follow the same transmission timing and processes to BMS as 
used for SAEs. (See Section 9.3.6 for reporting pregnancies).
Protocol Amendment No.: 05
Date: 02-Sep-2022
142
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
EVALUATING AES AND SAES
Assessment of Causality
•
The investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE. 
•
A “reasonable possibility” of a relationship conveys that there are facts, evidences, and/or 
arguments to suggest a causal relationship rather than a relationship cannot be ruled out.
•
The investigator will use clinical judgment to determine the relationship.
•
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration 
will be considered and investigated.
•
The investigator will also consult the Investigator Brochure IB and/or Product Information, 
for marketed products, in his/her assessment.
•
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
•
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to Sponsor. However, it is very important that the 
investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to Sponsor.
•
The investigator may change his/her opinion of causality in light of follow-up information 
and send a SAE follow-up report with the updated causality assessment.
•
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:
•
Mild: An event that is easily tolerated by the subject, causing minimal discomfort, and not 
interfering with everyday activities.
•
Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.
•
Severe: An event that prevents normal everyday activities. An AE that is assessed as severe 
should not be confused with an SAE. Severe is a category used for rating the intensity of an 
event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe.
Follow-up of AEs and SAEs
If only limited information is initially available, follow-up reports are required. Note: Follow-up 
SAE reports must include the same investigator term(s) initially reported. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
143
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
If an ongoing SAE changes in its intensity or relationship to study drug or if new information 
becomes available, the SAE report must be updated and submitted within 24 hours to BMS (or 
designee) using the same procedure used for transmitting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
REPORTING OF SAES TO SPONSOR OR DESIGNEE
•
SAEs, whether related or not related to study drug, and pregnancies must be reported to PRA 
Drug Safety within 24 hours of awareness of the event.
•
SAEs must be recorded on the SAE Report Form. 
−
The required method for SAE reporting is through the electronic case report form 
(eCRF).
−
The paper SAE Report Form is intended only as a back-up option when the electronic 
data capture system is unavailable/not functioning for transmission of the eCRF to BMS 
(or designee).
♦In this case, the paper form is transmitted via email or confirmed facsimile 
transmission.
•
When paper forms are used, the original paper forms are to remain on site.
•
Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via 
email or confirmed facsimile (fax) transmission to:
SAE Email Address: 
SAE Fax Number: 
Americas: 
-434-951-3482)
Europe/East Asia Pacific:
SAE Telephone Contact: For questions on SAE/pregnancy reporting, please call:
Americas: 
Europe/East Asia Pacific:
Protocol Amendment No.: 05
Date: 02-Sep-2022
144
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
145
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
146
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
147
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 5
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
Appendix 5 provides general information and definitions related to Woman of Childbearing 
Potential and methods of contraception that can be applied to most clinical trials. For information 
specific to this study regarding acceptable contraception requirements for female and male 
subjects, refer to Section 6.1 of the protocol. Only the contraception methods as described in 
Section 6.1 are acceptable for this study.
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP:
•
Premenarchal
•
Premenopausal female with 1 of the following:
−
Documented hysterectomy
−
Documented bilateral salpingectomy
−
Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the subject’s medical records, 
medical examination, or medical history interview.
•
Postmenopausal female
−
A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 
45 years in the absence of other biological or physiological causes. In addition, females 
under the age of 55 years must have a serum follicle-stimulating hormone (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement therapy (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. Suggested 
guidelines for the duration of the washout periods for HRT types are presented below. Investigators 
should use their judgement in checking serum FSH levels.
•
1 week minimum for vaginal hormonal products (rings, creams, gels)
•
4 week minimum for transdermal products
•
8 week minimum for oral products
Other parenteral products may require washout periods as long as 6 months. If the serum FSH 
level is > 40 mIU/mL at any time during the washout period, the woman can be considered 
postmenopausal.
Protocol Amendment No.: 05
Date: 02-Sep-2022
148
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
End of Relevant Systemic Exposure
End of relevant systemic exposure is the timepoint where the Investigational Medicinal Product 
(IMP) or any active major metabolites have decreased to a concentration that is no longer 
considered to be relevant for human teratogenicity or fetotoxicity. This should be evaluated in 
context of safety margins from the no-observed-adverse-effect level or the time required for 
5 half-lives of the IMP to pass.
CONTRACEPTION GUIDANCE FOR FEMALE SUBJECTS OF CHILDBEARING
POTENTIAL
At least an acceptable, less than highly effective means of contraception should be continued until 
the end of treatment.
Local laws and regulations may require use of alternative and/or additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of < 1% per year when used consistently and correctly.a
•
Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulation and/or implantation. (This method of contraception can only be used 
by WOCBP subjects in studies where hormonal contraception is permitted by the study 
protocol.)b
−
Oral (birth control pills)
−
Intravaginal (rings)
−
Transdermal 
•
Combined (estrogen- and progestogen-containing) hormonal contraception must begin at 
least 30 days prior to initiation of study therapy.
•
Progestogen-only hormonal contraception associated with inhibition of ovulation. (This 
method of contraception can only be used by WOCBP subjects in studies where hormonal 
contraception is permitted by the study protocol.)b
−
Oral 
−
Injectable 
•
Progestogen-only hormonal contraception must begin at least 30 days prior to initiation of 
study therapy.
Highly Effective Methods That Are User Independent
•
Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation 
•
Intrauterine device (IUD)b
•
Intrauterine hormone-releasing system (IUS)c
•
Bilateral tubal occlusion
•
Vasectomized partner 
Protocol Amendment No.: 05
Date: 02-Sep-2022
149
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 
•
Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the subject.
•
Continuous abstinence must begin at least 30 days prior to initiation of study therapy.
•
It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
•
WOCBP subjects who choose complete abstinence must continue to have pregnancy tests, 
as specified in Section 2 of the protocol. 
•
Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP subjects chooses to forego complete abstinence 
•
Periodic abstinence (including, but not limited to, calendar, symptothermal, postovulation 
methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea 
method (LAM) are not acceptable methods of contraception for this study.
NOTES: 
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for subjects participating in clinical studies. 
b Hormonal contraception may be susceptible to interaction with the study treatment, which may reduce the 
efficacy of the contraceptive method. Hormonal contraception is permissible only when there is sufficient 
evidence that the IMP and other study medications will not alter hormonal exposures such that contraception 
would be ineffective or result in increased exposures that could be potentially hazardous. In this case, alternative 
methods of contraception should be utilized. For information specific to this study regarding permissibility of 
hormonal contraception, refer to .Sections 6.1 INCLUSION CRITERIA and 7.7.1 PROHIBITED AND/OR 
RESTRICTED TREATMENTS of the protocol.
c Intrauterine devices and intrauterine hormone-releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter 
contraception effectiveness
Less Than Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of > 1% per year when used consistently and correctly.
•
Male or female condom with or without spermicide. Male and female condoms cannot be 
used simultaneously
•
Diaphragm with spermicide
•
Cervical cap with spermicide
•
Vaginal Sponge with spermicide
•
Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action. (This method of contraception cannot be used by WOCBP 
subjects in studies where hormonal contraception is prohibited.)
Protocol Amendment No.: 05
Date: 02-Sep-2022
150
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Unacceptable Methods of Contraception
•
Periodic abstinence (calendar, symptothermal, post-ovulation methods)
•
Withdrawal (coitus interruptus).
•
Spermicide only
•
Lactation amenorrhea method 
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnancy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.3.6 and APPENDIX 3, Adverse Events and Serious 
Adverse Events Definitions and Procedures for Evaluating, Follow-up, and Reporting.
Protocol Amendment No.: 05
Date: 02-Sep-2022
151
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
152
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 7
EXAMPLES OF WASHOUT TIMES REQUIRED PRIOR TO 
RANDOMIZATION 
Medications/treatments
Discontinuation Prior to Randomization 
5-azathioprine
≥ 4 weeks
6-mercaptopurine
≥ 4 weeks
Abatacept (CTLA4Ig)
≥ 12 weeks
Adalimumaba
≥ 8 weeks
Washout period waived if undetectable levels on TDM assay
Alemtuzumab
≥ 12 months
Apheresis: lymphocyte apheresis or selective 
monocyte or granulocyte apheresis (eg, 
Cellsorba™)
≥ 12 months
Atacicept (TACI-Ig)
≥ 48 weeks
Belimumab
≥ 14 weeks
Certolizumab pegola
≥ 8 weeks
Washout period waived if undetectable levels on TDM assay
Cyclophosphamide
≥ 4 weeks
Cyclosporine
≥ 4 weeks 
Danazol
≥ 4 weeks
Dapsone
≥ 4 weeks
Darvadstrocel
≥ 24 weeks
Eculizumab
≥ 12 weeks
Epratuzumabb
≥ 18 weeks
Infliximaba
≥ 8 weeks
Washout period waived if undetectable levels on TDM assay
Interferon
≥ 12 weeks (or more than 5 half-lives, whichever is longer)
Intravenous Globulin
≥ 4 weeks
Investigational therapies
≥ 4 weeks
Janus kinase inhibitors
≥ 8 weeks
Leflunomide
≥ 12 weeks (or more than 5 half-lives, whichever is longer)
Lenalidomide with cholestyramine
≥ 24 weeks
Methotrexate
≥ 4 weeks
Mycophenolate mofetil
≥ 4 weeks
Natalizumab
≥ 8 weeks
Ocrelizumaba
≥ 24 weeks
Pimecrolimus
≥ 4 weeks
Plasmapheresis
24 weeks
Protocol Amendment No.: 05
Date: 02-Sep-2022
153
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Medications/treatments
Discontinuation Prior to Randomization 
Retinoids
≥ 4 weeks
Rituximab
≥ 12 months
Sirolimus
≥ 4 weeks
Tabalumab
≥ 14 weeks
Tacrolimus
≥ 4 weeks 
Thalidomide
≥ 4 weeks
Other TNF inhibitors
≥ 8 weeks
Washout period waived if undetectable levels on TDM assay
Tocilizumab
≥ 12 weeks
Ustekinumaba
≥ 8 weeks
For subjects who have received > 12 weeks of ustekinumab 
treatment: washout period waived if undetectable levels on a 
TDM assay
Vedolizumaba
Subjects who have completed > 14 weeks vedolizumab 
treatment: ≥ 4 weeks, or washout period waived if undetectable 
levels on a TDM assay
Subjects who have received ≤ 14 weeks of vedolizumab 
treatment: ≥ 8 weeks.
a The washout period for the following biologics can be waived for subjects who have an undetectable drug level 
on a TDM assay, performed either in routine clinical practice or during the Screening Period: (i) infliximab, (ii) 
adalimumab, (iii) certolizumab pegol, or (iv) vedolizumab (if received at least 14 weeks of vedolizumab therapy), 
(v) ustekinumab (if received > 12 weeks of therapy). Subjects who have received < 14 weeks of vedolizumab 
therapy, or < 12 weeks of ustekinumab therapy must complete the washout period for those medication. If a TDM 
assay is used to waive the washout period for one of the 5 biologics listed above, the result of the TDM assay must 
be available in source documents and the subject cannot receive another dose of that biologic after the TDM assay 
is obtained.
b For epratuzumab, ocrelizumab, and any other B-cell-depleting agent, follow the required washout or document 
recovery of B cells (CD19+) after discontinuation of these therapies before a subject can be randomized.
Note: Investigators should consult with the PRA medical monitor for information about compounds not included in 
this list.
Protocol Amendment No.: 05
Date: 02-Sep-2022
154
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 8
SUBJECT DIARY 
For each study day, subjects will also record the date and time of study treatment administration, 
and the number of capsules taken. A paper copy of the Bristol Stool Scale 
 
will be provided to subjects to help with the daily documentation of the number of very soft (loose) 
or liquid (watery) stools (BSS Type 6 or 7). Only Type 6 and Type 7 stools are to be recorded and 
considered for the calculation of the stool frequency for measures of disease activity and clinical 
status, eg, remission. The frequency of Type 1 through Type 5 stools are not to be recorded.
Day/Date
How many 
liquid or 
very soft 
stools?
How would you 
rate your 
abdominal pain?
How would you rate your 
general well-being?
Did you use diphenoxylate 
or loperamide for 
diarrhea? (Also mark 
“Yes” if any narcotics were 
used.)
Sunday
__ / __ /__
mm dd yy
None……..0
Mild……...1
Moderate...2
Severe……3
Generally well…….0
Slightly under par…1
Poor……………….2
Very Poor…………3
Terrible…………...4
Yes
No
Monday
__ / __ /__
mm dd yy
None……..0
Mild……...1
Moderate...2
Severe……3
Generally well…….0
Slightly under par…1
Poor……………….2
Very Poor…………3
Terrible…………...4
Yes
No
Tuesday
__ / __ /__
mm dd yy
None……..0
Mild……...1
Moderate...2
Severe……3
Generally well…….0
Slightly under par…1
Poor……………….2
Very Poor…………3
Terrible…………...4
Yes
No
Wednesday
__ / __ /__
mm dd yy
None……..0
Mild……...1
Moderate...2
Severe……3
Generally well…….0
Slightly under par…1
Poor……………….2
Very Poor…………3
Terrible…………...4
Yes
No
Thursday
__ / __ /__
mm dd yy
None……..0
Mild……...1
Moderate...2
Severe……3
Generally well…….0
Slightly under par…1
Poor……………….2
Very Poor…………3
Terrible…………...4
Yes
No
Friday
__ / __ /__
mm dd yy
None……..0
Mild……...1
Moderate...2
Severe……3
Generally well…….0
Slightly under par…1
Poor……………….2
Very Poor…………3
Yes
No
Protocol Amendment No.: 05
Date: 02-Sep-2022
155
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Day/Date
How many 
liquid or 
very soft 
stools?
How would you 
rate your 
abdominal pain?
How would you rate your 
general well-being?
Did you use diphenoxylate 
or loperamide for 
diarrhea? (Also mark 
“Yes” if any narcotics were 
used.)
Terrible…………...4
Saturday
__ / __ /__
mm dd yy
None……..0
Mild……...1
Moderate...2
Severe……3
Generally well…….0
Slightly under par…1
Poor……………….2
Very Poor…………3
Terrible…………...4
Yes
No
Protocol Amendment No.: 05
Date: 02-Sep-2022
156
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 9
INTERPRETATION OF HBV AND HCV TEST RESULTS
I. HBV
As BMS-986165 is predicted to have immunomodulatory effects in this study, subjects with 
potentially active hepatitis B (HBV) infection and subjects at risk of reactivation of HBV infection 
will be excluded (see Section 6.2).
Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), and hepatitis B surface 
antibody (HBsAb) are evaluated at screening, with reflex to HBV DNA testing in subjects with 
HBsAg negative, anti-HBc positive serology (as listed in the “Interpretation unclear” scenario, 
below). Notes on interpretation of HBV serology within this study are given below:
Susceptible – does not meet exclusion criteria on HBV
•
HBsAg negative
•
anti-HBc negative
•
HBsAb negative
Immune due to natural infection - does not meet exclusion criteria on HBV
•
HBsAg negative
•
anti-HBc positive
•
HBsAb positive
Immune due to hepatitis B vaccination - does not meet exclusion criteria on HBV
•
HBsAg negative
•
anti-HBc negative
•
HBsAb positive
Acutely infected – meets exclusion criteria on HBV
•
HBsAg positive
•
anti-HBc positive
•
IgM anti-HBc positive
•
HBsAb negative
Chronically infected - meets exclusion criteria on HBV
•
HBsAg positive
•
anti-HBc positive
•
IgM anti-HBc negative
•
HBsAb negative
Interpretation unclear
•
HBsAg negative
•
anti-HBc positive
•
HBsAb negative
HBV DNA testing will be performed in subjects with a negative HBsAg, but a positive anti-HBc 
antibody at screening. Subjects with detectable HBV DNA at screening are excluded. Subjects in 
this subgroup may be eligible for inclusion if HBV DNA is undetectable on this assay during 
screening.
Subjects with HBsAg negative, anti-HBc positive serology and undetectable HBV DNA at 
screening will have follow-up HBV DNA testing throughout their participation in the study, as 
detailed in the Schedule of Activities (Section 2). 
Protocol Amendment No.: 05
Date: 02-Sep-2022
157
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
•
During the study, subjects in this subgroup will have HBV DNA tested at Weeks 4, 8, 12 
and approximately every 3 months thereafter.
•
Subjects in this subgroup who have a clinical response at Week 12, who then enter the 
Maintenance Period and subsequently lose response and enter the open-label LOR arm will 
have additional HBV DNA testing at the first 3 study visits after entry to the LOR arm.
•
Subjects in this subgroup who do not have a clinical response at Week 12 and who enter 
the open-label BMS-986165 6 mg BID PO study arm, will have HBV DNA testing at 
Weeks 16, 22 and 26, and approximately every 3 months thereafter.
•
Subjects who enter the open-label extension period at Week 52 will have HBV DNA tested 
at Weeks 56, 60 and 64, and approximately every 3 months thereafter.
•
If subjects in this subgroup have detectable HBV DNA at any time, they must permanently 
discontinue study treatment, enter the Post-treatment Follow-up Period and the investigator 
should consider referring them for appropriate specialty care and follow-up.
II. HCV
Testing for HCV is a two-step process: (i) anti-HCV antibody, and (ii) HCV RNA.
Subjects with a negative anti-HCV antibody may be eligible for the study.
Subjects with a positive or indeterminate anti-HCV antibody require additional HCV RNA testing 
to determine eligibility. Subjects with negative or undetectable HCV RNA may be eligible for the 
study. Subjects with positive or detectable HCV RNA have HCV infection, are excluded from the 
study and should be referred for appropriate assessment and consideration for treatment. 
Subjects who were previously treated with an approved, treatment regimen for HCV infection may 
be eligible to participate in the study provided they achieve a Week 24 Sustained Virologic 
Response; that is negative or undetectable HCV RNA 24 weeks after completion of a full course 
of an approved treatment regimen for HCV infection. Such subjects must be discussed with the 
medical monitor prior to screening. 
Protocol Amendment No.: 05
Date: 02-Sep-2022
158
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 10
CROHN'S DISEASE ACTIVITY INDEX VARIABLES
The CDAI score consists of eight variables including 4 subject-reported outcomes. Variables 1, 2, 
3, and 5 will be obtained from the subject diary, as outlined in Section 9.1. The Standard Height 
and Weight Table (below) must be used to calculate variable 8. The score from each variable is 
weighted by applying the multiplier shown. The total CDAI score is then determined by calculating 
the sum of the individual, weighted scores.
CDAI Score
VARIABLE #
VARIABLE DESCRIPTION
MULTIPLIER
1
Number of liquid or soft stools (each day for 7 days)
x2
2
Abdominal pain 
(0=none, 1=mild, 2=moderate, 3=severe)
x5
3
General well-being 
(0=generally well,1=slightly under par, 2=poor, 3=very poor, 
4=terrible)
x7
4
Number of listed complications 
(arthritis or arthralgia, iritis or uveitis, erythema nodosum or 
pyoderma gangrenosum or aphthous stomatitis, anal fissure 
or fistula or abscess, other fistula, fever over 37.8°C [100°F])
x20
5
Use of diphenoxylate or loperamide for diarrhea
(0=no, 1=yes)
x30
6
Abdominal mass 
(0=no, 2=questionable, 5=definite)
x10
7
Hematocrit 
(males, 47-Hct [%], females, 42-Hct [%])
x6
8
Body weight (1 - weight/standard weight) x 100 
(add or subtract according to sign)
x1
TOTAL CDAI SCORE
SUM OF ABOVE
CDAI = Crohn’s Disease Activity Index; Hct = hematocrit
Sources: Best et al, Gastroenterology 1976;70:439-444; Best et al, Gastroenterology 1979;77: 843-846; Sandborn et 
al, Gastroenterology 2002;122:512-530.
Protocol Amendment No.: 05
Date: 02-Sep-2022
159
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
STANDARD HEIGHT AND WEIGHT TABLES (Use to calculate CDAI Score)
Actual Height cm (Inches)
Standard Weight - Men
kg (Pounds)
Standard Weight – Women
kg (Pounds)
147.3 (58.0)
52.2 (115.0)
148.6 (58.5)
52.6 (116.0)
149.9 (59.0)
53.1 (117.0)
151.1 (59.5)
53.6 (118.3)
152.4 (60.0)
54.2 (119.5)
153.7 (60.5)
54.8 (120.8)
154.9 (61.0)
55.3 (122.0)
156.2 (61.5)
56.0 (123.5)
157.5 (62.0)
61.7 (136.0)
56.7 (125.0)
158.8 (62.5)
62.1 (137.0)
57.4 (126.5)
160.0 (63.0)
62.6 (138.0)
58.0 (128.0)
161.3 (63.5)
63.0 (139.0)
58.7 (129.5)
162.6 (64.0)
63.5 (140.0)
59.4 (131.0)
163.8 (64.5)
64.1 (141.3)
60.1 (132.5)
165.1 (65.0)
64.6 (142.5)
60.8 (134.0)
166.4 (65.5)
65.2 (143.8)
61.4 (135.5)
167.6 (66.0)
65.8 (145.0)
62.1 (137.0)
168.9 (66.5)
66.4 (146.5)
62.8 (138.5)
170.2 (67.0)
67.1 (148.0)
63.5 (140.0)
171.5 (67.5)
67.8 (149.5)
64.2 (141.5)
172.7 (68.0)
68.5 (151.0)
64.9 (143.0)
174.0 (68.5)
69.2 (152.5)
65.5 (144.5)
175.3 (69.0)
69.8 (154.0)
66.2 (146.0)
176.5 (69.5)
70.5 (155.5)
66.9 (147.5)
177.8 (70.0)
71.2 (157.0)
67.6 (149.0)
179.1 (70.5)
71.9 (158.5)
68.3 (150.5)
180.3 (71.0)
72.6 (160.0)
68.9 (152.0)
181.6 (71.5)
73.4 (161.8)
69.6 (153.5)
182.9 (72.0)
74.1 (163.5)
70.3 (155.0)
184.2 (72.5)
75.0 (165.3)
185.4 (73.0)
75.7 (167.0)
186.7 (73.5)
76.6 (169.0)
Protocol Amendment No.: 05
Date: 02-Sep-2022
160
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Actual Height cm (Inches)
Standard Weight - Men
kg (Pounds)
Standard Weight – Women
kg (Pounds)
188.0 (74.0)
77.5 (171.0)
189.2 (74.5)
78.4 (172.8)
190.5 (75.0)
79.1 (174.5)
191.8 (75.5)
80.2 (176.8)
193.0 (76.0)
81.2 (179.0)
*Height in shoes with one-inch heels
*Indoor clothing weighing 5 pounds for men and 3 pounds for women
*Centimeters x 0.3937 = inches/ *Pounds x 0.4535 = kilograms
Protocol Amendment No.: 05
Date: 02-Sep-2022
161
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
162
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 12
DEFINITIONS OF SIMPLE ENDOSCOPIC SCORE FOR 
CROHN'S DISEASE 
Definitions of Simple Endoscopic Score for Crohn’s Disease
Simple Endoscopic Score for Crohn’s Disease values 
Variable
0
1
2
3
Size of Ulcers
None
Aphthous ulcers
Large ulcers
Very large ulcers
(Ø 0.1 to 0.5 cm)
(Ø 0.5 to 2 cm)
(Ø>2 cm)
Ulcerated 
Surface
None
<10%
10-30%
>30%
Affected surface
Unaffected 
segment
<50%
50-75%
>75%
Presence of 
narrowings
None
Single, can be 
passed
Multiple, can be passed
Cannot be passed
Ø = diameter
Reference: Daperno M, D’Haens G, et al. Development and validation of a new, simplified 
endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
Protocol Amendment No.: 05
Date: 02-Sep-2022
163
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
164
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
165
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
166
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
167
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
168
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
169
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
170
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
171
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
172
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
173
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
174
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
175
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
176
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
177
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
178
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
179
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
180
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
181
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
 
Protocol Amendment No.: 05
Date: 02-Sep-2022
182
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
183
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
184
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
Protocol Amendment No.: 05
Date: 02-Sep-2022
185
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 19
COVID-19 VACCINES
If a subject has received a specific coronavirus disease of 2019 (COVID-19) vaccination, the type 
of vaccine received should be recorded on the concomitant medication page, if given during the 
study, or the past history page, if given prior to enrollment.
•
Administration of a live vaccine is prohibited 90 days prior to the randomization visit; during 
the induction period, maintenance period, or open-label extension (OLE) period; or within 
2 months after the last dose of IP.
•
Administration of a non-live vaccine is allowed during the study. However, the efficacy and 
safety of non-live vaccines (including non-live COVID-19 vaccines) in subjects receiving 
BMS-986165 is unknown.
•
The following are NOT live vaccines: inactivated vaccines (eg, heat-killed and formalin-killed 
vaccines), subunit vaccines (eg, influenza and pneumococcal vaccines), toxoid vaccines, 
nucleic acid vaccines that do not encode potentially infectious virus (eg, Pfizer/BioNTech and 
Moderna COVID-19 vaccines) and replication-incompetent recombinant vector vaccines (eg, 
AstraZeneca/University of Oxford COVID-19 vaccine).
•
For COVID-19 vaccines requiring more than one dose, the full series (eg, both doses of a 
2-dose series) should be completed prior to enrollment when feasible, and when a delay in 
enrollment would not put the study subject at risk. Ideally, AEs attributable to a vaccine should 
have resolved prior to enrollment.
•
Administration of vaccinations must be reported along with dosage information, dates of 
administration and vaccine name/trade name on the Prior and Concomitant Medications form. 
A separate logline should be entered for each vaccine administered with the dose number 
following the vaccine name/trade name.
Please contact the medical monitor with any questions related to COVID-19 vaccines.
Protocol Amendment No.: 05
Date: 02-Sep-2022
186
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 20
CLOSTRIDIUM DIFFICILE INFECTION SCREENING
Subjects must provide a stool sample for Clostridium difficile (C. difficile) testing at the screening 
visit. The central lab performs glutamate dehydrogenase (GDH) and C. difficile toxin analysis on 
the sample to confirm the subject is negative for the bacterium. The following chart presents the 
procedures to be followed to determine eligibility:
C. difficile = Clostridium difficile; GDH = glutamate dehydrogenase; PCR = polymerase chain reaction
Please contact the medical monitor with any questions related to C. difficile testing or infection.
Protocol Amendment No.: 05
Date: 02-Sep-2022
187
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
APPENDIX 21
PROTOCOL AMENDMENT SUMMARY OF CHANGE HISTORY
Overall Rationale for the Protocol Amendment 4, 06-Aug-2021
The primary purpose of this protocol amendment is to include the following updates:
•
Reconfiguration of secondary and exploratory study endpoints in response to expert consensus 
on treatment targets in inflammatory bowel disease (IBD)
•
 
•
Removal of exclusion criterion that prohibited the participation of subjects who had previously 
experienced inadequate response or loss of response to ustekinumab
•
Addition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic 
testing, as well as an exclusion criterion and study procedures pertaining to SARS-CoV-2 
infection 
•
Inclusion of coronavirus disease 2019 (COVID-19) benefit-risk information and vaccination 
guidelines
•
 
 
The amendment will be implemented after the Investigator receives all appropriate agency and 
IRB/EC approvals.
Generally, only major additions and deletions are provided in this summary of changes document, 
and all minor grammatical, formatting, rephrasing, stylistic changes, or clarifications, as well as 
organizational changes are not included. All changes applied to the protocol body were applied to 
the protocol synopsis, as necessary; synopsis changes are not included in the summary of key 
changes table. 
The rationale for the change to this amendment is provided in the summary of key changes table, 
as shown below:
SUMMARY OF CHANGES OF PROTOCOL AMENDMENT 04
Section Number & Title
Description of Change
Brief Rationale
2 Schedule of Activities, Tables 1-4
3.2.3 Benefit/Risk Assessment
4.3 Exploratory Endpoints
6.2 Exclusion Criteria
7.7.1 Prohibited and/or Restricted Treatments
8.2.1 Temporary IP Discontinuation (new 
section)
9.3.2 Time Period and Frequency for AE/SAE 
Collection
9.10 SARS-CoV-2 Testing (new section)
Added information, 
instructions, and measures to 
be taken related to 
SARS-CoV-2 infection 
including the following:
• Diagnostic testing at 
screening 
•
 
• Exclusion criteria for 
known, active infections of 
COVID-19
Provides guidance to 
investigators related to SARS-
CoV-2 
Protocol Amendment No.: 05
Date: 02-Sep-2022
188
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
SUMMARY OF CHANGES OF PROTOCOL AMENDMENT 04
Section Number & Title
Description of Change
Brief Rationale
Appendix 19 COVID-19 Vaccines (new 
appendix)
• Criteria for temporary 
discontinuation of IP
• Documentation of AE/SAE 
related events
• Administration of COVID-
19 vaccine prior to or 
during study enrollment
2 Schedule of Activities, Table 1
Removed fasting requirement 
for blood tests at screening 
Reduces subject burden
2 Schedule of Activities, Table 1
6.5.1 Retesting During the Screening Period; 
Rescreening
Appendix 20 Clostridium Difficile Infection 
Screening
Clarified screening algorithm 
for C. difficile testing
Clarifies screening process for 
subjects who have 
indeterminate C. difficile 
screening test results
 
 
 
 
2 Schedule of Activities, Tables 2-4
5.1.1 Screening Period
Clarified that endoscopies 
should be performed within a 
window of 7 days prior to the 
visit day
Limits confounding effects of 
bowel preparation, endoscopy 
procedure, and sedation on 
other clinical assessments
2 Schedule of Activities, Tables 2-3
9.2 Laboratory Assessments
9.5.3 Clinical Safety Laboratory Assessments
Clarified hematocrit may be 
performed by a local 
laboratory at Weeks 2, 4, 8, 
and 52, in addition to Weeks 
12 through 44
Ensures prompt CDAI score 
calculation
3.2.3 Benefit/Risk Assessment
Added efficacy and safety 
findings from recent 
BMS-986165 studies
Adds further safety and 
efficacy context for how 
BMS-986165 is expected to 
affect CD subjects
4 Objectives and Endpoints
10.3.2 Secondary Endpoints
10.3.3 Exploratory Endpoints
10.4.6 Adjustment for Multiplicity of Co-
primary and Secondary Endpoints, Table 18
Reconfigured secondary and 
exploratory endpoints
Endpoints updated in response 
to STRIDE II expert 
consensus on treatment targets 
in IBDa
5.1.1 Screening Period
6.1 Inclusion Criteria
6.2 Exclusion Criteria
7.7.1 Prohibited or Restricted Treatments
 
 
 
Removed exclusion of 
subjects with inadequate 
response or loss of response to 
ustekinumab
Allows previously excluded 
subjects to participate based 
on results from other BMS-
986165 studies
Protocol Amendment No.: 05
Date: 02-Sep-2022
189
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
SUMMARY OF CHANGES OF PROTOCOL AMENDMENT 04
Section Number & Title
Description of Change
Brief Rationale
5.1.4 Open-label Extension Period
Clarified subjects who need 
rescue treatment must 
discontinue study treatment
Clarifies participation 
requirement that was 
previously implied
5.1.4 Open-label Extension Period
5.1.4.1 Post-treatment Follow-up 
7.8 Treatment After the End of the Study
 
 
Clarifies subject options for 
continuing treatment
6.1 Inclusion Criteria
New Inclusion Criterion 3)l 
was added. Inclusion Criterion 
3)j was changed to “Not 
applicable” and its content 
was amended to create new 
criterion 3)m.
Clarifies contraceptive 
requirements for male and 
female subjects to align with 
BMS-986165 program 
guidance
6.2 Exclusion Criteria
Exclusion Criteria 1)m, 1)o, 
3)d, and 4)m were changed to 
“Not applicable.” These 
previous exclusion criteria 
were amended to create new 
criteria 1)s, 1)t, 3)e, and 4)n, 
respectively. 
Clarifies previously 
unspecified details and 
exceptions to specific 
exclusion criteria 
6.2 Exclusion Criteria
7.7.1 Prohibited and/or Restricted Treatments
Added types of vaccines that 
are not prohibited before, 
during, or after the study
Clarifies previously 
unspecified exceptions to the 
prohibition of vaccine 
administration before, during,
and after the study
6.2 Exclusion Criteria
Exclusion Criterion 4)e was 
clarified to not exclude 
subjects with Gilbert’s 
syndrome
Clarifies previously 
unspecified exception to the 
exclusion of subjects with high 
bilirubin
7.3.3 Unblinding for Week 12 Analysis (new 
section)
Included details for unblinding 
BMS personnel for the 
Week 12 analysis
Clarifies unblinding 
procedures for the Week 12 
analysis and clinical study 
report
8.1 Discontinuation from Study Treatment
Included criteria for liver-
related laboratory 
abnormalities 
Clarifies procedures and 
discontinuation criteria for 
subjects with elevated liver-
related laboratory values
9 Study Assessments and Procedures
Clarified that study data may 
be used for additional analyses 
related to CD and other 
inflammatory diseases
Clarifies potential future 
analyses
9.1 Efficacy Assessments
Changed Robarts Clinical 
Trials to Alimentiv Clinical 
Trials
Updates vendor information
Protocol Amendment No.: 05
Date: 02-Sep-2022
190
2.0
Approved
930173322
2.0
v
Approved
1.0
v

Clinical Protocol
IM011023
BMS-986165
TYK2 Inhibitor
SUMMARY OF CHANGES OF PROTOCOL AMENDMENT 04
Section Number & Title
Description of Change
Brief Rationale
9.3.8 Potential Drug-induced Liver Injury
Added language to mandate 
follow-up testing in subjects 
with suspected DILI AEs.
Includes analysis of root cause 
in potential DILI occurrences 
to ensure subject safety
Study Acknowledgment/Disclosure
6.2 Exclusion Criteria
6.5 Screen Failures
7.3.1 Maintaining the Blind
7.8 Treatment After the End of the Study
9.3.2 Time Period and Frequency for 
Collecting AE and SAE Information
9.8.1 Additional Research Collection
Appendix 2 Study Governance Considerations
Appendix 3 Adverse Events and Serious 
Adverse Events: Definitions and Procedures 
for Recording, Evaluating, Follow-up and 
Reporting
Appendix 5 Women of Childbearing Potential 
Definitions and Methods of Contraception
Updated text in multiple 
sections of the protocol due to 
changes in BMS protocol 
standards
Reflects current BMS 
procedures, policies, and 
guidelines
a Refer to: Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the Selecting Therapeutic Targets in 
Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): 
Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160(5):1570-83.
Protocol Amendment No.: 05
Date: 02-Sep-2022
191
2.0
Approved
930173322
2.0
v
Approved
1.0
v